

The logo for the Società Italiana di Farmacologia (SIF) consists of the letters 'SIF' in a bold, white, sans-serif font, set against a dark teal background.

SOCIETÀ ITALIANA  
DI FARMACOLOGIA

# 38° Congresso Nazionale

## Farmaci, Salute, e Qualità della Vita



Palacongressi di **Rimini**  
25-28 ottobre 2017



## President Letter

Con il suo 38° Congresso Nazionale la SIF intende mettere in luce gli aspetti più importanti correlati agli straordinari progressi raggiunti dal Mondo del Farmaco che negli ultimi decenni, dotandosi di una moderna e intensa attività di ricerca, ha determinato una vera rivoluzione in termini di innovazione terapeutica. Tuttavia, le numerose problematiche che sono sorte con il trasferimento di tali innovazioni ai pazienti richiedono studi più ampi e approfondimenti di tipo regolatorio, etico e di sostenibilità.

La scienza, con la sua ricerca, e l'economia, con le sue esigenze, debbono trovare un punto di equilibrio per garantire il diritto alla salute del cittadino in termini di fruibilità delle innovazioni terapeutiche. Oggi l'allungamento della vita media e l'aumento di "senescenti" in buona condizione di salute organica determinano un incremento significativo delle malattie cronicodegenerative quali, ad esempio, quelle neurodegenerative, quelle oncologiche o quelle dismetaboliche, ovvero dei nuovi rischi causati da malattie infettive, fenomeni ai quali il farmaco può dare risposta.

Siamo consapevoli che la salute ha un costo e che il farmaco, aumentando le possibilità di salute, risponde alle prerogative etiche di tutela del paziente: soltanto una visione economicamente proiettata sul medio-lungo periodo può correttamente evidenziare il ruolo primario svolto dalla ricerca e dal conseguente sviluppo di farmaci innovativi. Su questa complessa problematica e sui corrispondenti temi di ricerca e sviluppo dei farmaci innovativi la SIF, in particolare con la sua Sezione di Farmacologia Clinica, è stata sempre presente in questi anni anche attraverso costruttive collaborazioni con altre Società scientifiche, con Organismi di Stato e con il Mondo del farmaco in generale.

Sulla base di queste premesse e riconoscendo che l'Università sta vivendo grandi trasformazioni, il prossimo Congresso Nazionale della SIF intende affrontare con la necessaria attenzione le problematiche della ricerca di base e, mediante una efficace strategia con il Collegio Nazionale dei Farmacologi Universitari (CNFU), dibatterà il tema della formazione del Farmacologo, nella convinzione che l'attività sperimentale abbia un ruolo essenziale per apprendere il metodo farmacologico di analisi critica per lo sviluppo del farmaco.

Il farmaco è un bene dell'Umanità che va posto in corretta luce e tutelato come contributo fondamentale al benessere dell'uomo e allo sviluppo della moderna Società. Con il 38° Congresso, la SIF avvierà una strategica opera di comunicazione educativa rivolta al cittadino per diffondere la conoscenza del corretto uso dei farmaci al fine di ridurre i possibili rischi e anche per contribuire al contenimento dei costi sanitari.

*Giorgio Cantelli Forti*

### SEDE DEL CONGRESSO

#### Palacongressi di Rimini

Via della Fiera, 23  
47922 Rimini

[www.riminipalacongressi.it](http://www.riminipalacongressi.it)

### SEGRETERIA ORGANIZZATIVA



#### Adria Congrex srl

Via Sassonia, 30  
47922 Rimini  
Tel. 0541 305873

[c.imola@adriacongrex.it](mailto:c.imola@adriacongrex.it)  
[www.adriacongrex.it](http://www.adriacongrex.it)

### SEGRETERIA SCIENTIFICA



#### SIF - Società Italiana di Farmacologia

Via Giovanni Pascoli, 3  
20129 Milano  
[sif.congressi@sigr.it](mailto:sif.congressi@sigr.it)  
[www.sifweb.org](http://www.sifweb.org)



## Committees

### COMITATO SCIENTIFICO DEL CONGRESSO

Giorgio Cantelli Forti  
Giuseppe Cirino  
Santa Cirmi  
Romano Danesi  
Monica Di Luca  
Filippo Drago  
Patrizia Hrelia  
Gabriela Mazzanti  
Teresita Mazzei  
Alessandro Mugelli  
Carlo Riccardi  
Francesco Rossi  
Gianni Sava  
Marco Scatigna  
Maria Angela Sortino  
Luca Steardo  
Luigia Trabace

### COMITATO SCIENTIFICO LOCALE

Giorgio Cantelli Forti (Presidente)  
Sabrina Angelini  
Fabrizio De Ponti  
Patrizia Hrelia  
Domenico Motola  
Andrea Pierini  
Elisabetta Poluzzi  
Patrizia Romualdi  
Andrea Tarozzi

### CONSIGLIO DIRETTIVO

**Presidente**  
Giorgio Cantelli Forti

**Presidente Eletto**  
Alessandro Mugelli

**Consiglieri**  
Monica Di Luca  
Gianni Sava  
Marco Scatigna  
Maria Angela Sortino  
Luca Steardo  
Luigia Trabace


**Segretario**  
Giuseppe Cirino

**Past President**  
Francesco Rossi

## Auspices




## Pianta Congressuale Piano Terra



### LEGENDA

- 1 ENVIGO
- 2 BIOLOGICAL
- 3 MENARINI
- 4 COSWELL
- 5 CHARLES RIVER
- 6 TECNIPLAST
- 7 NANOTEMPER
- 8

## Pianta Congressuale Piano Primo




**Program at a glance**
**Wednesday, October 25<sup>th</sup>, 2017 - Afternoon**

	SALA ANFITEATRO	SALA DELLA PIAZZA	SALA DEL TEMPIO 1	SALA DEL TEMPIO 2		SALA DEL PARCO	SALA DEL BORGO	SALA DELLA MARINA	SALA DEL LEVATOIO		
14.30 - 15.00				<b>SYMPOSIUM</b> Neurofunctional and Metabolic Alterations Induced by Maladaptive Eating and Stress. Searching for Novel Pharmacological Targets						14.30 - 15.00	
15.00 - 15.30		<b>SYMPOSIUM</b> Pediatric Pharmacology and the new EU Clinical Trial Regulation. Perspectives and Opportunities	<b>SYMPOSIUM</b> Acetylsalicylic Acid, 120 Years Later			<b>ORAL COMMUNICATIONS</b> Drug Abuse	<b>ORAL COMMUNICATIONS</b> Pharmacoeconomics, Pharmacoepidemiology & Pharmacovigilance I	<b>ORAL COMMUNICATIONS</b> Antineoplastic Drugs	<b>ORAL COMMUNICATIONS</b> Miscellaneous Pharmacology	15.00 - 15.30	
15.30 - 16.00											15.30 - 16.00
16.00 - 16.30											16.00 - 16.30
16.30 - 17.00	<b>OPENING CEREMONY</b>  <b>PLENARY LECTURE</b> Challenges and Opportunities for Future Sustainability of Pharmaceutical Expenditure Mario Melazzini										
17.00 - 17.30										17.00 - 17.30	
17.30 - 18.00	<b>ROUND TABLE PHARMACOLOGY IN ITALY: HOW CAN WE BUILD A BRIGHT FUTURE?</b>									17.30 - 18.00	
18.00 - 18.30										18.00 - 18.30	
18.30 - 19.00										18.30 - 19.00	
19.00 - 19.30	<b>CEREMONY IN HONOR OF PAOLO PREZIOSI</b> My life in Pharmacology: from basic studies to translational applications									19.00 - 19.30	
19.30 - 20.00	<b>SIF-FARMINDUSTRIA AWARDS</b>  <b>SIF ASSOGENERICI GRANTS</b>									19.30 - 20.00	

CME Session  
 Assemblies



## Program at a glance

 Thursday October 26<sup>th</sup>, 2017 - morning

	SALA DELLA PIAZZA	SALA DEL TEMPIO 1	SALA DEL TEMPIO 2		SALA DEL PARCO	SALA DEL BORGO	SALA DELLA MARINA	SALA DEL LEVATOIO			
8.30 - 9.00	<b>SYMPOSIUM</b> Phenotyping Chronic Obstructive Pulmonary Disease (COPD): Pharmacological and Toxicological Implications	<b>SYMPOSIUM</b> Heart Failure: Different Approaches to the Same Problem	<b>SYMPOSIUM</b> The Future of Pharmacovigilance and the Role of Risk Communication		<b>SYMPOSIUM</b> Translational Strategy for Assessing New Mechanisms for the Development of Innovative Therapeutic Approach in Psychiatric Disorders	<b>ORAL COMMUNICATIONS</b> To Switch or Not to Switch: the Role of Excitatory and Inhibitory GABA Transmission in Pathological and Physiological Conditions	<b>SYMPOSIUM</b> Stress-Induced Psychopathologies: Molecular Markers of Vulnerability and Novel Pharmacological Targets	<b>ORAL COMMUNICATIONS</b> Inflammation Pharmacology	8.30 - 9.00		
9.00 - 9.30				9.00 - 9.30		9.30 - 10.00			10.00 - 10.30	<b>MINISYMPOSIUM</b> Advances in Multiple Sclerosis	9.30 - 10.00
10.00 - 10.30				10.00 - 10.30		10.30 - 11.00			10.30 - 11.00		
10.30 - 11.00				10.30 - 11.00		10.30 - 11.00			10.30 - 11.00		
11.00 - 11.30	<b>SYMPOSIUM</b> New Approaches to the Inflammation Pharmacology	<b>ROUND TABLE</b> Vaccines, vaccinations in ethical and responsible community	<b>SYMPOSIUM</b> Current Topics and Perspectives of Precision Therapy in Oncology		<b>SYMPOSIUM SIF-SIN</b> #Neurologytour Innovation in Neurological Disorders Therapies and Neuroprotection	<b>LECTURE</b> Gout 2017: New Therapeutic Opportunities	<b>SYMPOSIUM SIF-SITOX-SINUT</b> Nutraceutical Compounds: Current and Future Perspectives		11.00 - 11.30		
11.30 - 12.00				11.30 - 12.00		12.00 - 12.30			12.00 - 12.30	<b>LECTURE</b> Proton Pump Inhibitors 25 Years Later: Use and Misuse	11.30 - 12.00
12.00 - 12.30		<b>LECTURE</b> Antibiotics Resistance		12.00 - 12.30		12.00 - 12.30			<b>LECTURE</b> An Update on Gene Silencing	12.00 - 12.30	
12.30 - 13.00		<b>LECTURE</b> Inhibit Activation of Mast Cells and Eosinophils to Treat Allergic Diseases: The CD48 Story		<b>LECTURE</b> Advances in Uro-Oncology: Novel Tkis in Kidney Cancer		12.30 - 13.00			<b>MINISYMPOSIUM</b> Type 2 Diabetes: Glycemic Control and Innovation Therapy	12.30 - 13.00	
13.00 - 13.30									13.00 - 13.30		
13.30 - 14:00									13.30 - 14:00		

CME Session  
 Assemblies


**Program at a glance**
**Thursday October 26<sup>th</sup>, 2017 - afternoon**

	SALA ANFITEATRO	SALA DELLA PIAZZA	SALA DEL TEMPIO 1	SALA DEL TEMPIO 2		SALA DEL PARCO	SALA DEL BORGO	SALA DELLA MARINA	SALA DEL LEVATOIO					
14.00 - 14.30			<b>MINISYMPOSIUM</b> Pharmacological Control of Tumor Necrosis Factor (TNF) in Immunomediated Inflammatory Diseases (IMID): the Value of Adalimumab	<b>ROUND TABLE</b> Precision-Personalized (P-P) Medicine: Understanding Health and Sustainability Impact					<b>SYMPOSIUM</b> From Urate Deposition To Cv Risk: The Role Of The Xanthine-Oxidase Modulation	14.00 - 14.30				
14.30 - 15.00		<b>ROUND TABLE</b> Management of critical conditions: the drug-device interactions				<b>SYMPOSIUM</b> On the Bright and the Dark Side of Amyloid Beta: Looking over Alzheimer's Disease	<b>SYMPOSIUM SID-SIC</b> Clinical and Experimental Aspects of Novel Antidiabetic Therapies - From the Gut and the Kidney Towards the Cardiovascular System: the Last Ten Years of the Antidiabetic Drugs	<b>SYMPOSIUM</b> Clinical Perspectives of Nutraceuticals		14.30 - 15.00				
15.00 - 15.30												15.00 - 15.30		
15.30 - 16.00			<b>MINISYMPOSIUM</b> Innovation of Mechanism of Action in Oncology	<b>LECTURE</b> The Pharmacology of the Future: "In Vivo Veritas, In Vitro Dolo" the Challenges of CNS Drug Discovery								<b>ROUND TABLE</b> Problems Related to the use of Medicines in Developing Countries	15.30 - 16.00	
16.00 - 16.30	<b>PLENARY LECTURE</b> Advanced Therapies For The Treatment Of Rare Genetic Diseases Alessandro Aiuti												16.00 - 16.30	
16.30 - 17.00									16.30 - 17.00					
17.00 - 17.30		<b>SYMPOSIUM</b> Emerging Epigenetic Strategies in Pharmacological Therapy	<b>SYMPOSIUM</b> Study, Development and Rationale Use of Immunopharmacological Agents	<b>SYMPOSIUM</b> Psychiatric Vulnerability of the Developing Brain: Suggestions from Animal Models and Critical Time Windows for Pharmacological Intervention		<b>ROUND TABLE</b> Clinical Research, Ethics Committees and the new European Clinical Trials Regulation	<b>"GIAMPAOLO VELO" SYMPOSIUM</b> The Clinical Evolution of Pharmacology	<b>SYMPOSIUM</b> Effectiveness and Safety of Direct Oral Anticoagulants in Clinical Practice: Comparison of Viewpoints	<b>ORAL COMMUNICATIONS</b> Neuropharmacology I	17.00 - 17.30				
17.30 - 18.00														17.30 - 18.00
18.00 - 18.30														
18.30 - 19.00			<b>Collegio Nazionale dei Farmacologi Universitari</b> General Assembly							<b>Clinical Pharmacology Section General Assembly</b>	<b>ORAL COMMUNICATIONS</b> Cardiovascular Pharmacology I		18.30 - 19.00	
19.00 - 19.30										19.00 - 19.30				
19.30 - 20.00										19.30 - 20.00				
20.00 - 20.30			<b>POSTER SESSION</b>							20.00 - 20.30				
20.30 - 21.00										20.30 - 21.00				

CME Session  
 Assemblies


**Program at a glance**
**Friday October 27<sup>th</sup>, 2017 - morning**

	SALA ANFITEATRO	SALA DELLA PIAZZA	SALA DEL TEMPIO 1	SALA DEL TEMPIO 2		SALA DEL PARCO	SALA DEL BORGHO	SALA DELLA MARINA	SALA DEL LEVATOIO					
8.30 - 9.00			<b>SYMPOSIUM</b> New Directions in Orphan Drugs for Rare Diseases: from Clinical Trials to Regulatory Paths	<b>SYMPOSIUM</b> Environmental Enrichment and Brain Repair: the Therapeutic Effects of Cognitive Training in Neurological Diseases		<b>ROUND TABLE</b> Innovation Flow	<b>SYMPOSIUM</b> From Psychological Stress to Neurodegeneration: Novel Pharmacological Targets and Neuroprotective Approaches	<b>SYMPOSIUM</b> Novel Biological and Pharmacological Aspects in the Brain Tumors	<b>ORAL COMMUNICATIONS</b> Advances in Natural Medicines and Nutraceuticals	8.30 - 9.00				
9.00 - 9.30													9.00 - 9.30	
9.30 - 10.00														9.30 - 10.00
10.00 - 10.30				<b>SYMPOSIUM SIF-AIE</b> From Big Data to Smart Data: Aims, Tools and Knowledge in the Real World Evidence		<b>ROUND TABLE</b> The Italian Experience Between Scientific Evidences and Evolution of Prescriptive Models	<b>SYMPOSIUM</b> The Pharmacologist and the Microbiota Challenge		<b>SYMPOSIUM</b> Evolution of the Therapeutic Approach to the HIV Infection: not only "Viral Load"		10.00 - 10.30			
10.30 - 11.00		<b>SYMPOSIUM</b> Appropriate Use of Opiates and Risk of Abuse Liability											10.30 - 11.00	
11.00 - 11.30														11.00 - 11.30
11.30 - 12.00		<b>SYMPOSIUM</b> Efficacy, Safety and Effectiveness of iSGLT2: Current and Future Role	<b>MINISYMPOSIUM</b> Rare Diseases Therapy: from Clinical Needs to Therapeutic Solutions	<b>LECTURE</b> Equitable access to new high-priced medicines: challenges and strategies in European countries		<b>MINISYMPOSIUM</b> Patient Centricity	<b>SYMPOSIUM</b> The Pharmacologist and the Microbiota Challenge	<b>LECTURE</b> Haemophilia A: Raising the Bar for New Treatments	<b>SYMPOSIUM</b> Clinical Pharmacology of Cardio-Oncology		11.30 - 12.00			
12.00 - 12.30			<b>LECTURE</b> Autosomal Dominant Polycystic Kidney: is it a Rare Disease?								<b>LECTURE</b> The GCRP System in the Pathophysiology of Migraine and its Role as a New Therapeutic Target			12.00 - 12.30
12.30 - 13.00	<b>PLENARY LECTURE</b> Neuro-glia metabolic coupling: role in neuronal plasticity, neuroprotection and functional imaging Pierre Magistretti													
13.00 - 13.30												13.00 - 13.30		
13.30 - 14.00												13.30 - 14.00		
14.00 - 14.30												14.00 - 14.30		

CME Session  
 Assemblies







Program at a glance

Friday October 27<sup>th</sup>, 2017 - afternoon

	SALA ANFITEATRO	SALA DELLA PIAZZA	SALA DEL TEMPIO 1	SALA DEL TEMPIO 2		SALA DEL PARCO	SALA DEL BORGO	SALA DELLA MARINA	SALA DEL LEVATOIO		
14.30 - 15.00						<b>MINISYMPOSIUM</b> Pharmacological modulation of novel molecular systems in the management of patients with complex pathologies	<b>SYMPOSIUM</b> Neuroprotection and Neuroenhancement: Lessons Learned from Ocular Disorders	<b>SYMPOSIUM</b> Personalized Medicine and Pharmacological Treatment of Psychiatric Disorders	<b>ORAL COMMUNICATIONS</b> Pharmacognosy	14.30 - 15.00	
15.00 - 15.30		<b>SYMPOSIUM</b> Role of the "Real World Evidence" in the Italian Governance	<b>ROUND TABLE</b> SIF-SITOX The Health and Economic Effects of Counterfeit Drugs	<b>SYMPOSIUM</b> Th2 Pathway in Immunological Diseases: New Frontiers for Treatment of Atopic Disease							15.00 - 15.30
15.30 - 16.00											
16.00 - 16.30			<b>SYMPOSIUM</b> Translational Research Openings for the Cure of Amyotrophic Lateral Sclerosis	<b>JOINT SYMPOSIUM</b> SIF - SSFA Advanced Therapies and Medical Devices Combination with Innovative Therapies		<b>SYMPOSIUM</b> Hepatitis C Therapy: Pharmacokinetics, Pharmacodynamics and Clinical Outcomes	<b>WINNERS SELECTED REPORTS</b> SIF-MSD GRANTS 2015	<b>LECTURE</b> Role of Partial Agonists in the Treatment of Psychoses: State of Art and Future Perspectives	<b>ORAL COMMUNICATIONS</b> Cardiovascular Pharmacology II	16.00 - 16.30	
16.30 - 17.00		<b>SYMPOSIUM</b> Randomized Clinical Trials: the Need of Data and Integrative Sources				<b>ROUND TABLE</b> The management of the patient with diabetic macular edema: between therapeutic effectiveness, quality of vision and life					16.30 - 17.00
17.00 - 17.30								<b>SYMPOSIUM</b> The Endocannabinoid System and Autism Spectrum Disorders			17.00 - 17.30
17.30 - 18.00		<b>SYMPOSIUM</b> Experiences in RWE					<b>LECTURE</b> Adenosine Receptors as Key Players in Health and Disease				17.30 - 18.00
18.00 - 18.30									18.00 - 18.30		
18.30 - 19.00	<b>SIF GENERAL ASSEMBLY</b>									18.30 - 19.00	
19.00 - 19:30	<b>AWARDS CEREMONY:</b> Giampaolo Velo Grants SIF - Otsuka Grants Alberico Benedicenti Awards									19.00 - 19:30	
19.30 - 20:00	SIF - Fondazione Gianfranco Ferro Grants SIF 2017 - Lifetime Achievement Award									19.30 - 20:00	


SALA DEL FARO - 10.30	Extraordinary Assembly SITOX
SALA DEL FARO - 13.30	Extraordinary Assembly SIF

 CME Session  
 Assemblies


**Program at a glance**
**Saturday October 28<sup>th</sup>, 2017 - morning**

	SALA ANFITEATRO	SALA DELLA PIAZZA	SALA DEL TEMPIO 1	SALA DEL TEMPIO 2		SALA DEL PARCO	SALA DEL BORGO	SALA DELLA MARINA	SALA DEL LEVATOIO	
9.00 - 9:30		<b>SYMPOSIUM</b> The Purinergic System: a New Promising Target for Human Diseases	<b>ORAL COMMUNICATIONS</b> Ketamine and Pharmacology of Pshychiatric Diseases	<b>ORAL COMMUNICATIONS</b> Neuropharmacology II		<b>ORAL COMMUNICATIONS</b> Immunopharmacology	<b>ORAL COMMUNICATIONS</b> Pharmacoeconomics, Pharmacoepidemiology & Pharmacovigilance II	<b>JOINT SYMPOSIUM SIF - FADOI</b> Pharmacological Strategies Defending the Heart from Fat Attack: a New Role for DOAC? - The Epicardial Adipose Tissue (EPA), a Sick (Visceral) Fat Embracing the Heart	<b>ORAL COMMUNICATIONS</b> Pharmacogenetics, Pharmacogenomics and Gene Therapy	9.00 - 9:30
9.30 - 10:00	9.30 - 10:00									
10.00 - 10:30	10.00 - 10:30									
10.30 - 11:00	10.30 - 11:00									
11.00 - 11:30				<b>SYMPOSIUM</b> Old and New Fields for Ion Channel Pharmacology: Still Surfing on the Crest of a Wave	<b>ROUND TABLE SIF - SITOX</b> Therapeutic Cannabis	<b>JOINT SYMPOSIUM SIF - SIR</b> New Insights on Osteoporotic Drugs and Future Therapeutic Prospectives	<b>SYMPOSIUM</b> Cardiovascular Risk Prevention and the Chronic Patient		11.00 - 11:30	
11.30 - 12:00	11.30 - 12:00									
12.00 - 12:30	<b>PLENARY LECTURE</b> Pharmacology 2020: how to increase clinical trials efficiency beyond and above Big Data Luca Pani									12.00 - 12:30
12.30 - 13:00		12.30 - 13:00								
	<b>CONCLUSIONS</b>									
	<b>POSTER GRANTS</b>									

CME Session  
 Assemblies



## SALA DELLA PIAZZA

14.30-16.30 **SYMPOSIUM****PEDIATRIC PHARMACOLOGY AND THE NEW EUROPEAN UNION (EU)  
CLINICAL TRIAL REGULATION: PERSPECTIVES AND OPPORTUNITIES**

Chairpersons: *Adriana Ceci (Bari) - Alessandro Mugelli (Florence)*

**Management of therapy in a pediatric setting: from clinical to basic  
pharmacology**

*Carla Carnovale (Milan)*

**The European Regulation for the study of drugs in paediatrics:  
presentation and current implementation**

*Viviana Giannuzzi (Bari)*

**Pediatric formulations**

*Serena Tongiani (Rome)*

**Drug trials in pediatrics**

*Francesca Rocchi (Rome)*

**Pediatric pharmacovigilance**

*Alfredo Vannacci (Florence)*

**Therapeutic drug monitoring in pediatrics**

*Gabriele Stocco (Trieste)*

16.30-17.30 **OPENING CEREMONY****PLENARY LECTURE**

Introduced by: *Giorgio Cantelli Forti (Bologna)*

**CHALLENGES AND OPPORTUNITIES FOR FUTURE SUSTAINABILITY  
OF PHARMACEUTICAL EXPENDITURE**

*Mario Melazzini (Rome)*

17.30-19.00 **ROUND TABLE****PHARMACOLOGY IN ITALY: HOW CAN WE BUILD A BRIGHT FUTURE?**

Opening: *Giorgio Cantelli Forti (Bologna)*

Chairperson: *Andrea Cangini (Bologna)*

**Discussants:**

*Paolo Bonaretti (Rome)*

*Valeria Fedeli (Rome)*

*Enrique Hausermann (Rome)*

*Beatrice Lorenzin (Rome)*

*Mario Melazzini (Rome)*

*Massimo Scaccabarozzi (Milan)*

19.00-19.30 **CEREMONY IN HONOR OF PAOLO PREZIOSI**

Introduced by: *Giuseppe Nisticò (Rome)*

**MY LIFE IN PHARMACOLOGY:****FROM BASIC STUDIES TO TRANSLATIONAL APPLICATIONS**

*Paolo Preziosi (Rome)*

19.30-20.00 **SIF - FARMINDUSTRIA AWARDS****SIF - ASSOGENERICI GRANTS**

SALA DEL TEMPIO 1

14.30-16.30 SYMPOSIUM

**ACETYSALICYLIC ACID, 120 YEARS LATER**

*Chairpersons: Carlo Patrono (Rome) - Elena Tremoli (Milan)*

**Pharmacokinetic/Pharmacodynamic (PK/PD) determinants of the interindividual variability in the antiplatelet response: acetylsalicylic acid resistance revisited**

*Bianca Rocca (Rome)*

**Low-dose acetylsalicylic acid and bleeding: current estimates, mechanistic determinants and risk factors**

*Angel Lanas (Zaragoza - Spain)*

**Low-dose acetylsalicylic acid and cardiovascular prevention: established facts and open questions**

*Colin Baigent (Oxford-UK)*

**Acetylsalicylic acid and cancer: where do we stand in 2017**

*Paola Patrignani (Chieti)*



SALA DEL TEMPIO 2

14.30-16.30 SYMPOSIUM

**NEUROFUNCTIONAL AND METABOLIC ALTERATIONS INDUCED BY MALADAPTIVE EATING AND STRESS: SEARCHING FOR NOVEL PHARMACOLOGICAL TARGETS**

*Chairpersons: Carlo Cifani (Camerino)- Silvana Gaetani (Rome) - Laura Musazzi (Milan)*

**Histaminergic neurons partake in the gut-brain axis to modulate appetite and memory**

*M. Beatrice Passani (Florence)*

**High palatable food exposure and pain behavior: beyond cannabinoid receptors**

*Roberto Russo (Naples)*

**Genetic and epigenetic regulation of adenosine A<sub>2A</sub> receptor gene transcription on compulsive food consumption**

*Maria Vittoria Micioni Di Bonaventura (Camerino)*

**“The ugly the bad and the good”: how oleoylethanolamide can ameliorate neurochemical and behavioral aspects of eating disorders**

*Tommaso Cassano (Foggia)*

**Acute stress rapidly increases energy metabolism in prefrontal and frontal cortex and alters working memory performance**

*Laura Musazzi (Milan)*

**The endocannabinoid system: possible new pharmacological target in the treatment of anorexia nervosa**

*Paola Fadda (Cagliari)*



Wednesday, October 25<sup>Th</sup>

 Wednesday, October 25<sup>Th</sup>


## SALA DEL PARCO

## 14.30-16.30 ORAL COMMUNICATIONS

## DRUG ABUSE

 Chairpersons: *Girolamo Calò (Ferrara) - Patrizia Romualdi (Bologna)*

- 14.30**      **NOP receptor and functional selectivity**  
*Ruzza C., Ferrari F., Malfacini D., Asth L., Rizzi A., Zaveri N.T., Guerrini R., Calò G.*
- 14.40**      **N/OFFQ and CRF systems dysregulation in Marchigian Sardinian (msP) rats underlies their innate sensitivity to stress and alcohol preference**  
*Caputi F.F., Palmisano M., Rullo L., Ubaldi M., Candeletti S., Ciccocioppo R., Romualdi P.*
- 14.50**      **Targeting the nocceptine/orphanine FQ system to treat drug abuse**  
*Cannella N., Stopponi S., Borruto A.M., Fotia Y., Shen Q.W., Domi A., Ubaldi M., Ciccocioppo R.*
- 15.00**      **Dopamine D3 receptor-dependent changes in GABA<sub>A</sub> receptor alpha 6 subunit expression control voluntary ethanol intake**  
*Di Marco R., Leggio G.M., Torrisi S.A., Giurdanella G., Dahl K., Caraci F., Bucolo C., Aitta-aho T., Korpi E.R., Drago F., Salomone S.*
- 15.10**      **Rat Nicotine Sensitization Modulates mRNA Levels of Stress Peptides and Receptors in the Reward Pathway**  
*Carboni L., Romoli B., Zoli M., Romualdi P.*
- 15.20**      **Gestational cannabinoid exposure influences extracellular kynurenic acid and glutamate levels in the medial prefrontal cortex of adolescent offspring**  
*Beggiato S., Ferraro L., Schwarcz R.*
- 15.30**      **Emotional Disorders Induced by Hemopressin and RVD-Hemopressin (a) Injection in Rats**  
*Leone S., Ferrante C., Recinella L., Mollica A., Chiavaroli A., Martinotti S., Orlando G., Vacca M., Brunetti L.*

- 15.40**      **Results from an e-learning course designed to train medical students on how to treat nicotine dependence in clinical practice**  
*Grassi M.C., Sansone A., Basili S., Ferketich A.K.*
- 15.50**      **Real-time detection of ethanol in the nucleus accumbens shell of freely moving rats**  
*Rocchitta G., Peana A.T., Cossu A., Bazzu G., Farina D., Zinellu M., Migheli R., Serra P.A.*
- 16.00**      **DISCUSSION**

Wednesday, October 25<sup>Th</sup>

## SALA DEL BORGO

**14.30-16.30 ORAL COMMUNICATIONS**
**PHARMACOECONOMICS, PHARMACOEPIDEMIOLOGY &  
PHARMACOVIGILANCE I**

Chairpersons: Achille Patrizio Caputi (Messina) - Roberto Leone (Verona)

- 14.30** **Web-based reporting of adverse drug reactions in Italy**  
*Arzenton E., Sottosanti L., Opri S., Magro L., Viola E., Gonella L.A., Stoppa G., Lora R., Pagliarini M., Leone R., Moretti U.*
- 14.40** **Muscular adverse drug reactions associated with proton pump inhibitors: a disproportionality analysis using the italian national network of pharmacovigilance database**  
*Convertino I., Capogrosso Sansone A., Galiulo M., Salvadori S., Pieroni S., Knezevic T., Mantarro S., Marino A., Hauben M., Blandizzi C., Tuccori M.*
- 14.50** **Interactions between vaccines against influenza and drugs for chronic diseases: the analysis of the Vaccine Adverse Event Reporting System (VAERS) and VigiBase**  
*Carnovale C., Raschi E., Poluzzi E., Leonardi L., Moretti U., Gentili M., De Ponti F., Clementi E., Radice S.*
- 15.00** **Preventability of non-steroidal anti-inflammatory drugs adverse drug reaction**  
*Cimmaruta D., Sessa M., Sportiello L., Mascolo A., Scavone C., Gallipoli S., Di Mauro G., Rafaniello C., Capuano A.*
- 15.10** **Long-term safety of deferiprone in children with beta-thalassaemia major: comparative data from large multi-centre perspective studies**  
*Felisi M.G., Botzenhardt S., Bonifazi F., Bejaoui M., Conte R., Cosmi C., Del Vecchio G.C., El-Beshlawy A., Filosa A., Kattamis A., Kreka M., Maggio A., Manfredi C., Origa R., Padula R., Putti M.C., Wong I., Neubert A., Bonifazi D., Ceci A.*


 Wednesday, October 25<sup>Th</sup>

- 15.20** **Intussusception rates before and after the introduction of rotarix: a single-centre observational study**  
*Mecchio A., Galfo F., Puliafito A., Menniti Ippolito F., Arrigo T., Impellizzeri P., Altavilla D.*
- 15.30** **Facilitation Of Reporting in hospital Ward (FORWARD): an active monitoring project to improve adverse drug reactions reporting**  
*Giardina C., Cutroneo P., Mocciaro E., Spina E., Arcoraci V.*
- 15.40** **Incidence of ticagrelor-related dyspnea leading to emergency department admission: a three year population based cohort-study**  
*Lombardi N., Lucenteforte E., Torrini M., Balzi D., Mugelli A., Vannacci A.*
- 15.50** **Mapping the global safety profile of sodium-glucose co-transporter-2 inhibitors: analysis of international spontaneous reporting systems (faers, who-vigibase, eudravigilance)**  
*Raschi E., Parisotto M., Forcesi E., La Placa M., Marchesini G., Poluzzi E., De Ponti F.*
- 16.00** **Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study**  
*Scavone C., Bertini M., Brusco S., Illiano M., Di Mauro G., Ruggiero R., Rafaniello C., Sportiello L., Rossi F., Capuano A.*
- 16.10** **DISCUSSION**

Wednesday, October 25<sup>Th</sup>

## SALA DELLA MARINA

## 14.30-16.30 ORAL COMMUNICATIONS

## ANTINEOPLASTIC DRUGS

Chairpersons: Carmela Fimognari (Bologna)-Simona Ronchetti (Perugia)

- 14.30**      **MicroRNA-574-5p modulates microsomal prostaglandin E synthase expression and prostaglandin E2 biosynthesis in A549 human lung carcinoma cells**  
*Contursi A., Saul M.J., Baumann I., Dovizio M., Tacconelli S., Korotkova M., Jakobsson P.J., Suess B., Steinhilber D., Patrignani P.*
- 14.40**      **Anticancer effects of novel LDH-A and GLUT-1 inhibitors on human pancreatic adenocarcinoma cells ASPC-1**  
*Citi V., Granchi C., Piragine E., Testai L., Breschi M.C., Minutolo F., Calderone V., Martelli A.*
- 14.50**      **Dual targeting of EPH-EPHRIN system and VEGFR inhibits tumor growth and increases survival in glioblastoma**  
*Giorgio C., Castelli R., Festuccia C., Vacondio F, Gravina G.L., Chiodelli P., Rusnati M., Lodola A., Barocelli E., Tognolini M.*
- 15.00**      **Key pathways and emerging players in human melanoma development and progression**  
*Panza E., Ianaro A., De Cicco P., Armogida C., Ercolano G., Cirino G.*
- 15.10**      **Glucocorticoid-induced leucine zipper (GILZ) regulates tumor development in a mouse model of CEBPA mutant acute myeloid leukemia**  
*Bereshchenko O., Flamini S., Sorcini D., Donnini S., Adamo F., Gagliardi A., Bruscoli S., Riccardi C.*
- 15.20**      **Annexin A1 contributes to pancreatic cancer cell phenotype, behaviour and metastatic potential independently of Formyl Peptide Receptor pathway**  
*Belvedere R., Bizzarro V., Parente L., Petrella A.*


 Wednesday, October 25<sup>Th</sup>

- 15.30**      **High density lipoproteins inhibit oxidative stress-induced prostate cancer cell proliferation**

*Gomaraschi M., Ruscica M., Botta M., Ferri N., Giorgio E., Macchi C., Franceschini G., Magni P., Calabresi L.*

- 15.40**      **Non thermal plasma as innovative anticancer strategy**

*Turrini E., Catanzaro E., Calcabrini C., Greco G., Stancampiano A., Simoncelli E., Laurita R., Gherardi M., Colombo V., Hrelia P., Fimognari C.*

- 15.50**      **Interaction between mPGES-1 and iNOS in the activation of stem-like phenotype in EGFR-driven epithelial tumor cells**

*Terzuoli E., Giachetti A., Ziche M., Donnini S.*

- 16.00**      **DISCUSSION**

Wednesday, October 25<sup>Th</sup>

## SALA DEL LEVATOIO

## 14.30-16.30 ORAL COMMUNICATIONS

## MISCELLANEOUS PHARMACOLOGY

Chairpersons: Orazio Cantoni (Urbino) - Marina Ziche (Siena)

## 14.30 Butyrate reduces valproate-induced hepatotoxicity, oxidative stress and mitochondrial dysfunction in HepG2 cell line

*Pirozzi C., Lama A., Di Guida F., Annunziata C., Nitrato Izzo A., Cavaliere G., Trinchese G., Russo R., Mollica M.P., Mattace Raso G., De Sarro G., Calignano A., Meli R.*

## 14.40 Sex-dependent role of leukotrienes in airway hyperreactivity and pulmonary inflammation in an experimental model of allergen sensitization

*Rossi A., Roviezzo F., Sorrentino R., Pinto A., Werz O., D'Agostino B., Cirino G., Sautebin L.*

## 14.50 Comparative pre-clinical study on the effects of apixaban and dabigatran on intestinal mucosa

*Benvenuti L., Fornai M., Antonioli L., Pellegrini C., Natale G., Fulceri F., Limanaqi F., Tirota E., Gentile D., Colucci R., Blandizzi C.*

## 15.00 Remodeling of atrial repolarization and atrial chamber deformation: a potential link in the development of atrial fibrillation?

*Sartiani L., Cameli M., Dini L., Mondillo S., Maccherini M., Le Grand B., Mugelli A., Cerbai E.*

 15.10 *In vitro* effects of mediators derived from porcine vascular stem cells on intestinal expression of cannabinoid and opioid receptors under inflammatory conditions

*Dothel G., Asteriti E., Mazzarella A., Bernardini C., Zannoni A., Forni M., De Ponti F.*

 15.20 Palmitoylethanolamide improves HIV-1 Tat-induced diarrhea acting through selective PPAR $\alpha$ -dependent inhibition of enteric glial cells activation

*Esposito G., Sarnelli G., Gigli S., Seguella L., Steardo L.*


 Wednesday, October 25<sup>Th</sup>

## 15.30 Insulin analogue glargine 300 U/mL and 100 U/mL: the same active principle with a higher concentration involves a reduced subcutaneous depot and a different insulin dissolution rate, determining an improved clinical-pharmacological drug profile

*Angelini J., Pani A., Nunnari P., Rucci F., Marino R., Scaglione F.*

## 15.40 The anti-inflammatory protein Annexin A1 as new pharmacological approach to counteract the deleterious effects of diet-induced metabolic derangements

*Chiazza F., Purvis G.S., Chen J., Martin L., Collotta D., Mastrocola R., Nigro D., Aragno M., Cutrin J.C., Yaqoob M.M., Fantozzi R., Solito E., Thiemermann C., Collino M.*

## 15.50 PCSK9 (proprotein convertase subtilisin/kexin type 9) deficiency reduces insulin secretion and promotes glucose intolerance: the role of the ldl receptor

*Balzarotti G., Ruscica M., Di Cairano E., Perego C., Catapano A.L., Norata G.D.*

## 16.00 DISCUSSION



SALA DELLA PIAZZA

8.30-10.30 **SYMPOSIUM**

**PHENOTYPING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): PHARMACOLOGICAL AND TOXICOLOGICAL IMPLICATIONS**

Chairpersons: *Patrizia Hrelia (Bologna) - Paolo Montuschi (Rome)*

**Exposome, genetic traits and functional enzymatic activities as risk factors for COPD**

*Patrizia Hrelia (Bologna)*

**Basic pharmacology of new bronchodilators**

*Maria Gabriella Matera (Naples)*

**Clinical COPD phenotypes**

*Riccardo Pistelli (Rome)*

**Personalised pharmacological treatment of COPD**

*Leonardo Fabbri (Modena)*

**Breathomics for assessing pharmacological treatment in COPD**

*Paolo Montuschi (Roma)*

10.30-12.30 **SYMPOSIUM**

**NEW APPROACHES TO THE INFLAMMATION PHARMACOLOGY**

Chairpersons: *Salvatore Cuzzocrea (Messina) - Carlo Riccardi (Perugia)*

**Glucocorticoid and B lymphocytes function: role of glucocorticoid-induced leucine zipper (GILZ)**

*Stefano Bruscoli (Perugia)*

**Nuclear factor erythroid 2-related factor 2 (Nrf2) as a promising target for neuroinflammation**

*Emanuela Esposito (Messina)*

**Functional intestinal dysmotility associated with metabolic and neurological disorders: is enteric inflammation the common root?**

*Corrado Blandizzi (Pisa)*

**Nociceptin/orphanin FQ (N/OFQ) could represent a novel target for airway inflammation treatment**

*Bruno D'Agostino (Naples)*

**Rationale for blocking the JAK-STAT pathway in rheumatic disorder**

*Pier Luigi Meroni (Milan)*



SALA DELLA PIAZZA

12.30-13.00 **LECTURE**

*Introduced by: Carlo Riccardi (Perugia)*

**INHIBIT ACTIVATION OF MAST CELLS AND EOSINOPHILS TO TREAT ALLERGIC DISEASES: THE CLUSTER OF DIFFERENTIATION 48 (CD48) STORY**

*Francesca Levi-Schaffer (Jerusalem - Israel)*

14.00-16.00 **ROUND TABLE**

**MANAGEMENT OF CRITICAL CONDITIONS: THE DRUG-DEVICE INTERACTIONS**

*Chairperson & Opening: Renato Bernardini (Catania)*

*Discussants:*

*Claudio Borghi (Bologna)*

*Roberto Di Bartolomeo (Bologna)*

*Massimo Maria Gaetano Di Muzio (Ancona)*

*Diego Mazzatenta (Bologna)*

*Maria Rita Melotti (Bologna)*

*Livio Presutti (Modena)*

*Andrea Stella (Bologna)*



SALA DELLA PIAZZA

16.00-17.00 **PLENARY LECTURE**

*Introduced by: Alessandro Mugelli (Florence)*

**ADVANCED THERAPIES FOR THE TREATMENT OF RARE GENETIC DISEASES**

*Alessandro Aiuti (Milano)*



17.00-19.00 **SYMPOSIUM**

**EMERGING EPIGENETIC STRATEGIES IN PHARMACOLOGICAL THERAPY**

*Chairpersons: Lucio Annunziato (Naples) - Patrizia Romualdi (Bologna)*

**Epigenetic regulation of apoptosis and inflammation in brain ischemia**

*Marina Pizzi (Brescia)*

**Epigenetic Regulation of NCXs (sodium-calcium exchanger) Expression As A Pharmacological Strategy To Intervene In Stroke**

*Luigi Formisano (Naples)*

**Stress, Epigenetic Changes and Vulnerability to Psychiatric Disorders**

*Marco Riva (Milan)*

**Do mood stabilizers interfere with epigenetics? Focus on the role of microRNAs (miRNAs) in the mechanism of action of lithium**

*Alessio Squassina (Cagliari)*

**Addictive drugs and epigenetic regulation at opioid gene promoters in the rat brain reward circuitry**

*Francesca Felicia Caputi (Bologna)*

**microRNA (miRNA) deregulation as novel clinical biomarkers in gastrointestinal stromal tumors (GIST)**

*Sabrina Angelini (Bologna)*

19.00-21.00 **POSTER SESSION**



SALA DEL TEMPIO 1

8.30-10.30 **SYMPOSIUM**

**HEART FAILURE: DIFFERENT APPROACHES TO THE SAME PROBLEM**

*Chairpersons: Elisabetta Cerbai (Florence) - Francesco Rossi (Naples)*

**Endogenous cardiac regeneration: identification of the true cardiac stem cells**

*Daniele Torella (Catanzaro)*

**Mechanotransduction in cardiovascular physiology and pathology**

*Antonio Paolo Beltrami (Udine)*

**Microvascular dysfunction in acute coronary syndromes and heart failure: what is essential is invisible to the eye?**

*Domenico D'Amario (Rome)*

**Treatment of heart failure with preserved ejection fraction (HFpEF): an unresolved enigma**

*Konrad Urbanek (Naples)*

**Cachexia and heart failure: metabolic reprogramming to counteract skeletal muscle impairment**

*Elisabetta Ferraro (Rome)*

**Late sodium current inhibitors to prevent disease progression in hypertrophic cardiomyopathy**

*Raffaele Coppini (Florence)*

10.30-12.00 **ROUND TABLE**

**VACCINES, VACCINATIONS IN ETHICAL AND RESPONSIBLE COMMUNITY**

*Chairpersons & Opening: Giorgio Cantelli Forti (Bologna) - Fausto Francia (Bologna)*

*Discussants:*

*Anna Rosa Marra (Rome)*

*Caterina Rizzo (Rome)*

*Sergio Venturi (Bologna)*

*Alberto Villani (Rome)*

*Massimo Visentin (Rome)*

12.00-12.30 **LECTURE**

*Introduced by: Teresita Mazzei (Firenze)*

**ANTIBIOTICS RESISTANCE**

*Tommaso Giani (Siena)*



SALA DEL TEMPIO 1

12.30-13.00 **LECTURE**

*Introduced by: Tullio Florio (Genova)*

**ADVANCES IN URO-ONCOLOGY: NOVEL TKIS IN KIDNEY CANCER**

*Giario Conti (Como)*

14.00-15.00 **MINISYMPOSIUM**

**PHARMACOLOGICAL CONTROL OF TUMOR NECROSIS FACTOR (TNF) IN IMMUNOMEDIATED INFLAMMATORY DISEASES (IMID): THE VALUE OF ADALIMUMAB**

*Chairperson: Carmelo Scarpignato (Parma)*

**Pharmacological modulation of TNF in IMID: quality and safety profile**

*Corrado Blandizzi (Pisa)*

**Adalimumab value in adult IMID**

*Ennio Giulio Favalli (Milan)*

**Adalimumab value in child IMID**

*Anna Belloni Fortina (Padova)*

*This Minisymposium was sponsored by ABBVIE*

15.00-16.00 **MINISYMPOSIUM**

**INNOVATION OF MECHANISM OF ACTION IN ONCOLOGY**

*Chairperson: Pier Luigi Canonico (Novara)*

**NSCLC: Mechanism of Action of ALK inhibitors and 2nd generation**

**Immunotherapies**

*Romano Danesi (Pisa)*

**NSCLC updates on ALK inhibitors and 2nd generation immunotherapies clinical data**

*Federico Cappuzzo (Ravenna)*

*This Minisymposium was sponsored by ROCHE*



SALA DEL TEMPIO 1

17.00-18.30 **SYMPOSIUM**

**STUDY, DEVELOPMENT AND RATIONALE USE OF IMMUNOPHARMACOLOGICAL AGENTS**

*Chairpersons: Giuseppe Cirino (Naples) - Pasquale Maffia (Glasgow - UK)*

**Inhibitory receptors activation by antibodies on cancer cells:**

**A new immunopharmacological weapon in our arsenal?**

*Francesca Levi-Schaffer (Jerusalem - Israel)*

**The emotional side of autoimmune disorders: a new venue for treatment?**

*Fulvio D'Acquisto (London - UK)*

**Towards a stratified targeted approach with biologic therapies in rheumatoid arthritis**

*Costantino Pitzalis (London - UK)*

**Glucocorticoi-Induced Leucine Zipper (GILZ) as a mediator of Anti-inflammatory Effects of Glucocorticoids**

*Carlo Riccardi (Perugia)*

18.30-19.00 **COLLEGIO NAZIONALE DEI FARMACOLOGI UNIVERSITARI GENERAL ASSEMBLY**



Thursday, October 26<sup>Th</sup>

## SALA DEL TEMPIO 2

8.30-10.30 **SYMPOSIUM****THE FUTURE OF PHARMACOVIGILANCE AND THE ROLE OF RISK COMMUNICATION***Chairpersons: Annalisa Capuano (Naples) - Anna Rosa Marra (Rome) - Edoardo Spina (Messina)***Current roles of patients in Pharmacovigilance activities: regulatory perspective***Laura Sottosanti (Rome)***Frontiers in signal detection: from spontaneous reporting to big data and social media***Roberto Leone (Verona)***The Future of Pharmacovigilance: how to measure the efficacy and effectiveness of some pharmacovigilance processes with the aim of improving them***Concetta Rafaniello (Naples)***Pharmacovigilance and Pharmacogenetics: critique and ways forward***Emilio Clementi (Milan)***Introduction on Risk Communication: why now, what next?***Marco Tuccori (Pisa)***Experience of risk communication around the world***Paula Alvarado (Uppsala, Sweden)*

ECM SESSION

Thursday, October 26<sup>Th</sup>

## SALA DEL TEMPIO 2

11.00-13.00 **SYMPOSIUM****CURRENT TOPICS AND PERSPECTIVES OF PRECISION THERAPY IN ONCOLOGY***Chairpersons: Maria Francesca Cometa (Rome) - Nicola Normanno (Naples) - Gianni Sava (Trieste)***New perspectives of tumour immunotherapy***Romano Danesi (Pisa)***Precision therapy in oncology: the example of colon carcinoma***Enrico Mini (Florence)***Precision therapy in oncology: the example of lung cancer***Francesco Grossi (Genoa)***Inter-individual variability of the therapeutic response: genotype and phenotype role***Giuseppe Toffoli (Aviano)***Adverse events in the era of precision medicine***Sabrina Angelini (Bologna)*

ECM SESSION

Thursday, October 26<sup>Th</sup>

SALA DEL TEMPIO 2

**14.00-15.30 ROUND TABLE**

**PRECISION-PERSONALIZED (P-P) MEDICINE: UNDERSTANDING HEALTH AND SUSTAINABILITY IMPACT**

*Chairperson & Opening: Nello Martini (Verona)*

*Key note addresses:*

*Domenico Motola (Bologna)*

*Francesca Di Giuseppe (Rome)*

*Discussants:*

*Armando Genazzani (Novara)*

*Maurizio Grossi (Rimini)*

*Paolo Marchetti (Rome)*

*Nicola Normanno (Naples)*

*Antonella Pedrini (Bologna)*

**15.30-16.00 LECTURE**

*Introduced by: Giorgio Cantelli Forti (Bologna)*

**THE PHARMACOLOGY OF THE FUTURE: "IN VIVO VERITAS, IN VITRO DOLO" THE CHALLENGES OF CNS DRUG DISCOVERY**

*Sam Enna (Kansas City - USA)*



Thursday, October 26<sup>Th</sup>

SALA DEL TEMPIO 2

**17.00-19.00 SYMPOSIUM**

**PSYCHIATRIC VULNERABILITY OF THE DEVELOPING BRAIN: SUGGESTIONS FROM ANIMAL MODELS AND CRITICAL TIME WINDOWS FOR PHARMACOLOGICAL INTERVENTION**

*Chairpersons: Tiziana Rubino (Busto Arsizio) - Viviana Trezza (Rome)*

**Exposure to childhood maltreatment and cocaine-abuse: from the preclinical model to clinical research**

*Valeria Carola (Rome)*

**Nutritional omega-3 deficiency starting at adolescence impairs synaptic plasticity and emotional behavior at adulthood: implication of the metabotropic glutamate receptor 5 (mGluR5)-endocannabinoid signaling complex**

*Antonia Manduca (Marseille - France)*

**Role of the endocannabinoid system in adolescent brain maturation: from physiology to pathology**

*Pamela Prini (Busto Arsizio)*

**Adolescent exposure to cocaine impairs cognitive abilities and emotional response in the developing rat: focus on neuroplastic mechanisms**

*Lucia Caffino (Milan)*



Thursday, October 26<sup>Th</sup>

SALA DEL PARCO



**8.30-10.30 SYMPOSIUM**

**TRANSLATIONAL STRATEGY FOR ASSESSING NEW MECHANISMS FOR THE DEVELOPMENT OF INNOVATIVE THERAPEUTIC APPROACH IN PSYCHIATRIC DISORDERS**

*Chairpersons: Myriam Melis (Cagliari) - Vincenzo Micale (Catania)*

**Role of the endocannabinoid system in spatial learning**

*Carsten T. Wotjak (Munich - Germany)*

**Vesicular glutamate transporter as circuit-based therapeutic target for depression: evidence from a gender-oriented animal model**

*Anna Brancato (Palermo)*

**A precision medicine genetic marker for core cognitive deficits in schizophrenia**

*Francesco Papaleo (Genoa)*

**The Neurosteroidogenic Enzyme 5 $\alpha$ -Reductase Mediates Psychotic-Like Complications of Sleep Deprivation**

*Roberto Frau (Cagliari)*

**Early modulation of the endocannabinoid tone prevents the onset of a schizophrenia-like phenotype**

*Tibor Stark (Brno-Czech Republic)*

**Epigenetic regulation of CNR1 gene in schizophrenia**

*Claudio D'Addario (Teramo)*

**From single synapses to clinical studies. Therapeutic developments from optogenetics**

*Antonello Bonci (Baltimore - USA)*



Thursday, October 26<sup>Th</sup>

SALA DEL PARCO



**11.00-13.00 SYMPOSIUM SIF-SIN**

**#NEUROLOGYTOUR "INNOVATION IN NEUROLOGICAL DISORDERS THERAPIES AND NEUROPROTECTION"**

*Opening: Andrea Tarozzi (Rimini)*

*Chairpersons: Alessandro Mugelli (Florence) - Leandro Provinciali (Ancona)*

**Innovation and economic stagnation: challenges for the National Health Service (NHS) governante**

*Federico Spandonaro (Rome)*

**Present and future challenges in neurology**

*Leandro Provinciali (Ancona)*

**Round table: Challenges and innovation in the management of neurological disorders**

*Chairperson: Helga Cossu (Rome)*

*Discussants: G. Cantelli Forti (Bologna), P. De Carolis (Bologna), A. Mugelli (Florence), M. Di Luca (Milan), L. Provinciali (Ancona), P. Popoli (Rome), F. Spandonaro (Rome)*

Thursday, October 26<sup>Th</sup>

## SALA DEL PARCO

## 14.00-16.00 SYMPOSIUM

**ON THE BRIGHT AND THE DARK SIDE OF AMYLOID BETA: LOOKING OVER ALZHEIMER'S DISEAS***Chairpersons & Opening: Vincenzo Cuomo (Rome)- Luigia Trabace (Foggia)***β-Amyloid and cell cycle activation in Alzheimer's disease: perspectives for drug development***Filippo Caraci (Catania)***Neuroinflammation and Alzheimer's disease: towards multi-target therapies***Claudia Balducci (Milan)***Soluble beta amyloid as bridge between Depression and Alzheimer's disease: evidences from an animal model***Maria Grazia Morgese (Foggia)***Targeting pathologic amyloid without perturbing amyloid physiological activity***Stefano Govoni (Pavia)*

## 17.00-18.30 ROUND TABLE

**CLINICAL RESEARCH, ETHICS COMMITTEES AND THE NEW EUROPEAN CLINICAL TRIALS REGULATION***Chairpersons: Alessandro Mugelli (Florence) - Marco Scatigna (Milan)**Discussants:**Maurizio Agostini (Rome)**Laura Canavacci (Florence)**Fabrizio De Ponti (Bologna)**Sandra Petraglia (Rome)**Patrizia Popoli (Rome)*Thursday, October 26<sup>Th</sup>

## SALA DEL BORGO

## 8.30-9.30 ORAL COMMUNICATIONS

**TO SWITCH OR NOT TO SWITCH: THE ROLE OF EXCITATORY AND INHIBITORY GABA TRANSMISSION IN PATHOLOGICAL AND PHYSIOLOGICAL CONDITIONS***Chairpersons: Flavia Antonucci (Milan) - Davide Pozzi (Milan)*8.30 **ATM inhibition as innovative strategy to enhance KCC2 expression and promote GABAergic development***Antonucci F., Pizzamiglio L., Focchi E., Menna E.*8.40 **KCC2 is a key target of oxytocin in the first-postnatal life and is potentially involved in the pathogenesis of neurodevelopmental disorders***Busnelli M., Leonzino M., Antonucci F., Verderio C., Mazzanti M., Chini B.*8.50 **Intracellular chloride accumulation impairs GABAergic signaling and memory in Down syndrome***Contestabile A., Parrini M., Naskar S., Alberti M., Colombi I., Pasquale V., Chiappalone M., Ronzitti G., Mingozi F., Cancedda L.*9.00 **Role of the inflammation in the control of the GABA switch in cultured hippocampal neurons***Pozzi D., Desiato G., Mirabella F., Filipello F., Matteoli M.*9.10 **DISCUSSION**

Thursday, October 26<sup>Th</sup>

## SALA DEL BORGO

9.30-10.30 **MINISYMPOSIUM****ADVANCES IN MULTIPLE SCLEROSIS***Chairperson: Maria Angela Sortino (Catania)***Neuroimmunology of Multiple Sclerosis (MS):  
focus on B cell target therapy***Luca Massacesi (Florence)**This Minisymposium was sponsored by ROCHE*11.00-11.30 **LECTURE***Introduced by: Armando Genazzani (Novara)***GOUT 2017: NEW THERAPEUTIC OPPORTUNITIES***Renato Bernardini (Catania)**This Lecture was sponsored by GRUNENTHAL*11.30-12.00 **LECTURE***Introduced by: Francesco Rossi (Naples)***PROTON PUMP INHIBITORS 25 YEARS LATER: USE AND MISUSE***Carmelo Scarpignato (Parma)**This Lecture was sponsored by TAKEDA*Thursday, October 26<sup>Th</sup>

## SALA DEL BORGO

12.00-12.30 **LECTURE***Introduced by: Amelia Filippelli (Salerno)***AN UPDATE ON GENE SILENCING***Danilo Norata (Milan)*12.30-13.00 **MINISYMPOSIUM****TYPE 2 DIABETES: GLYCEMIC CONTROL AND INNOVATION THERAPY***Chairpersons: Achille Patrizio Caputi (Messina)***Glycemic control in type 2 Diabetes: clinical benefit and barriers to  
insulin intensification***Giorgio Sesti (Catanzaro)***A new combination therapy for type 2 Diabetes: Basal insulin plus GLP-  
1 receptor agonists, from physiopathology to synergy of actions***Giovambattista De Sarro (Catanzaro)**This Minisymposium was sponsored by NOVO NORDISK*



Thursday, October 26<sup>Th</sup>

## SALA DEL BORGO

14.00-16.00 **JOINT SYMPOSIUM SID-SIC**

CLINICAL AND EXPERIMENTAL ASPECTS OF NOVEL ANTIDIABETIC THERAPIES. FROM THE GUT AND THE KIDNEY TOWARDS THE CARDIOVASCULAR SYSTEM:  
THE LAST TEN YEARS OF THE ANTIDIABETIC DRUGS.

Chairpersons: Alessandro Mugelli (Florence) - Francesco Rossi (Naples)

**The point of view of the diabetologist**

Angelo Avogaro (Padova)

**The point of view of the cardiologist**

Pasquale Perrone Filardi (Naples)

**A matter of safety?**

Annalisa Capuano (Naples)

**The EMPAREG-OUTCOME study and the dilemma of the cardiovascular protection**

Edoardo Mannucci (Florence)

**What the research tells us: mechanistic hypotheses of empaglifozin protection**

Raffaele Coppini (Florence)

**Wrap-up/conclusion**

Giorgio Sesti (Catanzaro)



ECM SESSION

Thursday, October 26<sup>Th</sup>

## SALA DEL BORGO

17.00-18.30 **"GIAMPAOLO VELO" SYMPOSIUM**

THE CLINICAL EVOLUTION OF PHARMACOLOGY

Chairpersons: Annalisa Capuano (Naples) - Giorgio Minotti (Rome)

**The role of clinical research in National Health Service: opportunities and Challenges**

Carlo Nicora (Bergamo)

**Clinical pharmacology and entrepreneurship**

Loredana Bergamini (Milan)

**The job of a consultant clinical pharmacologist**

Carmelo Scarpignato (Parma)

**The role of clinical pharmacologist in treatment personalization**

Emilio Clementi (Milan)

**The clinical pharmacologist and new concepts in patient stratification**

Romano Danesi (Pisa)

**The clinical pharmacologist and clinical research**

Gualberto Gussoni (Rome) - Roberto Leone (Verona)

18.30-19.00 **CLINICAL PHARMACOLOGY SECTION GENERAL ASSEMBLY**

Thursday, October 26<sup>Th</sup>

## SALA DELLA MARINA

## 8.30-10.30 SYMPOSIUM

**STRESS-INDUCED PSYCHOPATHOLOGIES: MOLECULAR MARKERS OF VULNERABILITY AND NOVEL PHARMACOLOGICAL TARGETS***Chairpersons: Raffaella Molteni (Milan) - Luigia Trabace (Foggia)***Correlation between long-lasting psychosocial stress and adipose tissues in the rat: alteration of adipogenesis, cannabinoid systems and oxidative stress***Giulia Maria Camerino (Bari)***Impact of different stress intensities on cognition and emotion: a focus on endocannabinoids***Maria Morena (Calgary - Canada)***Involvement of the glutamatergic system in the activation of local protein synthesis during a cognitive performance: influence of chronic stress exposure***Francesca Calabrese (Milan)***Early blood brain barrier dysfunctions in the social isolation rat model of psychosis: relation to sodium-calcium exchanger (NOX)-derived oxidative stress***Stefania Schiavone (Foggia)***Maladaptive plasticity induced by acute/chronic stress and glutamate-based drug treatment approaches***Maurizio Popoli (Milan)***Corticotropin-releasing hormone receptor 1 (CRF1) antagonists as novel pharmacological treatment for bingeing-related eating disorders***Carlo Cifani (Camerino)*Thursday, October 26<sup>Th</sup>

## SALA DELLA MARINA

## 11.00-13.00 JOINT SYMPOSIUM SIF-SITOX-SINUT

**NUTRACEUTICAL COMPOUNDS: CURRENT AND FUTURE PERSPECTIVES***Chairpersons: Patrizia Hrelia (Bologna) - Marina Ziche (Siena)***Nutrients: when are they marketed as medicinal products or food supplements?***Paola Minghetti (Milan)***Biochemical mechanisms of nutraceutical compounds: more than antioxidants***Silvana Hrelia (Bologna)***Nutraceuticals pre-clinical research***Gioacchino Calapai (Messina)***Clinical research applied to nutraceuticals***Arrigo F. G. Cicero (Bologna)***Adverse reactions to botanicals used as such or as ingredients of food supplements***Patrizia Restani (Milan)*

## 14.00-16.00 SYMPOSIUM

**CLINICAL PERSPECTIVES OF NUTRACEUTICALS***Chairpersons: Arrigo F. G. Cicero (Bologna) - Giorgio Racagni (Milan)***Nutraceutical, microbiota and central nervous system***Ferdinando Nicoletti (Rome)***Nutraceuticals and gastro-intestinal inflammation***Mario Dell'Agli (Milan)***Nutraceutical and cardiovascular functionality***Giovambattista Desideri (L'Aquila)***Sport and Dietary supplements: efficacy, safety and doping risk***Francesca Maffei (Rimini)***Botanicals and vigilance***Annabella Vitalone (Rome)*

Thursday, October 26<sup>Th</sup>

## SALA DELLA MARINA



## 17.00-18.00 SYMPOSIUM

**EFFECTIVENESS AND SAFETY OF DIRECT ORAL ANTICOAGULANTS  
IN CLINICAL PRACTICE: COMPARISON OF VIEWPOINTS***Chairpersons: Achille Patrizio Caputi (Messina) - Domenico Motola (Bologna)***The introduction of new oral anticoagulants in clinical practice;  
Benefits, Risks and Sustainability**  
*Anna Maria Marata (Bologna)***Prescriptive appropriateness of DOACs: Italian real world data**  
*Gianluca Trifirò (Messina)***The added value of new oral anticoagulants in the management of  
atrial fibrillation and venous thromboembolism**  
*Letizia Riva (Bologna)*Thursday, October 26<sup>Th</sup>

## SALA DELLA MARINA

## 18.00-19.00 ORAL COMMUNICATIONS

**CARDIOVASCULAR PHARMACOLOGY I***Chairpersons: Salvatore Amoroso (Ancona) - Marina Camera (Milan)*

- 18.00** **Protective effect of ndp- $\alpha$ -msh on heart, spleen and liver, via the vagus nerve and JAK/ERK/STAT signaling, in myocardial ischemia in rats**  
*Canalini F., Ottani A., Vandini E., Calevro A., Bitto A., Squadrito F., Giuliani D., Guarini S.*
- 18.10** **Pivotal role of NCX1 in glutamate-enhanced ATP synthesis and of cell survival in rat heart-derived H9c2 myoblasts exposed to hypoxia/reoxygenation injury**  
*Magi S., Maiolino M., Castaldo P., Lariccia V., Piccirillo S., Amoroso S.*
- 18.20** **Activation of AMPK/SIRT-1 axis is required for protective effects of adiponectin on myocardial ischemia-reperfusion (i/r) injury in rat hearts**  
*Potenza M.A., Sgarra L., Nacci V., De Salvia M.A., Montagnani M.*
- 18.30** **Sphingosine 1-phosphate and atherosclerosis: new evidence from transgenic animal models**  
*Potì F., Buckhardt R., Giva L.B., Mancini T., Simoni M., Nofer J.R.*
- 18.40** **Shedding light on PCSK9 function: a new role as a co-activator of platelet reactivity**  
*Rossetti L., Camera M., Ferri N., Marchianò S., Canciani B., Trabattoni D., Santilli F., Davì G., Tremoli E.*
- 18.50** **DISCUSSION**

Thursday, October 26<sup>Th</sup>

## SALA DEL LEVATOIO

## 8.30-10.30 ORAL COMMUNICATIONS

## INFLAMMATION PHARMACOLOGY

Chairpersons: Emira Maria Ayroldi (Perugia) - Francesca Levi-Schaffer (Jerusalem - Israel)

## 8.30 The bile acid receptor GPBAR1 regulates M1/M2 phenotype of intestinal macrophage and its activation rescues from murine colitis

Biagioli M., Carino A., Cipriani S., Francisci D., Marchianò S., Scarpelli P., Sorcini D., Zampella A., Fiorucci S.

 8.40 A role for fibroblast growth factor-2 (FGF-2) in the anti-inflammatory effect mediated by A<sub>2a</sub> receptor activation, *in vivo*

Caiazzo E., Ialenti A., Cicala C.

## 8.50 Effects of a co-micronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia

Cordaro M., Impellizzeri D., Siracusa R., Gugliandolo E., Fusco R., Inferrera A., Esposito E., Di Paola R., Cuzzocrea S.

 9.00 Platelet-derived microparticles of obese individuals induce endothelial-to-mesenchymal transition and produce higher levels of thromboxane A<sub>2</sub>: a possible mechanism in obesity-driven tumorigenesis

Dovizio M., Grande R., Fullone R., Schiavone S., Tacconelli S., Marchisio M., Lanuti P., Caprodossi A., Mingrone G., Patrignani P.

## 9.10 VEGF exacerbates damage induced by high-glucose in human retinal endothelial cells

Giuridanella G., Bucolo C., Lazzara F., Salomone S., Drago F.

## 9.20 Lack of the NLRP3 inflammasome improves mice recovery following traumatic brain injury

Irrera N., Pizzino G., Pallio G., Mannino F., Arcoraci V., Minutoli L., Squadrito F., Giuliani D., Guarini S., Altavilla D., Bitto A.

## 9.30 A novel interaction between glucocorticoid receptor and beta-arrestin proteins

Petrillo M.G., Cidlowski J.A.

## 9.40 Megalin and Sodium-Hydrogen Exchanger (NHE)3 modulation participate to the beneficial effect of JNJ39758979 in diabetic nephropathy

Rosa A.C., Pini A., Grange C., Catarinicchia S., Argenziano M., Camussi G., Chazot P.L., Thurmond R.

 9.50 Alpha-Lipoic Acid, But Not Dihydrolipoic Acid, Activates Nrf2 Pathway in TNF- $\alpha$ -Challenged HUVECs

Speciale A., Fratantonio D., Bashllari R., Muscarà C., Molonia M.S., Virgili F., Saija A., Cimino F.

## 10.00 DISCUSSION


 Thursday, October 26<sup>Th</sup>

## SALA DEL LEVATOIO

## 14.00-15.00 SYMPOSIUM

## FROM URATE DEPOSITION TO CV RISK: THE ROLE OF THE XANTHINE-OXIDASE MODULATION

Chairperson: Franco Bernini (Parma) - Giorgio Cantelli Forti (Bologna)

## Which are the aspects of pharmacological relevance?

Giuseppe Cirino (Naples)

## What is the clinical evidence?

Claudio Borghi (Bologna)

## 15.00-16.00 ROUND TABLE

## PROBLEMS RELATED TO THE USE OF MEDICINES IN DEVELOPING COUNTRIES

Chairpersons &amp; Opening: Orazio Cantoni (Urbino) - Marina Ziche (Siena)

## Discussants:

Piero Abbruzzese (Torino)

Orazio Cantoni (Urbino)

Giuseppe Nubile (Chieti)

Marina Ziche (Siena)



ECM SESSION

**Thursday, October 26<sup>th</sup>**
**SALA DEL LEVATOIO**
**17.00-19.00 ORAL COMMUNICATIONS**  
**NEUROPHARMACOLOGY I**

Chairpersons: James Barrett (Philadelphia - USA), Walter Fratta (Cagliari), Luca Steardo (Rome)

**17.00** Molecular basis of adenosine A<sub>3</sub> receptor-mediated analgesic effect: an *in vitro* electrophysiological study on isolated rat dorsal root ganglion neurons  
 Coppi E., Fusco I., Pedata F., Pugliese A.M.

**17.10** Chronic treatment with fluoxetine induces sex-dependent analgesic effects and modulates HDAC2 and mGlu2 expression in female mice  
 Chiechio S., Zammataro M., Merlo S., Barresi M., Parenti C., Hu H., Sortino M.A.

**17.20** Dimethyl fumarate reduces tactile allodynia in a gender dependent manner in two different models of peripheral neuropathic pain  
 Luongo L., Boccella S., Guida F., De Gregorio D., Mazzitelli M., De Novellis V., Maione S.

**17.30** Buspirone rescues MK-801-induced disruption of prepulse inhibition and temporal order recognition in mice: A repositioning approach  
 Torrisi S.A., Leggio G.M., Geraci F., Maurel O.M., Caraci F., Bucolo C., Drago F., Salomone S.

**17.40** The acetylcholinesterase donepezil differently affects the expression of the α7 nicotinic receptor, CHRNA7, and its human-restricted duplicated form, CHRFA7A: implications in the «Cholinergic anti-inflammatory pathway» activation in Alzheimer's disease  
 Benfante R., Di Iascio S., Maroli A., Cardani S., Locati M., Drufulca L., Fornasari D.

**17.50** Mechanism of hydrogen sulfide against progression of severe Alzheimer's disease  
 Calevro A., Canalini F., Ottani A., Vandini E., Giuliani D., Guarini S.

**18.00** Neuroprotective effect of caffeic acid phenethyl ester on mice model of Alzheimer's disease involves NRF2/ARE signaling pathway  
 Morroni F., Sita G., Graziosi A., Tarozzi A., Hrelia P.

**18.10** Real-time monitoring of MPTP-induced changes of striatal oxygen, glucose, lactate and movement in freely moving rats  
 Bazzu G., Rocchitta G., Carta S., Migheli R., Peana A.T.

**18.20 DISCUSSION**
**Friday, October 27<sup>th</sup>**
**SALA DELLA PIAZZA**
**10.30-11.30 SYMPOSIUM**
**APPROPRIATE USE OF OPIATES AND RISK OF ABUSE LIABILITY**

Chairpersons: Daniela Parolaro (Busto Arsizio) - Paola Sacerdote (Milan)

**Molecular mechanisms and rationale for opioid utilization in chronic pain therapy**  
 Patrizia Romualdi (Bologna)

**Opioid medications: indispensable to alleviate human suffering. Accessible and not unduly restricted**  
 Diego Fornasari (Milan)

**The position of the Italian Society of Pharmacology and the Italian situation**  
 Guido Mannaioni (Florence)


**11.30-12.30 SYMPOSIUM**
**EFFICACY, SAFETY AND EFFECTIVENESS OF ISGLT2 (SODIUM GLUCOSE CO-TRANSPORTER TYPE 2 INHIBITOR): CURRENT AND FUTURE ROLE**

Chairpersons: Nicoletta Brunello (Modena) - Pier Luigi Canonico (Novara)

**Efficacy and Safety of iSGLT2**  
 Domenico Mannino (Reggio Calabria)

**Effectiveness of iSGLT2 and iDPP4**  
 Gianluca Aimaretti (Novara)

**Current use of SGLT2: comparing Italy versus EU**  
 Gianluca Trifirò (Messina)


**12.30-13.30 PLENARY LECTURE**

Introduced by: Monica Di Luca (Milan)

**NEURO-GLIA METABOLIC COUPLING: ROLE IN NEURONAL PLASTICITY, NEUROPROTECTION AND FUNCTIONAL IMAGING**

Pierre Magistretti (Lausanne -Switzerland)



Friday, October 27<sup>th</sup>

## SALA DELLA PIAZZA

## SESSION I

**14.30-16.10** **ROLE OF THE “REAL WORLD EVIDENCE” IN THE ITALIAN GOVERNANCE**
*Chairperson: Patrizia Popoli (Rome)*
**14.30** **Bullet point of the document “Real World Data e Real World Evidence: considerations and proposals from a network of scientific societies”**  
*Giovanni Corrao (Milan)*
**14.40** **Collection and analysis of real world data for a better governance: considerations on the document from scientific societies**  
*Andrea Mandelli (Rome), Laura Bianconi (Rome), Lucio Romano (Rome)*
**15.00** **ROUND TABLE**  
**The Real World Evidence in the regulatory decisions for a better management of citizen’s health: the point of view of institutions, scientific societies and citizens**  
*Chairpersons: Francesco Rossi (Naples), Alessandro Mugelli (Florence)*
*Discussants: Sandra Petraglia (Rome), Francesca Moccia (Rome), Giovanni Corrao (Milan), Leandro Provinciali (Ancona), Nello Martini (Legnago)*
**15.50** **CONCLUSIONS**  
**Real World Evidence e real world data in the digital healthcare system: future perspectives**  
*Patrizia Popoli (Rome)*

## SESSION II

**16.10-17.20** **RANDOMIZED CLINICAL TRIALS: THE NEED OF DATA AND INTEGRATIVE SOURCES**
*Chairpersons: Marcello Pani (Pisa) - Andrea Pizzini (Rome)*
**16.10** **Real World Evidence: innovation and sustainability**  
*Anna Maria Porrini (Rome)*
**16.25** **New anticoagulant drugs: more lights than shadows?**  
*Giancarlo Agnelli (Perugia)*
**16.40** **The Real World Evidence in the health technology assessment (HTA) in Italy**  
*Luca Frassinetti (Forlì)*

 Friday, October 27<sup>th</sup>
**16.55** **The importance of post authorisation safety study (PASS) and post-authorisation efficacy study (PAES) in the evidences generation**  
*Carmela Macchiarulo (Rome)*
**17.10** **DISCUSSION**

## SESSION III

**17.20-18.10** **EXPERIENCES IN RWE**
*Chairpersons: Andrea Pierini (Milan) - Elena Paola Lanati (Milan)*
**17.20** **The E.Pic.A Study “Economic appropriateness in the integrative care path”**  
*Mattia Altini (Meldola)*  
*Exchange of opinions: Claudio Zamagni (Bologna), Luca Frassinetti (Forlì)*
**17.50** **The European experience in pediatry**  
*Gianluca Trifirò (Messina)*  
*Exchange of opinions: Emilio Clementi (Milan)*
**18.10-18.30** **CONCLUSION**  
**Future perspectives for the real words evidence: what could we expect from the scientific societies’ report?**  
*Alessandro Mugelli (Firenze)*
**18.30-20.00** **SIF GENERAL ASSEMBLY**

## AWARDS AND GRANTS CEREMONY

- “Giampaolo Velo” Grants
- SIF-Otsuka Grants
- “Alberico Benedicenti” Awards
- SIF - “Fondazione Gianfranco Ferro” Grants
- SIF 2017 Lifetime Achievement Award

Friday, October 27<sup>th</sup>

## SALA DEL TEMPIO 1

**8.30-11.00 SYMPOSIUM**
**NEW DIRECTIONS IN ORPHAN DRUGS FOR RARE DISEASES: FROM CLINICAL TRIALS TO REGULATORY PATHS**

 Chairpersons: *Liberato Berrino (Naples), Annamaria De Luca (Bari)*
*Part I: An update on regulatory issues /clinical trial/post marketing surveillance*
**Innovation in orphan drugs: the regulatory path in Italy**
*Patrizia Popoli (Rome)*
**Clinical Research of drugs for rare disease: Issues and open questions**
*Marco Scatigna (Milan)*
**Orphan drugs: post-marketing surveillance in Italy**
*Annalisa Capuano (Naples)*
*Part II: A focus on the access to cure of "rare" patients. The role of local Ethical Committees and regional networks*
**Ethics Committees and orphan drugs: Role and competence of the Ethical Committee for the human clinical investigations in orphan drugs development: procedures for pre-licencing access to the cure of rare diseases**
*Domenico Tricarico (Bari)*
**The role of regional coordination networks in patients management and access to therapies**
*Giuseppina Annicchiarico (Bari)*
*Part III: Round table on few examples of orphan drug development*
**Role of the cooperation among stakeholders in the development of orphan drugs: the example of inherited rare muscle diseases**
*Sabata Pierno (Bari)*
**Olaratumab in rare soft tissue sarcoma**
*Andrea Marrari (Milan)*
**Obeticholic acid in primary biliary cholangitis**
*Domenico Alvaro (Rome)*
**Stem cells in the treatment of limbal stem cell deficiency**
*Diego Ardigò (Reggio Emilia)*
**Recombinant parathyroid hormone and hypoparathyroidism**
*Sabrina Corbetta (Milan)*
**OPEN DISCUSSION**

 Friday, October 27<sup>th</sup>

## SALA DEL TEMPIO 1

**11.00-12.00 MINISYMPOSIUM**
**RARE DISEASES THERAPY: FROM CLINICAL NEEDS TO THERAPEUTIC SOLUTIONS**

 Chairperson: *Annamaria De Luca (Bari)*
**Fabry disease**
*Sandro Feriozzi (Viterbo)*
**Hereditary angioedema**
*Marco Cicardi (Milan)*
**Primary immune deficiency**
*Vassilios Lougaris (Brescia)*
*This Minisymposium was sponsored by SHIRE*
**12.00-12.30 LECTURE**

 Introduced by: *Achille Patrizio Caputi (Messina)*
**AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY: IS IT A RARE DISEASE?**
*Riccardo Magistroni (Modena)*


ECM SESSION

Friday, October 27<sup>th</sup>

## SALA DEL TEMPIO 1

14.30-16.00 **ROUND TABLE SIF-SITOX****THE HEALTH AND ECONOMIC EFFECTS OF COUNTERFEIT DRUGS**Chairperson & Opening: *Patrizia Hrelia (Bologna)*

## Discussants:

*Giorgio Cantelli Forti (Bologna)**Marco Cossolo (Rome)**Marta Gramazio (Rome)**Adelmo Lusi (Rome)**Massimo Scaccabarozzi (Milan)*16.00-18.00 **SYMPOSIUM****TRANSLATIONAL RESEARCH OPENINGS FOR THE CURE OF  
AMYOTROPHIC LATERAL SCLEROSIS (ALS)**Chairpersons: *Giambattista Bonanno (Genoa) - Maria Teresa Carrì (Rome)***Prospects for new therapy development in ALS/MND: a translational  
neuroscience***Pamela J. Shaw (Sheffield - UK)***Targeting Group I metabotropic glutamate receptors in ALS***Marco Milanese (Genoa)***Astrocytes as cell targets for therapeutic intervention in ALS***Daniela Rossi (Pavia)***Energy metabolism as a target for ALS therapy***Maria Teresa Carrì (Rome)***The role of protein quality control system in Amyotrophic Lateral Sclerosis***Valeria Crippa (Milan)*Friday, October 27<sup>th</sup>

## SALA DEL TEMPIO 2

8.30-9.30 **SYMPOSIUM****ENVIRONMENTAL ENRICHMENT AND BRAIN REPAIR: THE THERAPEUTIC  
EFFECTS OF COGNITIVE TRAINING IN NEUROLOGICAL DISEASES**Chairpersons: *Nicoletta Brunello (Modena) - Anna Maria Pittaluga (Genova)***Environmental enrichment modulates transmitter release and  
glutamate receptors in central nervous system***Anna Maria Pittaluga (Genova)***Fluoxetine counteracts the opposite effects of stress and enrichment on  
the inflammatory response and microglial status***Silvia Alboni (Modena)***Exercise attenuates myelin loss and astrogliosis in experimental  
Multiple Sclerosis***Antonietta Gentile (Pozzilli - IS)*9.30 - 11.30 **SYMPOSIUM****SYMPOSIUM SIF-AIE****FROM BIG DATA TO SMART DATA: AIMS, TOOLS AND KNOWLEDGE IN  
THE REAL WORLD EVIDENCE**Chairpersons: *Francesco Barone Adesi (Novara) - Elisabetta Poluzzi (Bologna)***Questions for the Real World Evidence***Roberto Raschetti (Rome)***The role of pharmaco-epidemiologist: education and employment  
opportunities***Gianluca Trifirò (Messina)***The role of data sources in Real World Evidence: claims databases  
versus electronic health records***Ursula Kirchmayer (Rome)***Opportunities and integrative methods of different sources***Rosa Gini (Florence)***The Role of REAL WORLD EVIDENCE in regulatory and clinical decisions***Nello Martini (Rome)**This Symposium was sponsored by CHIESI*



Friday, October 27<sup>th</sup>

## SALA DEL TEMPIO 2


## 11.30-12.30 LECTURE

*Introduced by: Fabrizio De Ponti (Bologna)***EQUITABLE ACCESS TO NEW HIGH-PRICED MEDICINES: CHALLENGES AND STRATEGIES IN EUROPEAN COUNTRIES***Sabine Vogel (Wien - Austria)*

## 14.30-16.00 SYMPOSIUM

**TH2 PATHWAY IN IMMUNOLOGICAL DISEASES:  
NEW FRONTIERS FOR TREATMENT OF ATOPIC DISEASE***Chairpersons: Giorgio Cantelli Forti (Bologna) - Carlo Riccardi (Perugia)***Atopy pathogenesis and the role of Th2 pathway: which cells and which cytokines involved***Walter Canonica (Milan)***New treatment strategies: monoclonal Abs for the Th2 pathway***Salvatore Cuzzocrea (Messina)***Severe atopic dermatitis as a proof of concept for atopy pathogenesis***Giovanni Pellacani (Modena)**This Symposium was sponsored by SANOFI*

## 16.00-18.00 JOINT SYMPOSIUM SIF-SSFA

**ADVANCED THERAPIES AND MEDICAL DEVICES COMBINATION WITH  
INNOVATIVE THERAPIES***Chairpersons: Pierluigi Navarra (Rome) - Roberto Fantozzi (Turin)***Medical devices: the new regulatory framework***Maria Grazia Leone (Rome)***Pulsed electromagnetic field mediates beneficial effects through  
adenosine receptor pathway***Katia Varani (Ferrara)***Combined Advanced Therapy Medicinal Products***Salvatore Bianco (Rome)***Non-human Viral Vectors for Vaccine Development?***Stefania Di Marco (Rome)*Friday, October 27<sup>th</sup>

## SALA DEL PARCO

8.30-10.00 ROUND TABLE  
INNOVATIONFLOW*Chairpersons & Opening: Maurizio Agostini (Rome) - Gianni Sava (Trieste)**Discussants:**Carlo Cifani (Camerino)**Monica Di Luca (Milan)**Armando Genazzani (Novara)**Gaetano Manfredi (Naples)**Giovanna Pescatore (Rome)*

## 10.00-11.30 LECTURE

*Introduced by: Giovanni Biggio (Cagliari)***10 YEARS OF BIOSIMILARS EXPERIENCE IN EU: WHAT HAVE WE LEARNED?***Speaker: Thijs Giezen (Haarlem-Netherlands)***ROUND TABLE  
THE ITALIAN EXPERIENCE BETWEEN SCIENTIFIC EVIDENCES AND  
EVOLUTION OF PRESCRIPTIVE MODELS***Chairperson & Opening: Ester Maragò (Rome)**Discussants:**Fabrizio Condorelli (Novara)**Patrizia Popoli (Rome)**Gianluca Trifirò (Messina)*11.30-12.30 MINISYMPOSIUM  
PATIENT CENTRICITY*Chairperson: Adriana Bazzi (Milan)**Tonino Aceti (Rome)**Giorgio Cantelli Forti (Bologna)**Massimo Scaccabarozzi (Milan)**This Minisymposium was sponsored by JANSSEN CILAG*

Friday, October 27<sup>th</sup>

## SALA DEL PARCO

14.30-15.30 **MINISYMPOSIUM****PHARMACOLOGICAL MODULATION OF NOVEL MOLECULAR SYSTEMS IN THE MANAGEMENT OF PATIENTS WITH COMPLEX PATHOLOGIES**

Chairpersons: Corrado Blandizzi (Pisa) - Romano Danesi (Pisa)

**The future of chronic inflammatory diseases' treatment: JAK pathway, a new mechanism**

Corrado Blandizzi (Pisa)

**Innovation in the treatment of patients with severe infections caused by Multi-Drug Resistant bacteria (MDR)**

Federico Pea (Udine)

**Inhibition of cyclin-dependent kinase 4/6: new perspectives in the breast cancer ER+/HER2-**

Romano Danesi (Pisa)

This Minisymposium was sponsored by PFIZER

15.30-16.30 **SYMPOSIUM****HEPATITIS C THERAPY: PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL OUTCOMES**

Chairperson: Giovambattista De Sarro (Catanzaro) - Francesco Scaglione (Milan)

**Pharmacology "in Clinical practice"**

Francesco Scaglione (Milan)

**Use of pharmacological data in clinical and therapeutic management: when and how**

Massimo Puoti (Milan)

16.30-17.30 **ROUND TABLE****THE MANAGEMENT OF THE PATIENT WITH DIABETIC MACULAR EDEMA: BETWEEN THERAPEUTIC EFFECTIVENESS AND QUALITY OF VISION**

Chairperson &amp; Opening: Filippo Drago (Catania)

Discussants:

Emilio Augusto Benini (Fano)

Eduardo Midenia (Padova)

Michele Reibaldi (Catania)

This round table was sponsored by SIFI

17.30-18.00 **LECTURE**

Introduced by: Giorgio Racagni (Milan)

**ADENOSINE RECEPTORS AS KEY PLAYERS IN HEALTH AND DISEASE**

Pier Andrea Borea (Ferrara)

Friday, October 27<sup>th</sup>

## SALA DEL BORGO

8.30-10.30 **SYMPOSIUM****FROM PSYCHOLOGICAL STRESS TO NEURODEGENERATION: NOVEL PHARMACOLOGICAL TARGETS AND NEUROPROTECTIVE APPROACHES**

Chairpersons: Fabrizio Gardoni (Milan) - Andrea Tarozzi (Rimini)

**Transcriptome Meta Analysis to Identify Novel Pharmacological Targets in Parkinson's Disease**

Andrea Tarozzi (Rimini)

**Update on treatment of Parkinson's Disease**

Manuela Contin (Bologna) e Pietro Cortelli (Bologna)

**Targeting GluN2A-containing N-Methyl-d-aspartate receptors (NMDA) in Parkinson's Disease and Levodopa-induced dyskinesia (L-DOPA)**

Fabrizio Gardoni (Milan)

**Evaluation of the possible therapeutic potential of palmitoylethanolamide in a transgenic animal model of Alzheimer's disease: focus on neuroinflammation and synaptic dysfunction**

Luca Nicola Ferraro (Ferrara)

**A preclinical study on the nootropic effects of ferulic acid through the heme oxygenase/carbon monoxide system**

Cesare Mancuso (Rome)

10.30-12.30 **SYMPOSIUM****THE PHARMACOLOGIST AND THE MICROBIOTA CHALLENGE**

Chairpersons: Giorgio Cantelli Forti (Bologna) - Carmelo Scarpignato (Parma)

**Methods of analysis and database**

Pamela Vernocchi (Rome)

**Microbiota and nutrition**

Maurizio Muscaritoli (Rome)

**Microbiota and clinical aspects**

Giovanni Barbara (Bologna)



Friday, October 27<sup>th</sup>

## SALA DEL BORGO

## 14.30-16.00 SYMPOSIUM

## NEUROPROTECTION AND NEUROENHANCEMENT: LESSONS LEARNED FROM OCULAR DISORDERS

Chairpersons: Filippo Drago (Catania) - Armando Genazzani (Novara)

**Novel pharmacological targets in ocular neurodegenerative diseases**  
Maria Angela Sortino (Catania)**The role of corneal innervation in ocular surface disease**  
Alessandro Lambiase (Rome)**Glaucoma and neurodegeneration**  
Gianluca Manni (Rome)**Neurodegeneration in retina and optic nerve diseases**  
Benedetto Falsini (Rome)

## 16.00-17.00 COMMUNICATIONS

WINNERS SELECTED REPORTS  
SIF-MSD GRANTS 2015

Chairpersons: Giorgio Cantelli Forti (Bologna) - Nicoletta Luppi (Bologna)

**β2 adrenergic receptors as novel players and targets in the modulation of adult hippocampal neurogenesis**  
Valeria Bortolotto (Novara)**Population pharmacokinetics and pharmacodynamics of levofloxacin in acutely hospitalized older patients with various degrees of renal function**  
Pier Giorgio Cojutti (Udine)**Pharmacological and molecular characterization of the functional and inflammatory alterations of neuro-immune pathways of the lower digestive tract in experimental Alzheimer's disease**  
Carolina Pellegrini (Pisa)**Neuroinflammation from the acute event to chronic neurodegeneration: molecular mechanisms and new neuroprotective strategies**  
Giulia Sita (Bologna)**L-Kynurenine modulates dendritic cell subsets activity and central nervous system inflammation via relb and aryl hydrocarbon receptor**  
Marco Gargaro (Perugia)

ECM SESSION

Friday, October 27<sup>th</sup>

## SALA DELLA MARINA

## 8.30-9.30 MINISYMPOSIUM

## NOVEL BIOLOGICAL AND PHARMACOLOGICAL ASPECTS IN THE BRAIN TUMORS

Chairpersons: Romano Danesi (Pisa) - Letteria Minutoli (Messina)

**Liposomal cytarabine in leptomeningeal carcinomatosis from primary brain tumors**  
Paola Gaviani (Milan)**Role of dickkopf-related protein 3 (Dkk-3) and claudin-5 in the neoplastic progression of meningiomas**  
Mariella Caffo (Messina)**Role of circulating tumor DNA in personalised medicine**  
Marzia Del Re (Pisa)

## 10.30-11.30 SYMPOSIUM

## EVOLUTION OF THE THERAPEUTIC APPROACH TO THE HIV INFECTION: NOT ONLY "VIRAL LOAD"

Chairpersons: Giorgio Cantelli Forti (Bologna)-Gianni Sava (Trieste)

**The pharmacological difference of TAF to TDF**  
Antonio D'Avolio (Turin)**The clinical outcome of pharmacological difference**  
Stefano Bonora (Turin)

## 11.30-12.00 LECTURE

Introduced by: Renato Bernardini (Catania)

**HAEMOPHILIA A: RAISING THE BAR FOR NEW TREATMENTS**  
Raimondo De Cristofaro (Rome)

This Lecture was sponsored by ROCHE

## 12.00-12.30 LECTURE

Introduced by: Ferdinando Nicoletti (Rome)

**THE GCRP SYSTEM IN THE PATHOPHYSIOLOGY OF MIGRAINE AND ITS ROLE AS A NEW THERAPEUTIC TARGET**  
Pierangelo Geppetti (Florence)

This Lecture was sponsored by NOVARTIS



ECM SESSION



ECM SESSION

**Friday, October 27<sup>th</sup>**
**SALA DELLA MARINA**
**14.30-16.00 SYMPOSIUM**
**PRECISION MEDICINE AND PHARMACOLOGICAL TREATMENT OF PSYCHIATRIC DISORDERS**

 Chairpersons: *Emilio Clementi (Milan) - Edoardo Spina (Messina)*
**Therapeutic drug monitoring of psychotropic drugs: usefulness and limitations**
*Marco Pozzi (Brindisi)*
**Monitoring of psychiatric drugs using efficacy and safety markers: usefulness and limitations**
*Annalisa Capuano (Naples)*
**Clinical applications of pharmacogenetics in psychiatry**
*Alessandro Serretti (Bologna)*
*Discussion: Edoardo Spina (Messina) - Emilio Clementi (Milan)*
**16.00-16.30 LECTURE**

 Introduced by: *Emilio Clementi (Milan)*
**ROLE OF PARTIAL AGONISTS IN THE TREATMENT OF PSYCHOSES: STATE OF ART AND FUTURE PERSPECTIVES**
*Edoardo Spina (Messina)*
**16.30-18.30 SYMPOSIUM**
**THE ENDOCANNABINOID SYSTEM AND AUTISM SPECTRUM DISORDERS**

 Chairpersons: *Daniela Parolaro (Milan) - Marie Woolley (London - UK)*
**Targeting anandamide metabolism rescues autistic-like symptoms in rats prenatally exposed to valproic acid**
*Viviana Trezza (Rome)*
**The non-psychotropic plant cannabinoid cannabidivarin ameliorates Rett syndrome-like phenotype in methyl CpG binding protein 2 (MeCP2) mutant mice**
*Erica Zamberletti (Busto Arsizio)*
**The endocannabinoid system as therapeutic target for fragile X syndrome and other cognitive disorders**
*Rafael Maldonado (Barcelona - Spain)*
**Endocannabinoid system dysregulation drives inflammatory state and human immune system cell alterations in autism spectrum disorders**
*Dario Siniscalco (Naples)*

**Friday, October 27<sup>th</sup>**
**SALA DEL LEVATOIO**
**8.30-10.30 ORAL COMMUNICATIONS**
**ADVANCES IN NATURAL MEDICINES AND NUTRACEUTICALS**

 Chairpersons: *Lucia Morbidelli (Siena) - Vincenzo Calderone (Pisa) - Gabriela Mazzanti (Rome)*
**8.30 Hydroxytyrosol inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in colorectal cancer**
*Donnini S., Terzuoli E., Ziche M.*
**8.40 Anti-cancer properties of erucin, an isothiocyanate present in many edible plants of brassicaceae family, on human pancreatic adenocarcinoma cells (ASPC-1): is H<sub>2</sub>S the hidden player?**
*Martelli A., Citi V., Piragine E., Testai L., Pagnotta E., Ugolini L., Cinti S., Malaguti L., Breschi M.C., Lazzeri L., Calderone V.*
**8.50 Naringenin protects myocardium against ageing-related injury**
*Testai L., Piragine E., Piano I., Martelli A., Citi V., Gargini M.C., Da Pozzo E., Martini C., Breschi M.C., Calderone V.*
**9.00 Nutraceutical properties of *Arthrospira platensis* and *Isochrysis T. lutea* rich diets in rats**
*Luceri C., Bigagli E., Cinci L., D'ambrosio M., Lodovici M., Niccolai A., Biondi N., Ridolfi L., Tredici M.*
**9.10 Inhibition of spontaneous colon tumorigenesis in pirc rats (F344/NTAC-APC<sup>AM1137</sup>), mutated in *apc*, and mechanistic studies *in vitro* and *ex-vivo*, suggest potential chemopreventive activity of a pomegranate mesocarp preparation**
*Tortora K., Femia A.P., Romagnoli A., Luceri C., Khatib M., Mulinacci N., Giovannelli L., Caderni G.*
**9.20 Potential of a flavonoid-rich extract from Bergamot juice as anticancer drug: preliminary data on its preventive effects in the Pirc rat (F344/NTac-Apc<sup>am1137</sup>), a genetic model of colorectal cancer**
*Navarra M., Femia A.P., Romagnoli A., Tortora K., Luceri C., Maugeri A., Cirmi S., Ferlazzo N., Caderni G.*
**9.30 Retinal bioavailability of curcumin after oral administration**
*Platania C.B., Bucolo C., Fidilio A., Lazzara F., Piazza C., Geraci F., Salomone S., Drago F.*

Friday, October 27<sup>th</sup>

## SALA DEL LEVATOIO

9.40 Evaluation of gastric anti-inflammatory activity of tannins from european chestnut fruits (*Castanea sativa* mill.): kernel for nutrition and rind for phytotherapy  
*Sangiovanni E., Piazza S., Vrhovsek U., Fumagalli M., Colombo L., Mattivi F., Dell'Agli M.*

9.50 β-Caryophyllene oxide as a new chemosensitizing agent to enhance sorafenib efficacy in liver cancer chemotherapy  
*Di Giacomo S., Sanchez-Vicente L., Di Sotto A., Monte M.J., Abete L., Mazzanti G., Marín J.J.G., Briz O.*

10.00 DISCUSSION

10.30-12.30 SYMPOSIUM

CLINICAL PHARMACOLOGY OF CARDIO-ONCOLOGY

Chairpersons: Liberato Berrino (Naples) - Giorgio Minotti (Rome)

**Anthracyclines and the problem of doses: lessons from a translational model of human heart**  
*Emanuela Salvatorelli (Rome)*

**Diastolic dysfunction in doxorubicin cardiotoxicity: a new therapeutic target?**  
*Antonella De Angelis (Naples)*

**Beyond anthracyclines: new drugs and clinical phenotypes of cardiotoxicity**  
*Giorgio Minotti (Rome)*

**Cardiotoxicity by Tyrosine Kinase Inhibitors: new cellular mechanisms**  
*Federico Quaini (Parma)*

**Cardiotoxicity-induced by antitumoral agents: prevention and treatment**  
*Daniela Cardinale (Milan)*

**Cardio-Oncology in the real life: dimension of the problem**  
*Carlo Gabriele Tocchetti (Naples)*


 Friday, October 27<sup>th</sup>

## SALA DEL LEVATOIO

14.30-15.30 ORAL COMMUNICATIONS  
PHARMACOGNOSY

Chairpersons: Carla Ghelardini (Florence) - Angelo Antonio Izzo (Naples) - Gabriela Mazzanti (Rome)

14.30 Herbal dietary supplements for erectile dysfunction: a systematic review and meta-analysis

*Borrelli E., Colalto C., Delfino D.V., Iriti M., Izzo A.A.*

14.40 Thistles from Sardinia: evaluation of the anti-inflammatory activity of different species in a cell model of gastric inflammation

*Fumagalli M.J., Marengo A., Sangiovanni E., Sanna C., Piazza S., Maxia A., Rubiolo P., Dell'Agli M.*

14.50 Aldose reductase inhibitors from *Cannabis sativa* L. standardized extracts

*Smeriglio A., Galati E. M., Giofrè S., Monforte M.T., Cicero N., D'Angelo V., Grassi G., Circosta C.*

15.00 Brassicaceae as source of H<sub>2</sub>S-releasers: tuscan black kale for pain relief

*Di Cesare Mannelli L., Lucarini E., Micheli L., Maresca M., Tenci B., Trallori E., Awada K., Iori R., Testai L., Martelli A., Calderone V., Ghelardini C.*

15.10 *Artocarpus tonkinensis*, a vietnamese herbal remedy, inhibits the development of th17 cells in mice with collagen-induced arthritis

*Adorisio S., Muscari I., Sung T.V., Thuy T.T., Riccardi C., Delfino D.V.*

15.20 Suspected adverse reactions to herbal dietary supplements for weight loss collected by the italian surveillance system on natural products

*Vitalone A., Menniti-Ippolito F., Da Cas R., Mazzanti G.*

15.30 DISCUSSION

Friday, October 27<sup>th</sup>Friday, October 27<sup>th</sup>

## SALA DEL LEVATOIO

## 16.00-18.00 ORAL COMMUNICATIONS

## CARDIOVASCULAR PHARMACOLOGY II

Chairperson: Francesco Squadrito (Messina) - Raffaella Sorrentino (Naples)

## 16.00 Flavonoids contained in flavocoxid reduce atherosclerosis development in ApoE ko mice fed with a western high fat diet

*Bitto A., Pizzino G., Irrera N., Pallio G., Galfo F., Mannino F., Minutoli L., Altavilla D., Squadrito F.*

## 16.10 Vitamin D levels and Tissue Factor expression in acute coronary syndrome patients

*Brambilla M., De Metrio M., Canzano P., Rossetti L., Cosentino N., Tremoli E., Marenzi G.C., Camera M.*

## 16.20 Different effect of hydrogen sulfide donors AP39 and AP123 in endothelial cells grown in hyperglycaemic environment

*Brancaleone V., Torregrossa R., Wood M.E., Vellecco V., Waters A., Bucci M., Whiteman M., Cirino G.*

## 16.30 Cardio-renal positive effects of dipeptidyl peptidase 4-inhibitor sitagliptin preserve diastolic function in a model of heart failure with preserved ejection fraction

*Cappetta D., Esposito G., D'Amario D., Ciuffreda L.P., Piegari E., Siracusano A., Berrino L., Rossi F., De Angelis A., Urbanek K.*

## 16.40 Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: role of the small G protein Rac1

*Marchianò S., Corsini A., Ferri N.*

## 16.50 Hydrogen sulfide pathway as a new target in cardiovascular risk associated to hyperhomocysteinemia

*Mitidieri E., Tramontano T., Gurgone D., Di Minno M.N., Di Minno G., Cirino G., D'Emmanuele Di Villa Bianca R., Sorrentino R.*17.00 Poor responsiveness to low-dose aspirin in polycythemia vera predicts residual *in vivo* platelet activation*Petrucci G., Ranalli P., Dragani A., Cavalca V., Porro B., Tremoli E., Patrono C., Rocca B.*

## 17.10 Effect of racemic and levo-methadone on action potential profile of human cardiomyocytes: implications for cardiac safety

*Sartiani L., Dini L., Diolaiuti L., Coppini R., Cerbai E., Mugelli A.*

## 17.20 Reduced variability to aspirin antiplatelet effect by the co-administration of statins in high-risk individuals for cardiovascular events

*Tacconelli S., Dovizio M., Di Francesco L., Meneguzzi A., D'Agostino I., Evangelista V., Manarini S., Capone M.L., Porreca E., Di Febbo C., Levantesi G., Fava C., Minuz P., Patrignani P.*

## 17.30 DISCUSSION

Saturday, October 28<sup>th</sup>Saturday, October 28<sup>th</sup>

## SALA DELLA PIAZZA

## 9.00-11.00 SYMPOSIUM

**THE PURINERGIC SYSTEM: A NEW PROMISING TARGET FOR HUMAN DISEASES**

Chairpersons: Maria Pia Abbracchio (Milan), Pier Andrea Borea (Ferrara), Felicità Pedata (Florence), Patrizia Popoli (Rome)

**Allosteric modulation of A<sub>1</sub> adenosine receptors as a novel and promising therapeutic strategy for anxiety**

Fabrizio Vincenzi (Ferrara)

**Obesity and related enteric neuromotor dysfunctions: what role for adenosine?**

Luca Antonioli (Pisa)

**Role of P2X7 receptor (purinoceptor 7) in immune response and extracellular ATP (adenosine triphosphate) modulation during oncogenesis**

Elena De Marchi (Ferrara)

**Proteomic analysis of ectosomes and exosomes provides new clues on microglia response to ATP (adenosine triphosphate)**

Marta Lombardi (Rozzano)

**Nucleotide derivatives as new ligands of the purinergic P2 Receptors**

Andrea Spinaci (Camerino)

**Adenosine A<sub>2B</sub> receptors and sphingosine kinase/sphingosine 1-phosphate signaling axis control maturation of oligodendrocyte precursor cells *in vitro***

Anna Maria Pugliese (Florence)



ECM SESSION

**Investigating microglia and oligodendroglial progenitor interactions: implications for new purinergic strategies to brain repair**

Marta Fumagalli (Milan)

**Influence of P2X<sub>7</sub> receptors (purinoceptor 7) on the osteogenic differentiation of mesenchymal stromal/stem cells derived from human subcutaneous adipose tissue**

Patricia Giuliani (Chieti)

## 12.00-13.00 PLENARY LECTURE

Introduced by: Vincenzo Cuomo (Rome)

**PHARMACOLOGY 2020: HOW TO INCREASE CLINICAL TRIALS EFFICIENCY BEYOND AND ABOVE BIG DATA**

Luca Pani (Miami-USA)



ECM SESSION

## 13.00

**POSTER GRANTS CONCLUSIONS**



**SALA DEL TEMPIO 1**

**9.00-11.00 ORAL COMMUNICATIONS**

**KETAMINE AND PHARMACOLOGY OF PSYCHIATRIC DISEASES**

*Chairpersons: Cristiano Chiamulera (Verona) - Fabio Fumagalli (Milan)*

- 9.00 Ketamine induced structural plasticity in human iPCS-derived dopaminergic neurons**  
*Collo G., Cavalleri L., Millan M.J., Chiamulera C., Spano P.F., Merlo Pich E.*
- 9.10 Post-synaptic glutamate dysfunction induced by ketamine self-administration**  
*Caffino L., Piva A., Mottarlini F., Giannotti G., Di Chio M., Venniro M., Yew D.T., Chiamulera C., Fumagalli F.*
- 9.20 Metaplastic treatments with ketamine and MK-801 affect instrumental appetitive memory reconsolidation in rats**  
*Gerace E., Piva A., Di Chio M., Padovani L., Pellegrini-Giampietro D.E., Chiamulera C.*
- 9.30 The multiple effects of the ketamine analog methoxetamine: preclinical evidence**  
*Fattore L., Zanda M.T., Mutti A., Fratta W., Chiamulera C.*
- 9.40 Ketamine modulation of PSD gene expression: implication for pathophysiology and treatment of behavioral disorders**  
*De Bartolomeis A.*
- 9.50 Dopamine D3 receptors control dysbindin-dependent executive functions alterations relevant to schizophrenia**  
*Leggio G.M., Torrisi S.A., Managò F., Chisari M., Mastrogiacomo R., Mereu M., De Luca M.A., Ciranna L., Salomone S., Drago F., Papaleo F.*
- 10.00 Clozapine as the most efficacious antipsychotic for activating ERK 1/2 kinases: role of 5-HT2A receptor agonism**  
*Scarselli M., Aringhieri S., Kolachalam S., Carli M.*

- 10.10 Effects of the PPAR-alpha agonist fenofibrate in an immune-mediated neurodevelopmental model of psychosis**  
*Pistis M., Sagheddu C., Aroni S., Muntoni A.L., Frau R., Fanni S., Pardu A., Devoto P., Melis M., De Felice M.*

**10.20 DISCUSSION**



Saturday, October 28<sup>Th</sup>

## SALA DEL TEMPIO 2

 9.00-10.30 **ORAL COMMUNICATIONS**
**NEUROPHARMACOLOGY II**

Chairpersons: Armando Genazzani (Novara) - Mariagrazia Grilli (Novara)

- 9.00 Meninges are a reservoir for new functional neurons of the cortex**  
*Bifari F., Decimo I., Pino A., Llorens-Bobadilla E., Zhao S., Lange C., Panuccio G., Giugliano M., Dewerchin M., Martin-Villalba A., Carmeliet P.*
- 9.10 Astrocytes and adult neural progenitors cross-talk: relevant role of NF- $\kappa$ B p50**  
*Bortolotto V., Cvijetic S., Manfredi M., Ranzato E., Marengo E., Canonico P.L., Grilli M.*
- 9.20 A2a-D2 heterodimers on striatal astrocytes**  
*Marcoli M., Cervetto C., Venturini A., Guidolin D., Maura G., Passalacqua M., Tacchetti C., Cortelli P., Genedani S., Fuxe K., Borroto-Esqueda D.O., Woods A.S., Agnati L.F.*
- 9.30 Modulation of astrocyte processes by gpcr: changes in cellular activity**  
*Chisari M., Ciranna L., Sortino M.A.*
- 9.40 Calcium and ATP-Dependent Potentiation of Na/Ca Exchange Function in Intact Cells: Comparison of NCX1 and NCX3 Exchangers**  
*Lariccia V., Lin M.J., Hilgemann D.W., Amoroso S.*
- 9.50 PGE1 delivered by liposomes antagonized dendritic spine loss and reduction of VEGF and VEGF-r2 in frontal cortex and hippocampus of diabetic rats**  
*Mostallino M.C., Biggio F., Locci V., Boi L., Manca M.L., Fadda A.M., Brotzu G., Biggio G.*
- 10.00 Inhibition of mammalian target of rapamycin (mTOR) improves neurobehavioral deficit and modulates inflammatory response after traumatic brain injury**  
*Campolo M., Paterniti I., Cordaro M., Esposito E., Cuzzocrea S.*
- 10.10 The silent information regulator 1 (SIRT1) is a key player in neuroprotective effects of melatonin in perinatal brain injury**  
*Carlioni S., Riparini G., Balduini W.*
- 10.20 DISCUSSION**


 Saturday, October 28<sup>Th</sup>

## SALA DEL TEMPIO 2

 10.30-12.00 **SYMPOSIUM**
**OLD AND NEW FIELDS FOR ION CHANNEL PHARMACOLOGY: STILL SURFING ON THE CREST OF A WAVE**

Chairpersons: Elisabetta Cerbai (Florence) - Diana Conte (Bari)

**Ion channels and cardiac diseases: the pharmacologist's view**

Elisabetta Cerbai (Florence)

**Bench to patient side development of precision medicine in skeletal muscle ion Channelopathies**

Jean-François Desaphy (Bari)

**Novel molecular targets for personalized treatment in epileptic encephalopathies**

Maurizio Tagliatela (Naples)

**hERG1 Channels: from antitargets to novel targets for cancer therap**

Annarosa Arcangeli (Florence)



ECM SESSION

Saturday, October 28<sup>th</sup>Saturday, October 28<sup>th</sup>

## SALA DEL PARCO

9.00-10.30 **ORAL COMMUNICATIONS**  
**IMMUNOPHARMACOLOGY**

Chairpersons: Salvatore Cuzzocrea (Messina) - Katia Varani (Ferrara)

9.00 **RNA-SEQ analysis of differential gene expression induced by lysozyme treatment in lymphoma cells**Bergamo A., Gerdol M., Pallavicini A., Sava G., Allardyce C., Dyson P.9.10 **Interleukin 4-induced gene-1 as novel immune regulatory pathway**Fallarino E., Gargaro M., Scalisi G., Turco A., Matino D., Puccetti P., Murphy K.M.9.20 **Effects of thrombin cleavage of osteopontin on experimental autoimmune encephalomyelitis and role of extracellular proteasome in regulating its chemotactic activity with implications in multiple sclerosis**Ferrara B., Dianzani C., Bellavista E., Liepe J., Gigliotti C.L., Clemente N., Boggio E., Comi C., Verderio C., Riganti L., Keller C., Chiocchetti A., Dianzani U., Mishto M.9.30 **Immunoregulatory synergism between arginine and tryptophan catabolism in dendritic cells**Mondanelli G., Volpi C., Orabona C., Pallotta M., Puccetti P., Grohmann U.9.40 **Reinstalling immune regulatory tryptophan catabolism in juvenile diabetes via tocilizumab, a licensed interleukin-6 receptor blockade**Orabona C., Mondanelli G., Pallotta M., Volpi C., Albini E., Fallarino F., Puccetti P., Grohmann G.9.50 **The proteasome inhibitor bortezomib controls IDO1 breakdown and restores immune regulation in autoimmune diabetes**Pallotta M.T., Mondanelli G., Albini E., Volpi C., Fallarino F., Belladonna M.L., Bianchi R., Vacca C., Grohmann U., Puccetti P., Orabona C.10.00 **Glucocorticoid-induced leucine zipper (GILZ) interacts with PU.1 thus promoting Annexin a1 expression under dexamethasone treatment in migrating neutrophils**Ronchetti S., Ricci E., Pericolini E., Gabrielli E., Cari L., Gentili M., Roselletti E., Migliorati G., Vecchiarelli A., Riccardi C.10.10 **IDO1 activity in selected immune cells controls antibody responses**Scalisi G., Gargaro M., Turco A., Iorio A., Puccetti P., Matino D., Fallarino F.10.20 **Human Peripheral blood mononuclear cells (PBMCs) from idiopathic pulmonary fibrosis patients release IL-1-like cytokines in an inflammasome independent manner**Sorrentino R.S., Terlizzi M.T., Colarusso C.C., Pinto A.P., Molino A.M.10.30-12.00 **ROUND TABLE SIF-SITOX**  
**THERAPEUTIC CANNABIS**

Chairpersons &amp; Opening: Michele Navarra (Messina) - Luca Steardo (Rome)

Discussants:

Germana Apuzzo (Rome)

Giacchino Calapai (Messina)

Patrizia Hrelia (Bologna)

Francesca Menniti Ippolito (Rome)

Domenico Quattrone (Messina)

Grazia Rocca (Genova)



## SALA DEL BORGO

## 9.00-11.00 ORAL COMMUNICATIONS

 PHARMACOECONOMICS, PHARMACOEPIDEMOLOGY &  
PHARMACOVIGILANCE II

Chairpersons: Elisabetta Poluzzi (Bologna) - Maurizio Rossini (Verona)

## 9.00 Drug interactions with levothyroxine therapy: tablets versus oral liquid formulations

Lapi F., Bianchini E., Guglielmi V., Cricelli I., Bellia A., Cricelli C.

## 9.10 Real-world evidence on the risk of acute cardiovascular events among elderly hypertensive patients treated with calcium channel blockers in secondary cardiovascular prevention

Bettiol A., Lucenteforte E., Vannacci A., Lombardi N., Onder G., Agabiti N., Vitale C., Trifirò G., Corrao G., Roberto G., Mugelli A., Chinellato A.

## 9.20 Adherence to therapy with different second-line hypoglycaemic drugs in patients with type 2 diabetes mellitus

Galimberti F., Casula M., Mozzanica F., Scotti L., Pirillo A., Corrao G., Tragni E., Catapano A.L.

## 9.30 Real world data on biological drugs used in oncology: a 5 years picture' in southern Italy

Lucchesi S., Marcianò I., Randazzo M., Panagia P., Intelisano R., Sgroi C., Santarpia M., Adamo V., Franchina T., Spina E., Trifirò G.

## 9.40 Comparative efficacy of antiepileptic drugs in children and adolescents: a network meta-analysis

Lucenteforte E., Rosati A., Ilvento L., Crescioli G., Mcgreevy K.S., Pugi A., Virgili G., Mugelli A., De Masi S., Guerrini R.

## 9.50 Effect of Chronic Kidney Diseases on Mortality in Patients Treated with Digoxin for Non-Valvular Atrial Fibrillation: A Nationwide Register-Based Retrospective Cohort Study

Mascolo A., Sessa M., Andersen M., Rosano G., Rossi F., Capuano A., Torp-Pedersen C.

## 10.00 Un-Suggested Prescriptions of Non-Cardio-Selective Beta-Blockers for Heart Failure in Patients with Concurrent Chronic Obstructive Pulmonary Disease

Sessa M., Mascolo A., Mortensen R., Andersen M., Rosano G., Capuano A., Rossi F., Gislason G., Enghusen-Poulsen H., Torp-Pedersen C.

## 10.10 Immune related adverse events associated with immune checkpoints inhibitors: a systematic review and meta-analysis

Spini A., Moscatelli V., Cucherat M., Roberto G., Gini R., Raschi E., Ziche M., Salvo F.

## 10.20 DISCUSSION

Saturday, October 28<sup>th</sup>

## SALA DEL BORGO

11.00-12.00 **JOINT SYMPOSIUM SIF-SIR****NEW INSIGHTS ON OSTEOPOROTIC DRUGS AND FUTURE THERAPEUTIC PROSPECTIVES***Chairpersons: Maurizio Rossini (Verona) - Francesco Squadrito (Messina)***Denosumab: not only postmenopausal osteoporosis***Maurizio Rossini (Verona)***Antiosteoporotic drugs use reduction in Sicily during the years 2013-2016: a medical choice or an health policy measures consequence?***Vincenzo Arcoraci (Messina)***Antisclerostin Antibody***Marco Atteritano (Messina)***Adenosine receptor stimulation improves glucocorticoid-induced osteoporosis***Alessandra Bitto (Messina)*Saturday, October 28<sup>th</sup>

## SALA DELLA MARINA

9.00-10.30 **JOINT SYMPOSIUM SIF - FADOI****PHARMACOLOGICAL STRATEGIES DEFENDING THE HEART FROM FAT ATTACK: A NEW ROLE FOR DIRECT-ACTING ORAL ANTICOAGULANTS DOAC? - THE EPICARDIAL ADIPOSE TISSUE (EPA), A SICK (VISCERAL) FAT EMBRACING THE HEART***Chairpersons: Gualberto Gussoni (Milan) - Alessandro Mugelli (Florence)***A new risk factor for coronary artery disease and atrial fibrillation***Giuseppe Ambrosio (Perugia)***A pharmacological target***Laura Raimondi (Florence)***The role of renin-angiotensin system in pathophysiology of atrial fibrillation***Francesco Rossi (Naples)***Fighting the pro-thrombotic risk with DOAC: the advantages of factor Xa inhibitors***Fulvio Pomero (Cuneo)*10.30-12.00 **SYMPOSIUM****CARDIOVASCULAR RISK PREVENTION AND THE CHRONIC PATIENT***Chairpersons: Alessandro Mugelli (Florence) - Francesco Rossi (Naples)***The clinical point of view: what to consider?***Enrico Strocchi (Bologna)***The general practitioner and patient care***Renzo Le Pera (Bologna)***Evidences from the administrative data***Luca Degli Esposti (Bologna)***Chronic diseases management: the national health service perspective***Barbara Polistena (Roma)***Co-morbidity and adherence : the pharmacologist's point of view***Alessandro Mugelli (Florence)*

Saturday, October 28<sup>th</sup>

## SALA DEL LEVATOIO

## 9.00-11.00 ORAL COMMUNICATIONS

## PHARMACOGENETICS, PHARMACOGENOMICS AND GENE THERAPY

Chairpersons: Sabrina Angelini (Bologna) - Diego Fornasari (Milan)

## 9.00 The predictive value of ABCB1, ABCG2, CYP3A4/5, and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions

Bernardi F.F., Rafaniello C., Vitale A., Sessa M., Mascolo A., Scavone C., Maccariello A., Rossi F., Capuano A.

## 9.10 Clopidogrel pharmacogenetics: a valid method to assure effectiveness and appropriateness of the antiplatelet therapy

Conti V., Manzo V., Sellitto C., Iannaccone T., Costantino M., Corbi G., Malangone P., Tarallo S., Iannello F., Nicoletta G., Accarino G., Filippelli A.

## 9.20 Comparison of four different assay methods for UGT1A1\*28 genotyping

Costanza F., Mancini I., Salvianti F., Gelmini S., Tassi R., Mazzei T., Nobili S., Mini E., Pazzagli M., Pinzani P., Simi L.

## 9.30 Pharmacogenetics of sofosbuvir, a new anti-HCV drug: a preliminary study

Cusato J., De Nicolò A., Boglione L., Ariaudo A., Favata F., Mornese Pinna S., Carcieri C., Di Perri G., D'Avolio A.

## 9.40 Tackle atherosclerosis via genome editing: CRISPR meets ApoA-I milano

Pizzino G., Mannino F., Irrera N., Pallio G., Galfo F., Mecchio A., Minutoli L., Squadrito F., Altavilla D., Bitto A.

## 9.50 PREPARE (PRE-emptive pharmacogenomic testing for Preventing Adverse drug REactions), a pharmacogenomic randomized clinical trial within the U-Pgx H2020 program, to drive pharmacogenomics into clinical practice in 7 european clinical environments, to improve patients safety and quality of life- THE ITALIAN EXPERIENCE

Cecchin E., Bignucolo A., Roncato R., Di Raimo T., De Mattia E., D'Andrea M., Giordano G., Foltran L., Berretta M., De Paoli A., Guardascione M., Lo Re G., Buonadonna A., Saracchini S., Favaretto A., Sandri P., Toffoli G.


 Saturday, October 28<sup>th</sup>

## 10.00 A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy

Nobili S., D' Aurizio R., Perrone G., Magi A., Lapucci A., Tassi R., Napoli C., Picariello L., Landini I., Brugia M., Mazzei T., Tonelli F., Mini E.

## 10.10 Immunogenetics of prostate cancer: first clinical insights

Dreussi E., Zanusso C., Gagno S., De Mattia E., Romanato L., Sartor F., Bortolus R., Romualdi C., Quartuccio L., Cecchin E., Toffoli G.

## 10.20 DISCUSSION



## Poster Session

### P1 POSTER SESSION

#### ANTIBACTERIAL AND ANTIVIRAL CHEMOTHERAPY. ANTI-HCV AND ANTI-HIV DRUGS

Chairpersons: Alberta Bergamo (Trieste) - Gianni Sava (Trieste)

- 1/1** A new UHPLC-MS/MS method for the evaluation of the intracellular pharmacokinetic of the new direct antiviral agents (DAA) in HCV positive patients samples  
*Ariando A., Favata F., Boglione L., Gontero E., De Nicolò A., Carcieri C., Simiele M., Cusato J., Di Perri G., D'Avolio A.*
- 1/2** Hepatitis C virus (HCV) infection evaluation of prevalence and related costs in the local health unit N.2, district of Treviso  
*Bellin A., Giusti P., Schiavon A., Franchin G., Bettiol A., Bolcato J., Pirolo R., Chinellato A.*
- 1/3** Clinical pharmacological advice (CPA) for optimization of linezolid therapy in hospitalized patients with multidrug resistant gram-positive infections  
*Cojutti P., Pea F., Merelli M., Bassetti M., Baraldo M.*
- 1/4** *In vitro* and *in vivo* antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors (NBTIs)  
*Di Matteo A., D'Atanasio N., Apicella C., Ombrato R., Magarò G., Milanese C., Di Giorgio F.P., Tongiani S.*
- 1/5** Interactions between antiretroviral drugs and human Arginase 1  
*Lisi L., Pizzoferrato M., Miscioscia F., Topai A., Navarra P.*
- 1/6** Pharmacokinetics of darunavir/cobicistat in an Italian observational, multicenter, prospective study (The START Of REzolsta "ST.O.RE" study - TMC114FD1HTX4003)  
*Gori A., Focà E., Antinori A., Vergori A., Maserati R., Rusconi S., Di Cristo V., Uglietti A., Termini R., Mancusi D.*
- 1/7** MIRNA-218 targets LIPIN-1 and GLUT-4 genes in lopinavir/ritonavir treated 3T3-L1 cells  
*Molteni L., Bresciani E., Saletti C., Squillace N., Torsello A., Rizzi L., Gori A., Locatelli V.*
- 1/8** Healthcare resources use in patients with Human Virus Infection (HIV). Real-world evidence from Italian administrative databases  
*Perrone V., Sangiorgi D., Buda S., Degli Esposti L.*

## Poster Session

- 1/9** Burden of comorbidities in HCV patients only and HIV-HCV co-infected patients in a real-world setting: retrospective study  
*Perrone V., Sangiorgi D., Buda S., Degli Esposti L.*

### P2 POSTER SESSION

#### ANTINEOPLASTIC DRUGS

Chairpersons: Giovanna Caderni (Firenze), Marzia Del Re (Pisa), Tullio Florio (Genoa), Francesca Levi-Schaffer (Jerusalem-Israel)

- 2/1** Acetyl deacylasadisulfide, a natural H<sub>2</sub>S donor molecule, inhibits metastatic melanoma  
*Armogida C., Panza E., De Cicco P., Ercolano G., Tagliatela-Scafati O., Cirino G., Ianaro A.*
- 2/2** Curcumin Potentiates Antitumor Activity of Paclitaxel in Rat Glioma C6 Cells  
*Bashllari R., Fratantonio D., Molonia M.S., Muscarà C., Cristani M., Saija A., Cimino F., Speciale A.*
- 2/3** Targeting the cancer resistome to restore tumour sensitivity through novel, existing and failed drugs  
*Angelini S., Bergamo A., Morbidelli L., Pacor S., Terzuoli E., Sava G.*
- 2/4** Melanocortin receptor-4 as a novel therapeutic target in glioblastoma  
*Vaglini F., Pardini C., Di Desidero T., Orlandi P., Pasqualetti F., Ottani A., Giuliani D., Guarini S., Bocci G.*
- 2/5** Over-expression of MIR-574-5P increases tumor growth in xenografts of human lung cancer cells via prostaglandin E2  
*Bruno A., Saul M.J., Baumann I., Contursi A., Dovizio M., Donnini S., Tacconelli S., Raouf J., Idborg H., Stein S., Korotkova M., Savai R., Salvatore T., Terzuoli E., Jakobsson P.J., Suess B., Steinhilber D., Patrignani P.*
- 2/6** A new synthetic isothiocyanate derivative (MG28) as an immunogenic cell death inducer: *in vitro* characterization of its pharmaco-toxicological profile  
*Catanzaro E., Calcabrini C., Milelli A., Sestili P., Agostinis P., Greco G., Turrini E., Hrelia P., Fimognari C.*
- 2/7** Tumor stemness and cancer drug-resistance: role of aldehyde dehydrogenase 1A1  
*Ciccone V., Terzuoli E., Donnini S., Morbidelli L., Ziche M.*



## Poster Session

- 2/8 Effects of NO and H<sub>2</sub>S releasing doxorubicin on a xenograft model of chemoresistant prostate cancer**  
*Cinci L., Bigagli E., De Angioletti M., Chegaev K., Riganti C., D' Ambrosio M., Saponara S., Luceri C.*
- 2/9 Role of mitochondria in cisplatin-resistance phenomena**  
*Cocetta V., Catanzaro D., Vianello C., Ragazzi E., Montopoli M.*
- 2/10 Growth hormone secretagogues prevent cisplatin-induced muscle wasting: characterization of multiple mechanisms involving sarcoplasmic reticulum and mitochondria**  
*Conte E., Pesce V., Camerino G.M., Mele A., Sirago G., De Bellis M., Pierno S., Rana F., Fonzino A., Rizzi L., Fehrentz J., Martinez J., Torsello A., Conte D., Cantatore P., Liantonio A.*
- 2/11 Pharmacological characterization of new antagonist of the EPH receptors endowed with anti-angiogenic activity**  
*Corrado M., Giorgio C., Incerti M., Russo S., Ballabeni V., Barocelli E., Lodola A., Tognolini M.*
- 2/12 Lipid content of human tumor exosomes may explain their resistance in biological fluids**  
*Accattatis F., Ferro S., De metrio S., Granata A., Corsini A., Huber V., Arnaboldi L.*
- 2/13 Inhibition of SIRT1 deacetylase uncouples anti-inflammatory and chemo-preventive actions of NSAIDs**  
*Dell'Omo G., Vantaggiato C., Parravicini C., Borroni A.P., Rizzi N., Bassi F.D., Prunerì G., Conti P., Eberini I., Maggi A., Ciana P.*
- 2/14 Metronomic vinorelbine is active on EGFR-WT and EGFR L858R/T790M non small cell lung cancer cells, alone and in combination with EGFR tyrosine kinase inhibitors**  
*Salvia C.G., Orlandi P., Di Desidero T., Muscatello B., Francia G., Bocci G.*
- 2/15 Colon cancer therapy beyond tumor progression: evaluation of the effects of switched schedules and related pharmacodynamic biomarkers**  
*Di Desidero T., Orlandi P., Fioravanti A., Cremolini C., Antoniotti C., Loupakis F., Falcone A., Bocci G.*
- 2/16 A multiple approach allowed unveiling the mechanism of action of the anti-cancer natural compound oridonin**  
*Vasaturo M., Fiengo L., Cotugno R., Belisario A., De Tommasi N., Filippelli A., Dal Piaz F.*

## Poster Session

- 2/17 Rimonabant kills colon cancer stem cells without inducing toxicity in normal colon organoids**  
*Fiore D., Ramesh P., Proto M.C., Piscopo C., Bifulco M., Medema J.P., Gazzero P.*
- 2/18 In vitro assessment of cabazitaxel activity in adrenocortical carcinoma cells**  
*Fragni M., Palma Lopez L.P., Rossini E., Galli D., Tiberio G.A., Berruti A., Memo M., Sigala S.*
- 2/19 Vanadium compounds inhibit cell proliferation via mapk and cell cycle arrest**  
*Gallicchio M., Barge A., Deagostino A., Ghibaudi E., Laurenti E., Marabello D., Cadamuro S., Diana E., Boscaro V.*
- 2/20 Surfaced-enhanced Raman spectroscopy (SERS) as an innovative pharmacological tool to quantify thiopurine metabolites in immortalized human hepatocytes (IHH)**  
*Genova E., Pelin M., Fornasaro S., Bonifacio A., Decorti G., Stocco G.*
- 2/21 Targeting S100B-P53WT protein-protein interaction with pentamidine: a novel approach to contrast chronic inflammation-induced colon cancer drift**  
*Gigli S., Sequella L., Pesce M., Steardo L., Sarnelli G., Esposito G.*
- 2/22 6-(methylsulfinyl) hexylisothiocyanate as potential chemopreventive agent: molecular and cellular profile in leukemia cell lines**  
*Lenzi M., Cocchi V., Hrelia P.*
- 2/23 Subcutaneous slow-release metformin formulation grants high tissue drug levels and induce antitumoral effects. An in vivo feasibility pilot study**  
*Mattioli F., Marini V., Fucile C., Solari A., Daga A., Pattarozzi A., Baldassarri S., Zuccari G., Barbieri F., Caviglioli G., Florio T.*
- 2/24 Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways**  
*Molonia M.S., Speciale A., Allegra A., Guglielmo L., Musolino C., Saija A., Cimino F.*
- 2/25 Glucose-6-phosphate dehydrogenase as pharmacological target to overcome cisplatin resistance**  
*Catanzaro D., Gaude E., Orso G., Guzzo G., Rasola A., Ragazzi E., Caparrotta L., Frezza C., Montopoli M.*
- 2/26 Selection and characterization of a human ovarian cancer cell line resistant to auranofin**  
*Nobili S., Landini I., Lapucci A., Pratesi A., Massai L., Napoli C., Perrone G., Pinzani P., Messori L., Mini E.*



## Poster Session

- 2/27** MDA-9/syntenin as a potential drug target in hepatocellular carcinoma  
*Notarbartolo M., Labbozzetta M., D'Alessandro N., Poma P.*
- 2/28** TRPM8 and experimental colorectal cancer: pharmacological evidence  
*Pagano E., Parisi O.A., D'Armineto M., Iannotti F., Aprea G., Pignatiello S., Izzo A.A., Borrelli F.*
- 2/29** Tryptophan 2,3-dioxygenase inhibition: a possible target in cancer immunotherapy  
*Parenti A., Cardellicchio M., Conciarelli G., Smedile T., Di Gennaro P., Gerlini G.*
- 2/30** Transient receptor potential vanilloid type 4 channel (TRPV4) is a key regulator of colorectal cancer development  
*Romano B.R., Petti L.P., Piontini A.P., Correale C.C., Izzo A.A., Danese S.D., Vetrano S.V.*
- 2/31** *In vitro* identification of molecular determinants that may enhance drug cytotoxicity in the testicular tumor germ cell line NTERA-2  
*Rossini E., Fragni M., Vezzoli S., Berruti A., Memo M., Sigala S.*

### P3 POSTER SESSION

#### BEHAVIOURAL PHARMACOLOGY AND TOXICOLOGY

Chairpersons: Gian Marco Leggio (Catania)- Fabio Tascedda (Modena)

- 3/1** E-cigarettes induce toxicological effects that can raise the cancer risk. A frame from drug-metabolism and antioxidant homeostasis  
*Canistro D., Vivarelli F., Cirillo S., Cardenia V., Rodriguez-Estrada M.T.*
- 3/2** Amphetamine and the "bath salt" 3,4-methylenedioxypyrovalerone (MDPV) alter accuracy of memory for emotional arousing experiences in rats  
*Colucci P., Mancini G.F., Santori A., Campolongo P.*
- 3/3** Next generation sequencing for identifying novel rare germline variants contributing to severe and life-threatening toxicity in patients treated with fluoropyrimidines  
*Ecca F., De Mattia E., Roncato R., Buonadonna A., De Paoli A., Berretta M., Mini E., Nobili S., Toffoli G., Cecchin E.*
- 3/4** Olfactory receptor 984 a new target for obesity in rats and humans?  
*Giusepponi M.E., Kern M., Micioni Di Bonaventura M.V., Polidori C., D'Addario C., Schon M., Dietrich A., Bluhner M., Klötting N., Cifani C.*

## Poster Session

- 3/5** Effects of subdiaphragmatic deafferentation on oleylethanolamide-induced fos expression in brain areas involved in the control of feeding behavior  
*Koczwara J.B., Romano A., Gallelli C.A., Azari E.K., Langhans W., Gaetani S.*
- 3/6** Changes in the endocannabinoid system underlie the altered social behavior observed in a rat model of autism spectrum disorders  
*Melancia F., Servadio M., Schiavi S., Manduca A., Cartocci V., Pallottini V., Trezza V.*
- 3/7** Chronic oleylethanolamide treatment in diet-induced obese rats: effect on food intake, body weight and gut microbiota  
*Romano A., Rastelli M.L., Everard A., Koczwara J.B., Gallelli C.A., Cani P.D., Gaetani S.*
- 3/8** Autistic-like behavioral abnormalities observed in female rat prenatally exposed to valproic acid  
*Schiavi S., Servadio M., Melancia F., Trezza V.*

### P4 POSTER SESSION

#### CARDIOVASCULAR PHARMACOLOGY

Chairpersons: Domenica Altavilla (Messina), Vincenzo Mollace (Catanzaro), Giuseppe Danilo Norata (Milan), Michael Spedding (Paris, France)

- 4/1** Carbaprostacyclin prevents venous thrombosis in COX-2 KO mice: the new role of monocytes  
*Amadio P., Sandrini L., Tarantino E., Tremoli E., Barbieri S.S.*
- 4/2** Targeting platelet purinergic signalling as a potential therapeutic approach for cancer  
*Ballerini P., Grande R., Dovizio M., Guillem-Ilobat P., Petragnani N., Patrignani P.*
- 4/3** Proatherosclerotic effect of trimethylamine-N-Oxyde: *in vitro* preliminary evidences  
*Battista S., Mele L., Adamo A., De Francesco R., Aragones G., Bernini F., Del Rio D., Zanotti I.*
- 4/4** Apolipoprotein E modulates adaptive immune response by promoting cellular cholesterol metabolism  
*Bonacina F., Coe D., Wang G., Baragetti A., Garlaschelli K., Pellegatta F., Grigore L., Catapano A., Marelli-Berg F., Norata D.*



## Poster Session

- 4/5 **G-protein coupled estrogen receptor (GPER) and phosphofructokinase-2/fructose-2,6-bisphosphatase 3 (PFKFB3) are involved in estrogen-mediated angiogenesis**  
*Boscaro C., Trenti A., Tedesco S., Ferri N., Trevisi L., Bolego C., Cignarella A.*
- 4/6 **Statin therapy: CLC-1 chloride channel as a biological marker of myopathy in humans**  
*Camerino G.M., Musumeci O., Conte E., Barca E., Toscano A., Pierno S.*
- 4/7 **Impaired glucose and lipid metabolism affects mitochondrial function in experimental diabetes-induced cardiac remodelling: role of MMP-2**  
*Gliozzi M., Scarano F., Saverio N., Scicchitano M., Musolino V., Carresi C., Maiuolo J., Maretta A., Muscoli C., Mollace V.*
- 4/8 **Bergamot polyphenols protect against doxorubicin-induced cardiomyopathy reducing ros production and promoting myocyte survival**  
*Carresi C., Musolino V., Gliozzi M., Giancotta C., Scarano F., Oppedisano F., Paone S., Palma E., Muscoli C., Mollace V.*
- 4/9 **Ranolazine attenuates adverse myocardial remodeling, lung capillaries and endothelial dysfunction in a model of heart failure with preserved ejection fraction**  
*Ciuffreda L.P., De Angelis A., Cappetta D., Esposito G., Piegari E., Urbanek K., Rossi F., Berrino L.*
- 4/10 **Fluoroscopy-associated oxidative stress and cellular damage in patients with atrial fibrillation or ventricular arrhythmias undergoing transcatheter ablation: prevention by N-acetylcysteine pre-treatment.**  
*Di Minno A., Casella M., Russo E., Ribatti V., Turnu L., Porro B., Manega C.M., Cavalca V., Tremoli E.*
- 4/11 **In vitro cardiovascular toxicity risk assessment of novel H<sub>2</sub>S-donating anthracycline**  
*Durante M., Frosini M., Fusi F., Riganti C., Gazzano E., Chegaev K., Saponara S.*
- 4/12 **S1PR1, S1PR3 and FTY720 in vascular tone and blood pressure regulation**  
*Gargiulo A., Cantalupo A., Dautaj E., Liu C., Zhang Y., Hla T., Bucci M., Di Lorenzo A.*
- 4/13 **Lipidomics of eicosanoids generated by the cross-talk between platelets and cancer cells: modulation by cyclooxygenase inhibitors**  
*Grande R., Schiavone S., Dovizio M., Tacconelli S., Fullone R., Hinz C., O'Donnell V., Patrignani P.*



## Poster Session

- 4/14 **3-Mercaptopyruvate relaxes aorta ring with a non enzymatic mechanism**  
*Gurgone D., Mitidieri E., Tramontano T., Donnarumma E., Citi V., Calderone V., Nagahara N., Papapetropoulos A., Cirino G., D'Emmanuele Di Villa Bianca R., Sorrentino R.*
- 4/15 **Vitamin D replacement in pre-menopausal women ameliorates cholesterol-related serum lipoprotein functions, adipokines profile and vascular markers of subclinical atherosclerosis**  
*Marchi C., Greco D., Kocyigit D., Adorni M.P., Ronda N., Bernini F., Gurses K.M., Oguz S.H., Gurlek A., Tokgözoğlu L., Zimetti F.*
- 4/16 **Sildenafil improves cardiac function in a rat model of cancer cachexia**  
*Musolino V., Carresi C., Gliozzi M., Bosco F., Nucera S., Giancotta C., Tavano D., Scarano F., Scicchitano M., Maiuolo J., Maretta A., Oppedisano F., Palma E., Muscoli C., Mollace V.*
- 4/17 **Potential mechanisms linking defects in methylene tetrahydrofolate reductase (MTHFR) and cryptogenic stroke predisposition. A preliminary study**  
*Nacci C., Potenza M.A., Sgarra L., Acquaviva T., De Cillis E., Bortone A.S., Montagnani M.*
- 4/18 **Recombinant LCAT rescues defective HDL mediated endothelial protection in acute coronary syndrome**  
*Ossoli A., Simonelli S., Varrenti M., Morici N., Oliva F., Stucchi M., Gomaraschi M., Arnaboldi L., Corsini A., Veglia F., Karathanasis S., Franceschini G., Calabresi L.*
- 4/19 **Cardiotoxic effects of short-term doxorubicin administration: involvement of connexin 43 in calcium impairment**  
*Pecoraro M., Ciccarelli M., Iaccarino G., Pinto A., Popolo A.*
- 4/20 **CM554, a new potent and selective inos inhibitor: synthesis, docking study, and ex vivo biological evaluation**  
*Potenza M.A., Macallini C., Di Matteo M., Gallorini M., Ammazalorso A., De Filippis B., Re N., Graziani V., Di Silvestre S., Fantacuzzi M.L., Giampietro L., Pandolfi A., Cataldi A., Amoroso R., Montagnani M.*
- 4/21 **Intermittent antagonism of BK2-receptor triggers the most effective kinin-dependent postconditioning**  
*Potenza M.A., Sgarra L., Leo V., Nacci C., De Salvia M.A., Montagnani M.*
- 4/22 **Environmental chronic stress induces abnormal megakaryopoiesis predisposing to thrombosis: protective effects of apocynin**  
*Sandrini L., Ieraci A., Amadio P., Popoli M., Tremoli E., Barbieri S.S.*



## Poster Session

- 4/23** Hypercholesterolemia modulates mitochondrial dysfunction in RAT diabetic cardiomyopathy  
*Scarano F., Gliozzi M., Musolino V., Carresi C., Nucera S., Scicchitano M., Maiuolo J., Mareta A., Bosco F., Giancotta C., Oppedisano F., Tavano D., Palma E., Muscoli C., Mollace V.*
- 4/24** The H<sub>2</sub>S-donor, 4-CPI, promotes anti-ischemic effects through activation of cardiac mitokapt and reduction of oxidative stress  
*Testai L., Brancaleone V., Breschi M., Bucci M., Cirino G., Citi V., Gargini M., Martelli A., Piano I., Calderone V.*
- 4/25** Anti-angiogenic effect of therapeutic concentrations of digitoxin  
*Trenti A., Zulato E., Pasqualini L., Indraccolo S., Bolego C., Trevisi L.*
- 4/26** Effects of digitoxin on cell migration in the ovarian cancer microenvironment  
*Trenti A., Boscaro C., Tedesco S., Cignarella A., Trevisi L., Bolego C.*
- 4/27** Pharmacological modulation of cardiac QT interval prolongation through ALR2 selective inhibition  
*Trotta M.C., Maisto R., D'Amico M., Di Filippo C.*

### P5 POSTER SESSION

#### DEMENTIA AND ALZHEIMER DISEASE

Chairpersons: Filippo Caraci (Catania), Elena Marcello (Milan), Yongxiang Zhang (Beijing, China)

- 5/1** GEBR-32A, a new promising PDE4D inhibitor for treatment of Alzheimer's disease  
*Balbi M., Rebosio C., Brullo C., Prickaerts J., Arancio O., Bruno O., Calcagno E., Ricciarelli R., Fedele E.*
- 5/2** Effect of palmytolethanolamide in 3XTG-AD astrocytes as an *in vitro* model of Alzheimer's disease  
*Bronzuoli M.R., Facchinetti R., Letizia A., Cassano T., Steardo L., Scuderi C.*
- 5/3** Behavioural and neuropathological effects of intranasal insulin treatment in a triple-transgenic mouse model of Alzheimer's disease (3xTG-AD)  
*Calcagnini S., Barone E., Lavecchia A.M., Lancioni M., Meconi A., Perluigi M., Cassano T.*

## Poster Session

- 5/4** Effect of ultramiconized-palmytolethanolamide on astrocyte dysfunction in a triple transgenic model of Alzheimer's disease  
*Facchinetti R., Bronzuoli M.R., Letizia A., Cassano T., Steardo L., Scuderi C.*
- 5/5** cGMP modulates long-term potentiation and memory by enhancing abeta production  
*Fedele E., Rebosio C., Balbi M., Calcagno E., Gulisano W., Arancio O., Palmeri A., Puzzo D., Ricciarelli R.*
- 5/6** Neuroprotective effects of the novel marine carotenoid fucoxanthin in human neuronal SH-SY5Y cells  
*Pruccoli L., Sita G., Morroni F., Hrelia P., Tarozzi A.*
- 5/7** The 6-(methylsulfinyl)hexyl isothiocyanate as neuroprotective agent in a murine model of Alzheimer's disease  
*Sita G., Morroni F., Graziosi A., Tarozzi A., Hrelia P.*
- 5/8** The contribution of microglia to the enhanced synaptic activity that precedes AB-induced neuronal death  
*Spampinato S.F., Merlo S., Beneventano M., Sortino M.A.*

### P6 POSTER SESSION

#### DRUGS, STEM CELLS AND CELL THERAPY

Chairpersons: Carla Ghelardini (Florence) - Mariagrazia Grilli (Novara)

- 6/1** bFGF/FGFR1 signaling is the main target of the cytotoxic activity of sorafenib in human pleural mesothelioma tumor-initiating cells  
*Barbieri F., Pattarozzi A., Delodi G., Favoni R.E., Wurth R., Daga A., Florio T.*
- 6/2** Glucocorticoid-Induced Leucine Zipper (GILZ) regulates hematopoietic stem and progenitors cell function  
*Bruscoli S., Flamini S., Frammartino T., Donnini S., Gagliardi A., Adamo F., Bereshchenko O., Riccardi C.*
- 6/3** The effect of ARA-C treatment on hematopoietic stem cell expansion and leukemogenesis in a mouse model of cebpa mutant acute myeloid leukemia  
*Flamini S., Bereshchenko O., Cimino M., Culicchi F., Bruscoli S., Riccardi C.*



## Poster Session

- 6/4** Angiotensin-II activates p-38 and the growth of human satellite cells: a role for type 1 receptor activation in self-renewal?  
*Laurino A., Blescia S., Mugelli A., Cerbai E., Sartiani L., Raimondi L.*
- 6/5** Measurement of deferasirox plasma concentrations in pediatric hematopoietic stem cell transplantation patients with iron overload. Is it useful the application in clinical practice?  
*Mattioli F., Fucile C., Marini V., Gregori M., Simeone R., Sonzogni A., Maximova N., Martelli A.*
- 6/6** Enhancement of cardiac differentiation of mouse pluripotent stem cells by  $\beta 3$  adrenoceptor stimulation  
*Spinelli V., Sartiani L., Laurino A., Raimondi L., Calvani M., Filippi L., Mugelli A., Cerbai E.*
- 6/7** Studying the mechanism of rat adipose derived stem cells in counteracting oxaliplatin-induced neuropathy: similarities with bevacizumab  
*Tenci B., Di Cesare Mannelli L., Micheli L., Maresca M., Lucarini E., Trallori E., Awada K., Vona A., Failli P., Ghelardini C.*
- 6/8** VEGF involvement in the oxaliplatin-induced neuropathy in rats: effect of adipose stem cells  
*Vona A., Tenci B., Di Cesare Mannelli L., Micheli L., Lucarini E., Ghelardini C., Failli P.*

### P7 POSTER SESSION

#### DRUGS OF ABUSE

Chairpersons: Carla Cannizzaro (Palermo) - Mariaelvina Sala (Milan)

- 7/1** An extract of *Hypericum perforatum* L. counteracts histone modifications elicited by prolonged cocaine administration in mouse hippocampus and prefrontal cortex  
*Dattoli S.D., De Pasquale D., Aguilar M.A., Fugazzotto F., Occhiuto F., Spampinato S.*
- 7/2** Evaluation of salivary catalase in smokers and non-smokers: role of oral hygiene and salivary PH  
*Giorgi G., Tornaboni G., Pannini S., Menchiari A., Micheli L., Loré F.*
- 7/3** Repeated exposure to cocaine during adolescence alters BDNF expression and signaling in reward-related brain regions  
*Messa G., Mottarlini F., Giannotti G., Caffino L., Racagni G., Fumagalli F.*

## Poster Session

- 7/4** Epigenetic mechanisms in the development of psychiatric disorders triggered by adolescent THC exposure in male rats  
*Penna F., Prini P., Sciuccati E., Parolaro D., Rubino T.*
- 7/5** Prosocial and anxiolytic effect of two synthetic phenethylamines in zebrafish: role of 5-HT<sub>2A/C</sub> subtype receptors  
*Ponzoni L., Braida D., Sala M.*
- 7/6** Role of dorsomedial striatum neuronal ensembles in incubation of methamphetamine craving after voluntary abstinence  
*Ratano P., Venniro M., Zhang M., Bossert J.M., Warren B.L., Hope B.T., Shaham Y., Caprioli D.*

### P8 POSTER SESSION

#### EXPERIMENTAL AND CLINICAL TOXICOLOGY

Chairpersons: Francesca Maffei (Bologna), Roberto Tonelli (Bologna), Aurelia Tubaro (Trieste)

- 8/1** Effects of electronic cigarette vapors exposure on oxidative damage and antioxidant status  
*Bigagli E., Canistro D., Paolini M., Vivarelli F., Cirillo S., Lodovici M.*
- 8/2** Analytically confirmed post-injection delirium/sedation syndrome (PDSS) occurred after olanzapine long-acting injection administration  
*Buscaglia E., Di Giulio S., Petrolini V.M., Scaravaggi G., Garbi M., Lodrini G., Carbone M., Lambiase C., Locatelli C.A.*
- 8/3** Methotrexate therapeutic error in non-oncology setting  
*Buscaglia E., Di Giulio S., Schicchi A., Lodrini G., Lonati D., Scaravaggi G., Vecchio S., Locatelli C.A.*
- 8/4** Gamma-hydroxybutyrate intoxication in Italy related to a pharmaceutical preparation  
*Di Giulio S., Buscaglia E., Petrolini V.M., Costa V., Crevani M., Garbi M., Scaravaggi G., Ricci G., Locatelli C.A.*
- 8/5** Characterization of the mechanisms of oxidative stress induction by graphene-based materials in human keratinocytes  
*Fusco L., Pelin M., Martín C., Sosa S., Vázquez E., Prato M., Tubaro A.*



## Poster Session

- 8/6 NO level and oxidative stress in viable spermatozoa of infertile males**  
*Fiaschi A.I., Cerretani D., Micheli L., Moltoni L., Moretti E., Collodel G., Giorgi G.*
- 8/7 Genetic identification of Na<sup>+</sup>/K<sup>+</sup> ATPase isoforms involved in the *in vitro* sensitivity to the algal toxin palytoxin**  
*Pelin M., Brovedani V., Florio C., Stocco G., Sosa S., Tubaro A.*
- 8/8 Cadmium and its role in brain dysfunction: neuroprotective effects of Polydeoxyribonucleotide administration in a murine model of cadmium toxicity**  
*Rinaldi M., Minutoli L., Marini H., Irrera N., Puzzolo D., Bitto A., Pallio G., Pizzino G., Adamo E.B., Altavilla D., Squadrito F.*
- 8/9 Antidote treatment in Viper envenomation in Italy: a comparison between two antivenoms during four-year experience**  
*Scaravaggi G., Lonati D., Di Giulio S., Schicchi A., Crevani M., Vecchio S., Buscaglia E., Locatelli C.A.*
- 8/10 Mitochondrial effects of trivalent arsenic**  
*Guidarelli A., Fiorani M., Cerioni L., Capellacci V., Crinelli R., Cantoni O.*

### P9 POSTER SESSION

#### IMMUNOPHARMACOLOGY

Chairpersons: Francesca Fallarino (Perugia), Giuseppe Nocentini (Perugia)

- 9/1 Fatty acid synthesis is crucial for immune cell activation: role of the sterol regulatory element binding protein in T cells**  
*Bonacina F., Cermenati G., Caruso D., Mitro N., Catapano A., Mitro N., Norata D.*
- 9/2 Immunosurveillance of tumors: ige as a new player**  
*Nigro E.A., Ferreira L.M., Achatz-Straussberger G., Ambrosi A., Sanvito F., Siccardi A., Vangelista L., Brini A.T.*
- 9/3 Prevention of diabetes in NOD mice by increasing GITR positive Treg cells by low doses of anti-GITR antibody**  
*Cari L., Nocentini G., Montanucci P., Basta G., Ricci E., Petrillo M.G., Shimizu J., Pescara T., Calafiore R., Riccardi C.*

## Poster Session

- 9/4 Effect of amphetamine on choroid plexus permeability and immune cell trafficking to the brain: a novel mechanism in the pharmacological management of ADHD**  
*Castellani G., Mereu M., Contarini G., Papaleo F., De Martin S.*
- 9/5 Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in SLE patients with prolonged inactive disease**  
*Pingeon M., Charlier B., Iudici M., Dal Piaz F., Finelli A., Izzo V., Filippelli A.*
- 9/6 A novel methodology for the dosage of hydroxychloroquine and its metabolites in whole blood of patients affected by autoimmune diseases**  
*Charlier B., Pingeon M., Dal Piaz F., Romano M., De Bonis E., Valentini G., Filippelli A.*
- 9/7 Stimulation of CB2 receptor affects activation and polarization of CD4<sup>+</sup> T lymphocytes**  
*Gentili M., Ricci E., De Novellis V., Ronchetti S., Maione S., Guida F., Riccardi C., Rossi F.*
- 9/8 Levels of soluble CD73 in melanoma patients**  
*Morello S., Sorrentino C., Capone M., Madonna G., Mallardo D., Grimaldi A., Pinto A., Ascierio P.*
- 9/9 High variability in tacrolimus blood levels in patients with kidney, liver or heart transplant**  
*Pallio G., Arcoraci V., Bitto A., Pizzino C.G., Galfo F., Irrera N., Mannino F., Rinaldi M.G., Minutoli L., Altavilla D., Squadrito F.*
- 9/10 Structure based approach for search of protein-protein interaction disruptors as inhibitors of GITRL-GITR signaling**  
*Platania C.B., Bucolo C., Riccardi C., Drago F., Salomone S.*
- 9/11 Myopericarditis and vaccines: gaining insights into vaccine adverse event reporting system**  
*Mei R., Raschi E., Forcesi E., Diemeberger I., Poluzzi E., De Ponti F.*
- 9/12 Crosstalk between adenosine and notch pathways in CD8<sup>+</sup> T-cells**  
*Sorrentino C., Rodriguez P.C., Hossain F., Pannuti A., Miele L., Morello S.*
- 9/13 Targeting nicotinamide phosphoryltransferase (NAMPT) in inflammatory bowel disease.**  
*Travelli C., Colombo G., Porta C., Galli U., Zito A., Malavasi F., Genazzani A.A.*

## Poster Session

## P10 POSTER SESSION

## INFLAMMATION PHARMACOLOGY

Chairpersons: Stefano Bruscoli (Perugia), Antonio Calignano (Naples), Giuseppina Cantarella (Catania), Fausto Chiazza (Turin), Massimo Collino (Turin), Emanuela Esposito (Messina)

- 10/1 Intestine as a source of inflammation in chronic kidney disease: effect of indoxyl sulfate**  
*Marzocco S., Adesso S., Campolo M., Cuzzocrea S., Di Iorio BR., Autore G., Pinto A.*
- 10/2 Nivalenol and deoxynivalenol induce inflammation and increase lipopolysaccharide and interferon-gamma effects on intestinal epithelial cells**  
*Adesso S., Severino L., Quaroni A., Autore G., Marzocco S.*
- 10/3 N-(1-carbamoyl-2-phenylethyl) butyramide (FBA), a butyrate-releasing derivative, improves antibiotic-induced intestinal injury in mice**  
*Annunziata C., Lama A., Pirozzi C., Di Guida F., Nitrato Izzo A., De Caro C., Mollica M.P., Calignano A., Mattace Raso G., Meli R.*
- 10/4 Characterization of adipokines serum levels in osteoarthritis mouse models STR/ort before the onset of the pathology and correlation between adiponectin serum levels and disease severity**  
*Bernini S.K., Giambelli R., Perrella M., Grotti A., Cavagnoli R., Samuelli G., Barbetta B., Garofalo P., Zanelli T., Caselli G., Rovati L.C.*
- 10/5 Blockade of EphB-ephrinB signalling protects against murine TNBS-induced colitis**  
*Bertoni S., Grandi A., Zini I., Cantoni A.M., Tognolini M., Vivo V., Castelli R., Barocelli E.*
- 10/6 Development of microparticles for oral administration of the non-conventional radical scavenger IAC and testing in an inflammatory rat model**  
*Cirillo S., Paolini M., Vivarelli F., Passerini N., Albertini B., Di Sabatino M., Corace G., Luppi B., Canistro D.*
- 10/7 Effect of ultrafine particle matter on human peripheral blood mononuclear cells of chronic obstructive pulmonary disease patients: involvement of the inflammasome**  
*Colarusso C., De Falco G., Terlizzi M., Imitazione P., Commodo M., Sirignano M., D'Anna A., Aquino R.P., Pinto A., Molino A., Sorrentino R.*



## Poster Session

- 10/8 Bergamot Juice extract treatment improved inflammatory process associated with periodontitis induced by lipopolysaccharide (LPS) injection**  
*D'Amico R., Fusco R., Gugliandolo E., Di Paola R., Cuzzocrea S.*
- 10/9 Antiallergic activity of a novel  $\alpha_4\beta_1$  integrin antagonist requires blockade of mast cells and eosinophil adhesion and degranulation**  
*Dattoli S.D., Baiula M., De Marco R., Gentilucci L., Spampinato S.*
- 10/10 Modulation of the inflammatory response by hydrogen sulfide in a model of colitis-associated cancer**  
*De Cicco P., Panza E., Ercolano G., Armogida C., Maloy K., Cirino G., Ianaro A.*
- 10/11 Effects of taurine in dry eye models**  
*Fidilio A., Bucolo C., Platania C.B., Lazzara F., Geraci F., Drago F.*
- 10/12 Inhibition of inflammasome activation improves lung acute injury induced by carrageenan in a mouse model of pleurisy**  
*Fusco R., Gugliandolo E., Biundo F., Campolo M., Di Paola R., Cuzzocrea S.*
- 10/13 Protective role of conventional dendritic cells in experimental model of sepsis**  
*Gargaro M., Briseño C.G., Durai V., Theisen D.J., Bagadia P., Manni G., Scalisi G., Turco A., Anderson III D.A., Davidson IV J.T., Huang X., Murphy T.L., Puccetti P., Murphy K.M., Fallarino F.*
- 10/14 Bisphosphonates modulate bone biomarkers in treated primary human osteoblasts**  
*Giannasi C., Niada S., Brini A.T.*
- 10/15 Sulodexide prevents high glucose damage in human retinal endothelial cells through inhibition of AGE/RAGE signaling**  
*Giurdanella G., Lazzara F., Caporarello N., Lupo G., Anuso C.D., Eiandi C.M., Leggio G.M., Drago F., Bucolo C., Salomone S.*
- 10/16 PEA/PLD association, reduce inflammatory process associated to experimental mouse model of atherosclerosis, induced by carotid artery ligation**  
*Gugliandolo E., Fusco R., Biundo F., D'Amico R., Di Paola R., Cuzzocrea S.*
- 10/17 Adenosine 2A receptor stimulation activates Wnt/Beta-catenin signalling in bone**  
*Irrera N., Corciulo C., Squadrito F., Altavilla D., Cronstein B.N.*

## Poster Session

- 10/18** Curcumin potentiates the anti-inflammatory activity of flavocoxid at a post-transcriptional level in human chondrocytes with an inflammatory phenotype  
*Irrera N., Pizzino G., Bitto A., Pallio G., Arcoraci V., Galfo F., Minutoli L., Squadrito F., Altavilla D.*
- 10/19** Carbonic anhydrase IX and COX-2 inhibitors as a new class of anti-inflammatory drugs in a model of pulmonary fibrosis in mice  
*Lucarini L., Lanzi C., Durante M., Turano F., Carta F., Supuran C.T., Masini E.*
- 10/20** CpG type-A induction of an early protective environment in experimental multiple sclerosis  
*Manni G., Crooks J., Gargaro M., Vacca C., Volpi C., Pirro M., Scalisi G., Turco A., Romani R., Martino D., Rostami A., Puccetti P., Gran B., Fallarino F.*
- 10/21** GPR17-expressing oligodendrocyte precursor cells differentially react to damage in experimental autoimmune encephalomyelitis and cuprizone-induced demyelination.  
*Marangon D., Coppolino G.T., Lecca D., Viganò F., Fumagalli M., Furlan R., Dimou L., Abbracchio M.P.*
- 10/22** *In vitro* protective effects of cyanidin-3-O-glucoside on human intestinal epithelial cells exposed to palmitic acid  
*Muscarà C., Bashllari R., Molonia M.S., Ferrari D., Cristani M., Cimino F., Saija A., Speciale A.*
- 10/23** ASC-derived conditioned medium (CM) stimulates viability of osteoblasts and counteracts TNF $\alpha$ -induced inflammation in chondrocytes  
*Niada S., Giannasi C., Brini A.T.*
- 10/24** Estrogen promotes macrophage proliferation and polarization  
*Pepe G., Villa A., Maggi A., Locati M., Vegeto E.*
- 10/25** Small molecules to treat diabetic retinopathy: structure based *in-silico* approach for discovery of HuR inhibitors  
*Bucolo C., Platania C.B., Pittalà V., Pascale A., Drago F.*
- 10/26** Platelet-dependent activation of myofibroblasts and its prevention by selective inhibition of platelet cyclooxygenase-1 by aspirin  
*Sacco A., Dovizio M., Alberti S., Grande R., Tacconelli S., Bruno A., Patrignani P.*



## Poster Session

- 10/27** Generation of 12- hydroxyeicosatetraenoic acid-phospholipid-esterified in platelet-cancer cell crosstalk  
*Schiavone S., Dovizio M., Tacconelli S., Grande R., Fullone R., Sacco A., Marchisio M., Lanuti P., Hinz C., O'Donnell V., Patrignani P.*
- 10/28** Modulation of oxidative and inflammatory pathways by nature-inspired new hybrids: relevance for Nrf2 transcription factor involvement  
*Serafini M.M., Catanzaro M., Marchesi N., Simoni E., Pascale A., Racchi M., Amadio M., Rosini M., Lanni C.*
- 10/29** Sex bias in lipid mediator biosynthesis during acute inflammation and resolution  
*Troisi F., Pace S., Rossi A., Bilancia R., Rizza R., Sautebin L., Werz O.*
- 10/30** Aryl hydrocarbon receptor: a novel target for the anti-inflammatory activity of statin therapy  
*Turco A., Scalisi G., Gargaro M., Pirro M., Fallarino F.*
- 10/31** Beneficial effects of pharmacological modulation of epha-ephrina system on mesenteric i/r-induced inflammation in mice  
*Zini L., Vivo V., Cantoni A.M., Grandi A., Tognolini M., Flammini L., Ballabeni V., Bertoni S., Barocelli E.*

## P11 POSTER SESSION

## ION CHANNELS AND TRANSPORT MECHANISMS

Chairpersons: Jean-Francois Desaphy (Bari), Manuela Marcoli (Genoa), Domenico Tricarico (Bari)

- 11/1** Searching for novel drugs in myotonia congenita: evaluation of anthracene-9-carboxylic acid and niflumic acid binding sites and chaperone activity on CLC-1 chloride channel mutants  
*Altamura C., Imbrici P., Sahbani D., Toscano A., Mantegazza R., Lo Monaco M., Mangiatordi G.F., Nicolotti O., Carratù M.R., Desaphy J.F., Conte Camerino D.*
- 11/2** Skeletal muscle CLC-1 channel: from gene to protein, from birth to aging toward a personalized medicine  
*Conte E., Fonzino A., Cibelli A., De Luca A., Pierno S., Nicchia G.P., Camerino G.M.*

## Poster Session

- 11/3** Development of new benzothiazolamines to enhance use-dependent inhibition of voltage-gated sodium channels  
*Farinato A., Altamura C., Cavaluzzi M.M., Lentini G., Carratù M.R., Conte Camerino D., Desaphy J.F.*
- 11/4** Bartter's syndrome and kidney CLC-K channels: a pharmacovigilance-based drug discovery strategy to reprofile sartans as novel ligands  
*Imbrici P., Tricarico D., Mangiatordi G.F., Nicolotti O., Conte D., Liantonio A.*
- 11/5** Functional comparison among three variants affecting the same critical residue in the Kv7.2 potassium channel gene identified in patients with epilepsy and/or severe developmental impairment  
*Lauritano A., Miceli F., Cimino M., Onore M.E., Nappi P., Weckhuysen S., Cooper E.C., Tagliatela M.*
- 11/6** Stargazin regulates the biochemical and functional properties of Kv7.2 voltage-gated potassium channels  
*Manocchio L., Soldovieri M.V., Ambrosino P., Mosca I., Caldeira G., Rodrigues M., Carvalho A.L., Tagliatela M.*
- 11/7** Compound heterozygosis in the KCNQ3 gene in a patient with Early-Onset Epileptic Encephalopathy (EOEE)  
*Mosca I., Soldovieri M.V., Ambrosino P., Freri E., Castellotti B., Gellera C., Difrancesco J.C., Tagliatela M.*
- 11/8** Understanding the pathogenesis of oxaliplatin-induced peripheral neurotoxicity  
*Riva B., Potenzieri A., Lim D., Dionisi M., Carozzi V., Cavaletti G., Distasi C., Genazzani A.A.*

## P12 POSTER SESSION

## MEDICAL DEVICES AND NANOTECHNOLOGIES

Chairpersons: Arianna Carolina Rosa (Turin) - Antonello Petrella (Naples) -  
Katia Varani (Ferrara)

- 12/1** Importance of adherence to treatment in cardio-vascular pathologies and interventions for its improvement  
*Bianco S., Nunziata A.*
- 12/2** Clinical validation of the realquality RQ-HPV HR multiplex assay based on meijer's guidelines  
*Dalla Pozza A., Tiozzo S., Bortolozzo K., Mason S., Paladin D., Giusti P.*



## Poster Session

- 12/3** Molecular monitoring of chronic myeloid leukemia (CML): assessment of major molecular response (MMR) by a one-step RT-real-time PCR assay  
*Gonzalez Ruiz P., Gani A., Costanzi G., Mason S., Paladin D., Giusti P.*
- 12/4** Hepatitis C Virus Genotype 3H: the problem of the misdiagnosis  
*Tiozzo S., Bortolozzo K., Renesto A., Paladin D., Maestrelli P.*
- 12/5** Pulsed electromagnetic fields treatment mediates anti-inflammatory and chondroprotective effects through adenosine receptor pathway  
*Varani K., Vincenzi F., Ravani A., Pasquini S., Merighi S., Gessi S., Setti S., Cadossi M., Borea P.A., Cadossi R.*
- 12/6** Effects of Prisma® Skin dermal regeneration device containing glycosaminoglycans on re-epithelialization and granulation processes  
*Petrella A., Belvedere R., Bizzarro V., Parente L.*
- 12/7** Cutaneous hypoxia: effect of oxygen-loaded nanodroplets in human keratinocytes and fibroblasts  
*Piazza S., Fumagalli M., Prato M., Sangiovanni E., Finesso N., Troia A., Garibaldi G., Basilico N., Dell'Agli M.*
- 12/8** Solid lipid nanoparticles carrying temozolomide for melanoma treatment  
*Ferrara B., Dianzani C., Battaglia L., Muntoni E., Clemente N., Capucchio M.T., Biasibetti E., Schiffer D., Annovazzi L., Mellai M.*
- 12/9** Palmitoylethanolamide loaded in new nanostructured lipid carrier: an ocular PK study  
*Geraci F., Bucolo C., Platania C., Romano G., Puglia C., Pignatello R., Sommella E., Campiglia P., Ostacolo C., Drago F.*

## Poster Session

## P13 POSTER SESSION

## NEUROPHARMACOLOGY

Chairpersons: James Barrett (Philadelphia - USA), Sam Enna (Kansas City - USA), Cesare Mancuso (Rome), Annamaria Pittaluga (Genoa), Patrizia Romualdi (Bologna), Caterina Scuderi (Rome), Salvatore Salomone (Catania)

- 13/1** Therapeutic effect of systemic injection of human adipose stem cells or their secretome in an mouse model of diabetic neuropathy  
*Amodeo G., Moschetti G., Ferreira L.M., Franchi S., Borsani E., Brini A.T., Sacerdote P.*
- 13/2** Butyrate attenuates motor deficits and antibiotic-induced intestinal damage in 6-hydroxydopamine model of Parkinson's Disease in mice  
*Avagliano C., Russo R., De Caro C., Cristiano C., La Rana G., Meli R., Mattace Raso G., Calignano A.*
- 13/3** Conditioned medium of human periodontal stem cells from Multiple Sclerosis patients reduces the expression and release of inflammatory cytokines in human monocytic cell line (THP-1) challenged with Lipopolysaccharide (LPS)  
*Ballerini P., Trubiani O., Diomedea F., Petragnani N., Merciaro I., Bruno A., Patrignani P.*
- 13/4** Salmeterol, a selective and long-lasting  $\beta_2$ -adrenergic agonist, promotes hippocampal neuroplasticity  
*Bondi H., Bortolotto V., Cuccurazzu B., Rinaldi M., Canonico P.L., Grilli M.*
- 13/5** Studying social withdrawal in a mouse model of autism spectrum disorders using the visible burrow system  
*Bove M., Trabace L.*
- 13/6** Influence of chronic stress exposure on cognitive performance: a role for glucocorticoid receptors  
*Brivio P., Calabrese F., Racagni G., Papp M., Riva M.A.*
- 13/7** Differential contribution of IH in dendritic excitability in substantia nigra and ventral tegmental area dopaminergic neurons  
*Carbone C., Costa A., Provensi G., Mannaioni G., Masi A.*
- 13/8** Cross-disease analysis of Alzheimer's disease and type-2 diabetes highlights the role of autophagy in the pathophysiology of two highly comorbid diseases  
*Carboni L., Lauria M., Nguyen T.P., Rimondini R., Maioli S., Cedazo-Minguez A., Sita G., Morroni F., Corsi M., Caberlotto L.*



## Poster Session

- 13/9** Dimethyl fumarate attenuates neuroinflammation and neurobehavioral deficits induced by experimental traumatic brain injury  
*Casili G., Campolo M., Paterniti I., Lanza M., Filippone A., Cuzzocrea S., Esposito E.*
- 13/10** Involvement of NCX in glutamate-induced neuroprotection in an *in vitro* model of ischemia/reperfusion injury  
*Castaldo P., Macrì M.L., Piccirillo S., Bastioli G., Magi S., Lariccia V., Amoroso S.*
- 13/11** Vulnerability to seizures and astrocytes: a model mouse of deregulated polyamine metabolism  
*Cervetto C., Marcoli M., Venturini A., Vergani L., Passalacqua M., Berretta N., D'Amelio M., Maura G., Voci A., Mariottini P., Cervelli M.*
- 13/12** Effects of histone deacetylase inhibitors on the development of epilepsy and psychiatric comorbidity in WAG/RIJ rats  
*Citraro R., De Caro C., Leo A., Amodio N., Russo E., De Sarro G.*
- 13/13** The fat sensing molecule oleoylethanolamide induces antidepressant-related responses by targeting ppar- $\alpha$  and recruiting the histaminergic neurotransmission  
*Costa A., Cristiano C., Ghalardini C., Blandina P., Calignano A., Passani M.B., Provensi G.*
- 13/14** Hypothalamic circuit mediates therapeutic appetite suppressive effect of 5-HT obesity medication  
*Cristiano C., Burke L.K., D'Agostino G., Georgescu T., Roussel G., Calignano A., Heisler L.K.*
- 13/15** Behavioral and metabolic characterization of a mouse model of autism spectrum disorder and a possible therapeutic effect of palmitoylethanolamide  
*Cristiano C., Coretti L., Lama A., Russo R., Mattace Raso G., Lembo F., Chiariotti L., Meli R., Calignano A.*
- 13/16** The selective histamine  $H_4$  receptor antagonist JNJ7777120 protects from behavioural and histological damage after focal transient brain ischemia in the RAT  
*Dettori I., Gaviano L., Melani A., Lucarini L., Masini E., Pedata F.*
- 13/17** Transplantation of meningeal-derived oligodendrocytes remyelinate lysophosphatidylcholine (lpc) spinal cord lesion  
*Dolci S., Pino A., Berton V., Rodriguez F.J., Zorzin S., Amoroso C., Fumagalli G.F., Bifari F., Decimo I.*



## Poster Session

- 13/18 Synergistic association of valproate and resveratrol reduces brain injury in ischemic stroke**  
*Faggi L., Pignataro G., Parrella E., Lanzillotta A., Porrini V., Mota M., Benarese M., Tonin P., Annunziato L., Spano P., Pizzi M.*
- 13/19 Effects of clonidine on hippocampal synaptic energy metabolism: a functional proteomic study**  
*Ferrari F., Basci J., Bagini L., Viscardi P., Viotti A., Gorini A., Villa R.F.*
- 13/20 Pharmacological characterization of PWT2-UFP-101**  
*Ferrari F., Cerlesi M.C., Malfacini D., Rizzi A., Ruzza C., Marzola E., Guerrini R., Calò G.*
- 13/21 Absence of TLR4 reduces neuroinflammation in an experimental *in vivo* model of Parkinson's disease.**  
*Filippone A., Campolo M., Paterniti I., Casili G., Lanza M., Esposito E., Cuzzocrea S.*
- 13/22 PPAR $\gamma$  Activation reduces alcohol drinking through Modulation of the Mesolimbic Dopamine Transmission in Genetically selected Alcohol-Preferring Rats.**  
*Fotio Y., Aboufares El Alaoui A., Petrella M., Acciarini S., Fusari V., Ciccocioppo R.*
- 13/23 Overtreatment in pharmaco-resistant epilepsy: a prospective randomized study of an intervention aimed at reducing adverse effects**  
*Franco V., Canevini M.P., Capovilla G., De Sarro G., Galimberti C.A., Fattore C., Guerini R., La Neve A., Rosati E., Specchio L.M., Striano S., Tinuper P., Perucca E.*
- 13/24 The selective antagonism of adenosine A<sub>2B</sub> receptors prevents synaptic and neuronal damage induced by oxygen and glucose deprivation in CA1 RAT hippocampus**  
*Fusco L., Lana D., Coppi E., Ugolini F., Dettori I., Gaviano L., Giovannini M.G., Pedata F., Pugliese A.M.*
- 13/25 The down regulation of mGluR5 attenuates the reactive phenotype in ALS spinal cord adult astrocytes expressing the SOD1<sup>G93A</sup> mutation**  
*Gallia E., Provenzano F., Bonifacino T., Usai C., Milanese M., Bonanno G.*
- 13/26 Functional interaction between nicotinic and NMDA receptors on dopaminergic synapses.**  
*Grilli M., Padolecchia C., Olivero G., Chen J., Modugno M., Pittaluga A., Marchi M.*
- 13/27 Multiple mechanisms of dimethyl fumarate in amyloid  $\beta$ -induced neurotoxicity in human neuronal cells**  
*Lanza M., Campolo M., Casili G., Philippone A., Paterniti I., Cuzzocrea S., Esposito E.*



## Poster Session

- 13/28 Histamine H<sub>3</sub> receptor antagonism is enhanced by pharmacological association with a nitric oxide donor in a new zealand white rabbit model of glaucoma**  
*Lanzi C., Lucarini L., Durante M., Pini A., Stark H., Masini E.*
- 13/29 Central effects induced by systemic pharmacological administration of 3-iodothyroacetic acid (TA<sub>1</sub>), an endogenous derivative of Thyroid Hormone**  
*Laurino A., Landucci E., Resta F., De Siena G., Pellegrini-Gampietro D.E., Masi A., Mannaioni G., Raimondi L.*
- 13/30 Role of TGF- $\beta$ 1 in age-related macular degeneration**  
*Lazzara F., Bucolo C., Leggio G.M., Fisichella V., Platania C.B., Fidilio A., Geraci F., Drago F.*
- 13/31 Vildagliptin improves animal behavior and cognitive impairment in a rat model of streptozotocin induced diabetes**  
*Leo A., Palleria C., De Sarro C., Nesci V., Citraro R., Arturi F., Russo E.*
- 13/32 Involvement of the Prokineticin system in *in vivo* models of A $\beta$ -induced neurotoxicity**  
*Maftai D., Fusco I., Scuderi C., Balboni G., Ratano P., Nistico R., Campolongo P., Lattanzi R.*
- 13/33 Down regulation of pro-inflammatory pathways by tanshinone IIA and cryptotanshinone in a non-genetic mouse model of Alzheimer disease.**  
*Maione F., Piccolo M., De Vita S., Chini M.G., Cristiano C., De Caro C., Lippiello P., Miniaci M.C., Santanaria R., Irace C., De Feo V., Calignano A., Mascolo N., Bifulco G.*
- 13/34 Acid-sensing ion channel 1A is required for mGluR-dependent longterm depression and is involved in AB-induced synaptic toxicity in the rodent hippocampus**  
*Mango D., Nisticò R.*
- 13/35 Development of novel lactate-NA<sub>2</sub>EDTA buffer-based F-DOPA formulations: toxicological investigation in rats and mice**  
*Maquod F., Denora N., Mele A., Curci A., Camerino G.M., Lopodota A., Cutrignelli A., Laquintana A., Franco M., Dimiccoli V., Tolomeo A., Scilimati A., Tricarico D.*
- 13/36 Identification of transcription factors activating NA<sup>+</sup>/CA<sup>2+</sup> exchanger isoform 3 gene in brain**  
*Mascolo L., Formisano L., Guida N., Laudati G., Serani A., Molinaro P., Di Renzo G., Annunziato L.*

## Poster Session

- 13/37** A<sub>2B</sub> adenosine receptors stimulate IL-6 production in primary murine microglia through p38 MAPK kinase pathway  
*Merighi S., Bencivenni S., Battistello E., Vincenzi F., Pasquini S., Ravani A., Varani K., Borea P., Gessi S.*
- 13/38** Ferulic acid affects memory consolidation in rats exposed to emotionally arousing experiences: evidence for the involvement of heme oxygenase system  
*Mhillaj E., Trabace L., Mancuso C., Cuomo V.*
- 13/39** The protective effect of naringenin in REEP1 drosophila model of hereditary spastic paraplegia is mediated by induction of ER-phagy  
*Napoli B., D'Elia N., Gumeni S., Fantin M., Forgiarini A., Corrà M., Montopoli M., Giron M.C., Martinuzzi A., Orso G.*
- 13/40** Study of microglia proliferation in response to IL-4  
*Pepe G., Villa A., Maggi A., Vegeto E.*
- 13/41** Involvement of bradykinin B2 receptor in NGF neuroprotective activity  
*Petrella C., Maino B., Petrocchi Passeri P., Ciotti M.T., Possenti R., Cavallaro S., Calissano P., Nisticò R., Piccinin S., Severini C.*
- 13/42** Meningeal neural precursors contribute to cortical neurons of aged mice  
*Pino A., Dolci S., Zorzin S., Llorens-Bobadilla E., Zhao S., Lange C., Panuccio G., Vinckier S., Wyns S., Bouché A., Giugliano M., Dewerchin M., Martin-Villalba A., Carmeliet P., Bifari F., Decimo I.*
- 13/43** *In-vivo* effects of knocking-down metabotropic glutamate receptor 5 in the SOD1G93A mouse model of amyotrophic lateral sclerosis  
*Provenzano F., Bonifacino T., Milanese M., Cattaneo L., Gallia E., Puliti A., Melone M., Bossi S., Usai C., Conti F., Bonanno G.*
- 13/44** Nabilone and THC/CBD for the treatment of failed back surgery syndrome (FBSS) refractory pain  
*Quattrone D., Mondello E., Bova G., Cardia L., Barbagallo A., Mondello C., Calapai F., Mannucci C., Calapai G.*
- 13/45** Release of [<sup>3</sup>H]GABA evoked by high affinity GABA uptake through GAT1 transporters occurs by homoexchange and through GAT1-independent, CA<sup>2+</sup>-mediated mechanisms  
*Raiteri L., Romei C.*



## Poster Session

- 13/46** Autoregulation of retinal ganglion cell function to metabolic challenge in glaucoma  
*Romano G.L., Chou T.H., Porciatti V., Bucolo C., Drago F.*
- 13/47** Tocilizumab's effect on epileptogenesis and psychiatric comorbidity in WAG/RIJ rats  
*Russo E., Leo A., Cassano V., Nesci V., De Sarro C., Citraro R.*
- 13/48** Contribution of astrocytes to neurogenic deficits associated with down syndrome  
*Salvalai M.E., Cvijetic S., Bortolotto V., Xia E., Grilli M.*
- 13/49** Anti-inflammatory and neuroprotective effects of co-ultraealut in a mouse model of vascular dementia  
*Siracusa R., Impellizzeri D., Cordaro M., Crupi R., Esposito E., Cuzzocrea S.*
- 13/50** Study on protective action of hydrogen sulfide in rat and mouse models of Alzheimer's disease  
*Vandini E., Giuliani D., Ottani A., Calevro A., Canalini F., Guarini S.*
- 13/51** Sestrin 3 as a regulator of pro-epileptic agents: the knock out rat model  
*Zucchini S., Roncon P., Lovisari F., Paolone G., Soukupova M., Falcicchia C., Binaschi A., Labasque M., Rossetti T., Petretto E., Johnson M.R., Simonato M.*

## P14 POSTER SESSION

## NUTRACEUTICALS

Chairpersons: Mario Dell'Agli (Milan), Lucia Morbidelli (Siena), Piero Sestili (Urbino), Domenico Trombetta (Bari)

- 14/1** Phytochemical investigation and antioxidant activity of *L. decidua* for Nutraceutical application  
*Baldan V., Ferrari S., De Nadai G., Francescato S., Dall'Acqua S.*
- 14/2** HPLC-MS Analysis of glucosinolates in *B. oleracea* for the development of new nutraceuticals  
*Baldan V., Sut S., Francescato S., Dall'Acqua S.*
- 14/3** Anti-atherosclerotic effects of nutraceutical compound "OXXYNEA® OMD" in hypercholesterolemic model of hamster  
*Piemontese A., Battista S., Romain C., Rouanet J.M., Bernini F., Cases J., Zanotti I.*



## Poster Session

- 14/4** Pathological gambling new therapeutical approach  
*Nunziata A., Bianco S., Maione S., Guida F.*
- 14/5** Tagatose beneficial effects in a rich-in-fructose diet induced dysmetabolic syndrome  
*Cirronis M., Lanzi C., Durante M., Lucarini L., Sgambellone S., Laurino A., Provensi G., Masini E.*
- 14/6** Need for evidence-based guidelines for improving phytotherapy in clinical practice  
*Colalto C.*
- 14/7** SPA therapy: sulphurous mineral water in gynecological disorders  
*Costantino M., Manzo V., Conti V., Iannaccone T., Marongiu M.B., Bove G., Filippelli W., Filippelli A.*
- 14/8** Evaluation of protective effect of *Brassica oleracea* against hepatic steatosis in rats  
*Della Croce C.M., Vizzarri F., Casamassima D., Menchini M., Longo V., Pozzo L.*
- 14/9** Protective effect of genistein-loaded transferosomes against H<sub>2</sub>O<sub>2</sub>-induced oxidative stress in PC12 cells  
*Fancello S., Langasco R., Cossu M., Galleri G., Gavini E., Migheli R.*
- 14/10** Leaf extract of *Morus alba*, a component of lopiglik, reduces the expression of proprotein convertase subtilisin kexin type 9 (PCSK9) in HEPG2 cell line  
*Ferri N., Marchianò S., Lupo M., Izzo R., Rozza F., Corsini A.*
- 14/11** Apigenin supplementation prevents colonic motor dysfunctions associated with high fat diet-induced obesity  
*Gentile D., Fornai M., Colucci R., Pellegrini C., Tirota E., Benvenuti L., Segnani C., Ippolito C., Duranti E., Viridis A., Carpi S., Nieri P., Pistelli L., Bernardini N., Blandizzi C., Antonioli L.*
- 14/12** Evaluation of protective effect against H<sub>2</sub>O<sub>2</sub>-induced oxidative stress and cytotoxic activity of a phenolic-rich fraction obtained from the leaves of *Isatis tinctoria* L. (Brassicaceae)  
*Lombardo G.E., Miceli N., Taviano M.F., Filocamo A., Dugo P., Lepore S.M., Celano M., Cacciola F., Russo D., Ragusa S.*
- 14/13** *Tithonia diversifolia* (Hemsl.) A. Gray - A systematic review of its ethnomedical uses, phytochemistry, pharmacotoxicology and clinical relevance  
*Mabou Tagne A., Marino F., Cosentino M.*

## Poster Session

- 14/14** Anti-proliferative effects of Cynaropicrin on anaplastic thyroid cancer cells  
*Maggisano V., Celano M., Lombardo G.E., Lepore S.M., Bulotta S., Maiuolo J., Mollace V., Russo D.*
- 14/15** Survivin and NAIP in human benign prostatic hyperplasia: protective role of the association of *Serenoa repens*, lycopene and selenium from the randomized clinical study  
*Minutoli L., Morgia G., Micali A., Rinaldi M., Irrera N., Marini H., Puzzolo D., Russo G.I., Cimino S., Bitto A., Pizzino G., Pallio G., Altavilla D., Squadrito F.*
- 14/16** An omega-3 PUFA/Vitamin A enriched diet to prevent cognitive deficits induced by the social instability stress  
*Provinsi G., Schmidt S.D., Costa A., Rani B., Cocchi M., Blandina P., Passani M.B.*
- 14/17** Safety of food supplements containing alfa lipoic acid: clues from the analysis of adverse events submitted to the italian surveillance system  
*Raschi E., Girardi A., Da Cas R., Moro P.A., De Ponti F., Menniti-Ippolito F., Mazzanti G.*
- 14/18** Creatine preserves the myogenic capacity of oxidant-stressed C2C12 myoblasts through mitochondrially-targeted mechanisms  
*Sestili P., Calcabrini C., Fimognari C.*
- 14/19** *In vitro* and *in vivo* modeling of lipid bioaccessibility and digestion from almond muffins: the importance of the cell-wall barrier mechanism  
*Smeriglio A., Grassby T., Mandalari G., Grundy M.M., Edwards C.H., Bisignano C., Trombetta D., Chessa S., Ray S., Sanderson J., Berry S.E., Ellis PR., Waldron K.W.*
- 14/20** Antioxidant effects of a hydroxytyrosol-based pharmaceutical formulation on body composition, metabolic state, and gene expression: a randomized double-blinded, placebo-controlled crossover trial  
*Trombetta D., Di Renzo L., Smeriglio A., Bernardini S., Cioccoloni G., Miranda R., Gualtieri P., De Lorenzo A.*
- 14/21** The chemopreventive effects of isothiocyanate moringin isolated from *Moringa oleifera* seeds  
*Vivarelli F., Paolini M., Michl C., Rasclé A., Weigl J., De Nicola G., Iori R., Cirillo S., Canistro D.*
- 14/22** Nutraceutical role of taurine for skeletal muscle disorders: an overview of its potential therapeutic interest  
*Pierno S., Conte Camerino D., De Luca A.*

## Poster Session

## P15 POSTER SESSION

## PAIN PHARMACOLOGY

Chairpersons: Sanzio Candeletti (Bologna), Santina Chiechio (Catania), Livio Luongo (Naples)

- 15/1** Palmitoylethanolamide reduces neuropsychiatric behaviors by restoring cortical electrophysiological activity in a Mouse Model of Mild Traumatic Brain Injury  
*Belardo C., Guida F., Boccella S., Iannotta M., De Gregorio D., Giordano C., Romano R., Palazzo E., Scafuro M.A., Serra N., De Novellis V., Rossi F., Maione S., Luongo L.*
- 15/2** Palmitoylethanolamide, via PPAR-alpha receptor, restores the altered synaptic plasticity and ameliorates the compromised pain-related behaviours in the hippocampus in neuropathic mice  
*Boccella S., Luongo L., Guida F., Belardo C., Iannotta M., Mazzitelli M., De Gregorio D., Romano R., Marabese I., Palazzo E., De Novellis V., Maione S.*
- 15/3** Activation of PPAR $\gamma$  as a new pharmacological strategy to treat neuropathic pain  
*Borruto A.M., Brunori G., Benvenuti F., Tarquini L., Lunerti V., Ubaldi M., Ciccocioppo R.*
- 15/4** Pharmacological effect of perampanel, a new ampa antagonist, in animal models of acute and chronic pain  
*De Caro C., Russo E., Citraro R., Russo R., Leo A., Leporini C., Avagliano C., Cristiano C., La Rana G., Aiello E., Santangelo E., Calignano A., De Sarro G.*
- 15/5** Aromatase inhibitor-evoked pain is promoted by the enzyme substrate, androstenedione, via transient receptor potential ankyrin 1 (TRPA1) in mice  
*De Logu F., Tonello R., Nassini R., Fusi C., Coppi E., Li Puma S., Marone I., Sadofsky L., Morice A., Susini T., Terreni A., Di Tommaso M., Geppetti P., Benemei S.*
- 15/6** Isoform-selective blockade of HCN channels in dorsal root ganglion neurons as a potential pharmacological strategy against pain  
*Dini L., Del Lungo M., Resta F., Melchiorre M., Spinelli V., Laurino A., Sartiani L., Mugelli A., Mannaioni G., Cerbai E., Romanelli M.N.*
- 15/7** D-aspartic acid ameliorates cognitive impairment in a mouse model of spared nerve injury and reduces B-amyloid AB<sub>1-40</sub> and AB<sub>1-42</sub> peptides  
*Iannotta M., Rosaria R., Belardo C., D'Aniello A., Luongo L., De Novellis V., Maione S.*

## Poster Session

- 15/8** The role of SIRT3 pathway in neuropathic pain and oxidative stress  
*Ilari S., Giancotti L.A., Lauro F., Morabito C., Malafoglia V., Gliozzi M., Tafani M., Fini M., Russo M., Mollace V., Salvemini D., Muscoli C.*
- 15/9** The antimigraine butterbur ingredient, isopetasin, desensitizes peptidergic nociceptors via the transient receptor potential ankyrin 1 channel.  
*Li Puma S., Benemei S., De Logu F., Marone I., Coppi E., Ugolini F., Liedtke W., Pollastro F., Appendino G., Geppetti P., Materazzi S., Nassini R.*
- 15/10** Alteration of visceral sensitivity after induction of colitis in rats: focus on the role of tryptophan in the development of abdominal pain  
*Lucarini E., Di Cesare Mannelli L., Micheli L., Maresca M., Tenci B., Trallori E., Awada K., Cozzi A., Milla M., Fornai M., Antonioli L., Blandizzi C., Ghelardini C.*
- 15/11** Into the unexplored pathophysiological role of the blood brain barrier during oxaliplatin-induced neuropathy  
*Maresca M., Di Cesare Mannelli L., Branca J., Micheli L., Tenci B., Lucarini E., Trallori E., Awada K., Morucci G., De Bock M., Leybaert L., Pacini A., Gulisano M., Ghelardini C.*
- 15/12** A preclinical set up of a rat model of folfox-induced neuropathy: effect of dimiracetam  
*Micheli L., Di Cesare Mannelli L., Maresca M., Lucarini E., Tenci B., Trallori E., Awada K., Farina C., Scherz M.W., Ghelardini C.*
- 15/13** Role of prokineticin system in a murine model of chemotherapy-induced peripheral neuropathy  
*Moschetti G., Amodeo G., Lattanzi R., Sacerdote P., Franchi S.*
- 15/14** Development of an *in vitro* model to test new putative Pannexin-1 inhibitors against neuropathic pain  
*Trallori E., Di Cesare Mannelli L., Maresca M., Tenci B., Lucarini E., Micheli L., Awada K., Crocetti L., Giovannoni M.P., Ghelardini C.*
- 15/15** Chemotherapy-induced neuropathic pain: P2X7 receptor and recruitment of pannexin1  
*Venturini A., Marcoli M., Di Cesare Mannelli L., Cervetto C., Tenci B., Micheli L., Maura G., Ghelardini C.*
- 15/16** Anti-nociceptive effects of novel highly potent A<sub>2A</sub> adenosine receptor inverse agonists  
*Vincenzi F., Varano F., Ravani A., Pasquini S., Merighi S., Gessi S., Catarzi D., Colotta V., Borea P.A., Varani K.*



## Poster Session

### P16 POSTER SESSION

#### PERSONALISED MEDICINE AND BIOMARKERS

Chairpersons: Rocchina Colucci (Padua) - Sandra Sigala (Brescia)

- 16/1 Carotid plaque-thickness and common carotid IMT show additive value in cardiovascular risk prediction and reclassification**  
*Amato M., Veglia F., Ravani A., Frigerio B., Sansaro D., Coggi D., Bonomi A., Tedesco C.C., Tremoli E., Baldassarre D.*
- 16/2 A priori-defined mediterranean-like dietary pattern predicts carotid intima media thickness progression and vascular events in a large european cohort**  
*Baldassarre D., Veglia F., Amato M., Di Minno A., Ravani A., Frigerio B., Sansaro D., Coggi D., Tedesco C.C., Tremoli E.*
- 16/3 CYP27A1 genetic polymorphism in cholesterol metabolism on relationship between obesity, cardiovascular risk and premature aging: results from a human cross-sectional study on obese population enrolled in the sphere project**  
*Pavanello S., Angelici L., Rota F., Hoxha M., Campisi M., Bollati V.*
- 16/4 Development of a novel direct biomarker of aspirin action on CYCLOOXYGENASE-2**  
*D'Agostino I., Tacconelli S., Contursi A., Sacco A., Dovizio M., Patrignani P.*
- 16/5 The role of the mRNA binding protein tristetraprolin in inflammatory bowel disease as a potential therapeutic target**  
*Di Silvestre A., Lucafò M., De Iudicibus S., Marshall J., Stocco G., Martelossi S., Ventura A., Clark A., Decorti G.*
- 16/6 Observational, prospective clinical study to evaluate discrepancies and inappropriate drugs in internal medicine, according to a multidisciplinary medication reconciliation protocol: a preliminary analysis**  
*Nunnari P., Ceccarelli G., Pani A., Romano A., Angelini J., Colombo F., Scaglione F.*
- 16/7 Hypoxia regulates ANXA1 expression to support prostate cancer cell invasion and aggressiveness**  
*Bizzarro V., Belvedere R., Migliaro V., Romano E., Parente L., Petrella A.*
- 16/8 Modeling ROS1 translocation in lung cancer: a translational model to test drug's efficacy**  
*Pizzino G., Kannan R., Altavilla D., Squadrito F., Ventura A., Bitto A.*

## Poster Session

### 16/9 Renal impairment in very low birth weight infants: role of drugs and potential biomarkers

*Girardi A., Galletti S., Vitali F., Leonardi L., Raschi E., Poluzzi E., De Ponti F.*

### 16/10 MIR-139-5P and MIR-455-5P as potential novel biomarkers in gastrointestinal stromal tumours (GIST)

*Ravegnini G., Sammarini G., Nannini M., Pantaleo M.A., Hrelia P., Angelini S.*

### 16/11 Genetic markers in nuclear receptors and inflammation-related genes as independent predictors of overall survival in metastatic colorectal cancer patients receiving first-line folfiri treatment

*De Mattia E., Cecchin E., Polesel J., Labriet A., Guillemette C., Roncato R., Dreussi E., Buonadonna A., D'Andrea M., Lévesque E., Jonker D., Couture F., Toffoli G., Bignucolo A.*

### 16/12 Screening of human sulfotransferase form-selective inhibitors suitable for metabolic reaction phenotyping studies

*Di Paolo V., Morbioli L., Laufkötter O., Sturlese M., Pons N., Caccuri A.M., Breda M., Moro S., Quintieri L.*

### P17 POSTER SESSION

#### PHARMACOEPIDEMIOLOGY

Chairpersons: Fabrizio De Ponti (Bologna) - Roberto Leone (Verona)

### 17/1 Managing chronic myeloid leukemia: real-world evidence on use of tyrosine kinase inhibitors and related side effects

*Bettiol A., Pirolo R., Bolcato J., Franchin G., Giusti P., Chinellato A.*

### 17/2 Use of proton pump inhibitors and risk of cardiovascular events in the general population

*Casula M., Mozzanica F., Scotti L., Corrao G., Tragni E., Catapano A.L.*

### 17/3 Drugs prescription as a measure of chronicity in undocumented migrants

*Bini S., Fiorini G., Sartorio A., Rigamonti A.E., Cella S.G.*

### 17/4 Adverse drug reactions in paediatrics: data of an Italian active monitoring study of adverse drug reactions in emergency departments (MEREAFaPS).

*Crescioli G., Lombardi N., Lucenteforte E., Bettiol A., Vitiello A., Marconi E., Mugelli A., Vannacci A., Giovannelli L.*



## Poster Session

- 17/5** Ensure patients access to investigational medicines: compassionate use at the University Hospital of Catania  
*Longo L., Benfatto G., Gozzo L., Mansueto S., Vitale D.C., Lazzara A., Drago F.*
- 17/6** Real world data about biosimilar and originator somatropin use in clinical practice: an Italian population-based multiple databases study during the years 2009-2014  
*Ingrasciotta Y., Marciànò I., Giorgianni F., Ientile V., Chinellato A., Tari D.U., Gini R., Cannavò S., Pastorello M., Scondotto S., Cananzi P., Traversa G., Trotta F., Belleudi V., A. Genazzani A.A., Trifirò G.*
- 17/7** Intravitreal anti-VEGF injections: real-world data on the pattern of use using multiple administrative healthcare databases from Southern Italy  
*Marciànò I., Giorgianni F., Aliquò G., Scondotto G., Pollina Addario S.W., Scondotto S., Cananzi P., Puzo M.R., De Sarro G., De Francesco A., Trifirò G.*
- 17/8** Drug-utilization of new oral anticoagulants and Vitamin K antagonists in atrial fibrillation: a retrospective study within the REGULUS project.  
*Marconi E., Lucenteforte E., Lombardi N., Bettiol A., Crescioli G., Vitiello A., Mugelli A., Vannacci A.*
- 17/9** Access to the market of medicines: three years' experience of the Sicilian Regional Drug Formulary  
*Pizzimenti V., Formica D., Cananzi P., Spina E., Aiello A., D'Ausilio A., Corrao S., Trifirò G.*
- 17/10** Cost-evaluation of fluoropyrimidines-related toxicities associated with DPYD four-SNPS panel in patients genotype  
*Roncato R., Polesel J., Ecça F., Delle Fratte C., De Mattia E., Bignucolo A., Buonadonna A., De Paoli A., Berretta M., Mini E., Nobili S., Toffoli G., Cecchin E.*
- 17/11** Pharmacoutilization of Antidiabetic drugs: local preliminary analysis within the DRUG-ON project  
*Vitiello A., Lucenteforte E., Lombardi N., Bettiol A., Crescioli G., Marconi E., Mugelli A., Vannacci A.*

## P18 POSTER SESSION

### PHARMACOGENETICS, PHARMACOGENOMICS AND GENE THERAPY

Chairpersons: Sabrina Angelini (Bologna), Bhagirathkumar Patel (Gujarat, India)  
Salvatore Terrazzino (Novara)

## Poster Session

- 18/1** Tacrolimus therapeutic drug monitoring in stable kidney transplantations and individuations of CYP3A5 genotype  
*Allegrì L., Baldan F., Groppuzzo M., Vallone C., Tulissi P., Montanaro G., Damante G., Baraldo M.*
- 18/2** The ABCB1 pharmacogenetics of R-CHOP regimen in mantle cell lymphoma patients: a substudy from the FIL MCL-0208 trial  
*Arrigoni E., Ferrero S., Zaccaria G.M., Lo Schirico M., Ciabatti E., Petrini M., Cortelazzo S., Evangelista A., Palumbo G., Ladetto M., Danesi R., Galimberti S., Di Paolo A.*
- 18/3** The pharmacogenetics of the response to triptans in patients affected by migraine without aura  
*Carqin S., Viana M., Sances G., Tassorelli C., Canonico P.L., Genazzani A.A., Terrazzino S.*
- 18/4** Role of miR-34a as biomarker and therapeutic agent in cutaneous melanoma  
*Carpi S., Polini B., Romanini A., Fogli S., Ylösmäki E., Capasso C., Breschi M.C., Cerullo V., Nieri P.*
- 18/5** Detection of AR-V7 in plasma-derived exosomal RNA in metastatic prostate cancer patients treated with first-line hormonal therapy  
*Crucitta S., Del Re M., Biasco E., Rofi E., Galli L., Falcone A., Danesi R.*
- 18/6** Indomethacin inhibits proliferation in cells harbouring PIK3CA mutations  
*Gallicchio M., Lolli M., Spyraakis F., Bonanni D., Boscaro V.*
- 18/7** Liquid biopsy: a real clinical practice  
*Iacobelli C., Rofi E., Del Re M., Pino M.S., Pozzessere D., Belluomini L., Frassoldati A., Iannopolo M., Di Lieto M., Danesi R.*
- 18/8** Pharmacoeepigenomic markers involved in glucocorticoid response in children with inflammatory bowel disease  
*Lucafo M., De Iudibus S., Di Silvestre A., Martellosi S., Naviglio S., Ventura A., Stocco G., Decorti G.*
- 18/9** Convergent analysis of genome-wide genotyping and transcriptomic data suggests association of zinc finger genes with lithium response in bipolar disorder  
*Pisanu C., Congiu D., Costa M., Chillotti C., Ardaù R., Severino G., Angius A., Heilbronner U., Hou L., McMahon F.J., Schulze T.G., Del Zompo M., Squassina A.*



## Poster Session

- 18/10** Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer  
*Restante G., Rofi E., Del Re M., Bordi P., Tiseo M., Danesi R.*
- 18/11** Early variations of kras mutations in circulating cell-free tumor DNA: a promising biomarker to monitor chemotherapy resistance in pancreatic cancer  
*Rofi E., Vivaldi C., Del Re M., Fornaro L., Vasile E., Falcone A., Danesi R.*
- 18/12** DNA methylation: gene profiling in a chronic myeloid leukemia cell line resistant model  
*Sammarini G., Ravegnini G., Moran S., Esteller M., Hrelia P., Angelini S.*

### P19 POSTER SESSION

#### PHARMACOGNOSY

Chairpersons: *Gabriela Mazzanti (Rome), Alessandra Russo (Catania), Annabella Vitalone (Rome)*

- 19/1** Antiproliferative, antioxidant and antimicrobial activities of extracts obtained from *Sinapis alba* L. and *Sinapis nigra* L.  
*Boscaro V., Boffa L., Binello A., Amisano G., Fornasero S., Cravotto G., Gallicchio M.*
- 19/2** *Harpagophytum procumbens* aqueous extract inhibits HCT116 colon cancer cell viability and the production of inflammatory and lipoperoxidation markers in isolated rat colon challenged with LPS  
*Chiavaroli A., Ferrante C., Leone S., Recinella L., Martinotti S., Leporini L., Orlando G., Menghini L., Carradori S., Locatelli M., Brunetti L., Vacca M.*
- 19/3** Growth inhibition, cell-cycle arrest and apoptosis in SH-SY5Y human neuroblastoma cells by moringin derived from *Moringa oleifera* seeds  
*Cirmi S., Ferlazzo N., Maugeri A., Lombardo G.E., Bramanti P., Navarra M.*
- 19/4** *In vitro* evaluation of antioxidant, cytoprotective and antimicrobial properties of essential oil of *Pistacia vera* L. variety bronte hull  
*Denaro M., Smeriglio A., Barreca D., Calderaro A., Bisignano C., Ginestra G., Bellocco E., Trombetta D.*

## Poster Session

- 19/5** Effects of the metronomic treatment of  $\beta$ -caryophyllene in combination with low-dose doxorubicin in liver cancer cells  
*Abete L., Mancinelli R., Vecchiato M., Di Giacomo S., Vitalone A., Mazzanti G., Mammola C.L., Di Sotto A.*
- 19/6** Antiviral and antioxidant activity of a hydroalcoholic extract from *Humulus lupulus* L.  
*Di Sotto A., Celestino I., Toniolo C., Abete L., Di Giacomo S., Nicoletti M., Mazzanti G., Nencioni L.*
- 19/7** Antiproliferative effect of Cuban propolis in human colon carcinoma cells is associated with its composition  
*Fríón-Herrera Y., Gabbia D., Carrara M.*
- 19/8** Activity of *Aloe arborescens* leaf extracts: *in vitro* effects on human adenocarcinoma HT-29 cell line and free-radical species  
*Froldi G., Baronchelli F., Marin E., Fríón-Herrera Y., Gabbia D.*
- 19/9** A comparison between a cannabis extract with high content in cannabidiol and pure cannabidiol on experimental intestinal inflammation and hypermotility  
*Pagano E., Capasso R., Piscitelli F., Romano B., Parisi O.A., Finizio S., Lauritano A., Di Marzo V., Borrelli F., Izzo A.A.*
- 19/10** Myocardial anti-ageing effects of the Citrus flavonoid naringenin  
*Piragine E., Piano I., Martelli A., Citi V., Gargini M.C., Breschi M.C., Calderone V., Testai L.*
- 19/11** *Rosmarinus officinalis* extract protects human chondrocytes differentiated from mesenchymal stem cells by pro-inflammatory effects of interleukin-1 beta  
*Graziano A., Avola R., Troncoso N., Cardile V., Russo A.*
- 19/12** Phytochemical profile and phototoxicity of eleven *Hypericum* species extracts  
*Cristani M., Siracusa L., Carrubba A., Lazzara S., Speciale A., Cimino F., Saija A., Ruberto G., Napoli E.*
- 19/13** Effects of ethanolic extracts of four Ecuadorian plants on porcine Aortic Endothelial Cells (pAEC) stability  
*Tubon I., Bernardini C., Zannoni A., Mandrioli R., Vinueza D., Abdo S., Antognoni F., Forni M.*

## Poster Session

## P20 POSTER SESSION

## PHARMACOLOGICAL CONTROL OF CELL DEATH AND PROLIFERATION PROCESSES

Chairpersons: Nicoletta Brunello (Modena), Carlo Cifani (Camerino), Aldo Pinto (Salerno)

## 20/1 Morphine differently influences cell proliferation, migration and apoptosis in tumor cell lines endogenously expressing mu opioid receptor

*Bedini A., Spampinato S.*

20/2 An *in vitro* model for screening therapeutic strategies targeting the metastatic process: intercellular cross-talk, chemoresistance and micrnas

*Bigagli E., Cinci L., D'Ambrosio M., Luceri C.*

20/3 *Castanea sativa* mill. Bark extract exhibits chemopreventive properties triggering extrinsic apoptotic pathway in jurkat cells

*Lenzi M., Malaguti M., Cocchi V., Hrelia S., Hrelia P.*

## 20/4 Unraveling the mechanism of action of the antiproliferative effect of furoxans in smooth muscle cells: a proteomic approach

*Arnaboldi L., De Metrio S., Granata A., Rolando B., Lazzarato L., Fruttero R., Gasco A., Cannizzaro L., Carini M., Colzani M., Corsini A.*

## 20/5 Effect of cannabigerol, a non-psychotropic phytocannabinoid, on akt and mapk activation in cancer cells

*D'Aloia A., Ceriani M., Stucchi S., Costa B.*

## 20/6 Prion protein signalling controls glioblastoma stem cell tumorigenicity

*Florio T., Corsaro A., Nizzari M., Barbieri F., Daga A., Thellung S.*

20/7 Irreversible BK channel blocking mechanism reduces the phospho-AKT.1(PSER<sup>473</sup>) / PAN- AKT.1 ratio inducing cell cycle arrests in human neuroblastoma SHSY5Y cells and anti-proliferative effects

*Maqoud F., Curci A., Angelelli M., Coluccia M., Pannunzio A., Campanella F., Tricarico D.*

20/8 *In vitro* and *ex-vivo* effects of bisphosphonates on osteoclasts and osteoblasts proliferation

*Angelelli M., Maqoud F., Scala R., Scilimati A., Tortorella P., Tricarico D.*

## 20/9 COX-2 expression in malignant melanoma: latest evidence and clinical potential

*Panza E., De Cicco P., Ercolano G., Armogida C., Scognamiglio G., Anniciello A.M., Botti G., Cirino G., Ianaro A.*



## Poster Session

## 20/10 Rifaximin induces a PXR-mediated antiproliferative effect and inhibits angiogenic factors release in Caco-2 cell line

*Sequella L., Gigli S., Pesce M., Steardo L., Sarnelli G., Esposito G.*

## P21 POSTER SESSION

## PHARMACOLOGY OF DIGESTIVE SYSTEM

Chairpersons: Diego Currò (Rome) - Matteo Fornai (Pisa)

## 21/1 Involvement of catechol-O-methyltransferase activity in the modulation of enteric neuromotor function: implication in functional gastrointestinal disorders

*Caputi V., Marsilio I., Cerantola S., Contarini G., Mereu M., Galuppini F., Rugge M., Orso G., Crema F., Giaroni C., Papaleo F., Giron M.C.*

## 21/2 Antibiotic-induced dysbiosis affects the structure and activity of enteric nervous system in mouse small bowel during adolescence

*Cerantola S., Marsilio I., Caputi V., Orso G., Debetto P., Giaroni C., Giron M.C.*

## 21/3 Effects of tetraethylammonium on the non-adrenergic non-cholinergic relaxation of the rat gastric fundus

*Ipavec V., Currò D.*

## 21/4 Enteric glia is involved in colonic dysmotility associated with high fat diet-induced obesity

*Fornai M., Pellegrini C., Tirota E., Gentile D., Benvenuti L., Caputi V., Cerantola S., Giron M.C., Orso G., Bernardini N., Ippolito C., Segnani C., Scarpignato C., Blandizzi C., Colucci R., Antonioli L.*

## 21/5 Changes of small bowel inhibitory neurotransmission in mice lacking TLR4 signaling

*Marsilio I., Cerantola S., Caputi V., Napoli E., Giulivi C., Orso G., Giron M.C.*

## 21/6 Effect of carbachol and vip in human colonic diverticulosis

*Maselli M.A., Pallotta L., Ignazzi A., Scirocco A., Donghia R., Lorusso D., Pezzolla F., Severi C.*

## 21/7 Effects of L-dopa/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration

*Pellegrini C., Antonioli L., Colucci R., Tirota E., Gentile D., Benvenuti L., Segnani C., Ippolito C., Levandis G., Cerri S., Blandini F., Barocelli E., Ballabeni V., Bernardini N., Blandizzi C., Fornai M.*



## Poster Session

**21/8 Bifidobacterium longum and lactoferrin exert entero-protective effects in a rat model of diclofenac-induced intestinal injury**  
*Tirotta E., Fornai M., Gentile D., Benvenuti L., Pellegrini C., Antonioli L., Blandizzi C., Colucci R.*

## P22 POSTER SESSION

## PHARMACOLOGY OF METABOLISM AND ENDOCRINE SYSTEM

*Chairpersons: Carola Eva (Turin), Luca Gallelli (Catanzaro), Elisabetta Vegeto (Milan), Lucia Vicentini (Milano)*

**22/1 Sedentary-time: effect on pro- and anti-inflammatory cytokines plasma level and on urinary metabolic signatures in patients with type 2 diabetes enrolled in the ides 2 (italian diabetes and exercise study-2) clinical trial**

*Benetti E., Bressanello D., Cordero C., Liberto E., Vitarelli G., D'Errico V., Haxhi J., Pugliese G., Balducci S.*

**22/2 Effect of vitamin D on insulin sensibility and myosteatosis in a murine model of diet-induced insulin resistance**

*Benetti E., Mastrocola R., Chiazza F., Nigro D., D'Antona G., Bordano V., Fantozzi R., Aragno M., Collino M., Minetto M.*

**22/3 Activation of the EPOR-b common receptor complex by cibinetide ameliorates impaired wound healing in genetically diabetic mice**

*Bitto A., Irrera N., Pizzino G., Pallio G., Mannino F., Minutoli L., Squadrito F., Altavilla D.*

**22/4 The ages inhibitor pyridoxamine prevents kidney injury and dysfunction in mice fed high-fat high-fructose diet**

*Chiazza F., Mastrocola R., Cento A.S., Nigro D., Collotta D., Bitonto V., Cutrin J.C., Fantozzi R., Aragno M., Collino M.*

**22/5 Toxicological impact of high fructose intake on gut microbiota and liver/intestine integrity: any differences between solid and liquid formulations?**

*Chiazza F., Cento A.S., Nigro D., Ferrocino I., Rantsiou K., Bitonto V., Cutrin J.C., Querio G., Liberto E., Cordero C., Cocolin L., Fantozzi R., Aragno M., Mastrocola R., Masini E., Collino M.*

**22/6 Cold stress challenge is associated with early nerve grow factor activity in brown fat and testis regulating mRNA levels of osteocalcin and brain-derived neurotrophic factor in bone and brain of mice**

*Camerino C., Conte E., Fonzino A., Carratù M., Tricarico D.*



## Poster Session

**22/7 Lipidomics as a tool to unravel the role of bone marrow adipose tissue in aging and type 2 diabetes mellitus: study on samples derived from human hips**

*De Metrio S., Accattatis F., Granata A., Maselli D., Ferland-Mccollough D., Mangialardi G., Corsini A., Madeddu P., Spinetti G., Arnaboldi L.*

**22/8 Peripheral RVD-hemopressin( $\alpha$ ) administration inhibits food intake, in rats**

*Ferrante C., Orlando G., Recinella L., Leone S., Chiavaroli A., Di Nisio C., Martinotti S., Mollica A., Macedonio G., Stefanucci A., Vacca M., Brunetti L.*

**22/9 Role of the area postrema in the hypophagic effects of oleoylethanolamide**

*Gallelli C.A., Romano A., Koczwara J.B., Micioni Di Bonaventura M.V., Cifani C., Braegger F.E., Lutz T., Gaetani S.*

**22/10 Myotrophin and miR-375 as pharmacological target for 9cisRetinoic Acid**

*Gallelli L., Perri M., Cione E., Liu N., Kagechika H., Caroleo M.C., De Sarro G.*

**22/11 From metabolic fitness to metabolic illness: sex specific role of hepatic ERA**

*Lolli F., Della Torre S., Meda C., Maggi A.*

**22/12 White-to-brown adipose transdifferentiation, is there a role for genistein?**

*Mannino F., Aliquò F., Pizzino G., Irrera N., Pallio G., Minutoli L., Squadrito F., Altavilla D., Bitto A.*

**22/13 Palmitoylethanolamide attenuates insulin resistance and hepatic steatosis in diet-induced obese mice**

*Mattace Raso G., Di Guida F., Pirozzi C., Lama A., Annunziata C., Nitrato Izzo A., Santoro A., Cristiano C., Calignano A., Meli R.*

**22/14 The impact of ALDH-2 activity on mitochondria bioenergetic functions in endothelial cells**

*Nannelli G., Giorgio V., Donnini S., Bernardi P., Ziche M.*

**22/15 Early up-regulation of hepatic matrix metalloproteinases in a rat model of cardiometabolic syndrome**

*Nucera S., Scarano F., Bosco F., Musolino V., Carresi C., Gliozzi M., Giancotta C., Scicchitano M., Maiuolo J., Maretta A., Oppedisano F., Tavernese A., Mollace R., Muscoli C., Mollace V.*

**22/16 Effect of antibiotic-induced dysbiosis on enterohepatic bile acid cycling**

*Paccagnella N., D'Amore C., Castellani G., Giron M.C., Caputi V., Paladin D., De Martin S.*



## Poster Session

- 22/17 Safety and efficacy of GLP-1 receptor agonists in patients with type 2 diabetes mellitus and hepatic impairment: a pharmacological review**  
*Pani A., Angelini J., Agnelli F., Nunnari P., Rucci F., Romano A., Scaglione F.*
- 22/18 Effects of growth hormone-releasing hormone (GHRH) gene targeted ablation on ghrelin-induced feeding in mice**  
*Recinella L., Ferrante C., Shohreh R., Orlando G., Salvatori R., Leone S., Chiavaroli A., Di Nisio C., Vacca M., Brunetti L.*
- 22/19 Hedonic eating in Prader-Willi syndrome is associated with blunted PYY secretion**  
*Rigamonti A.E., Bini S., Piscitelli F., Lauritano A., Di Marzo V., Vanetti C., Agosti F., De Col A., Lucchetti E., Grugni G., Cella S.G., Sartorio A.*
- 22/20 Sex-dependent expression and function of eNOS in human endothelial cells**  
*Cattaneo M.G., Vanetti C., Decimo I., Di Chio M., Bifari F., Vicentini L.M.*
- 22/21 Influence of gender on SPA (salus per aquam) therapy in patients with plaque psoriasis**  
*Costantino M., Conti V., Corbi G., Marongiu M.B., Iannaccone T., Manzo V., Filippelli W., Filippelli A.*
- 22/22 Gender-dependent involvement of potassium channel in sarcopenia evaluated by ultrasonographic measurements**  
*Mele A., Rana F., Fonzino A., Camerino G.M., Maqoud F., Curci A., Conte Camerino D., Tricarico D.*
- 22/23 Fatty acids restore *in vitro* angiogenic properties in human male and female endothelial cells cultured in hormone-deprived serum**  
*Vanetti C., Bifari F., Vicentini L.M., Cattaneo M.G.*

### P23 POSTER SESSION

#### PHARMACOLOGY OF RESPIRATORY FUNCTION

Chairpersons: Bruno D'Agostino (Naples), Eeva Moilanen (Tampere - Finland)

- 23/1 Effects of lung resident mesenchymal stromal cells administration in an animal model of elastase-induced emphysema**  
*Esposito G., Spaziano G., Cappetta D., Tartaglione G., Sgambato M., Ciuffreda L.P., Liparulo A., Berrino L., Piegari E., De Angelis A., Urbanek K., D'Agostino B.*

## Poster Session

- 23/2 Therapeutic benefits of methylxanthine on primary human bronchial epithelial cells exposed to pro-inflammatory stimuli and steroid drugs**  
*Gallelli L., Cannataro R., Perri M.R., Pelaia G., Maselli R., De Sarro G.*
- 23/3 TLR4 is involved in S1P/S1P<sub>1</sub> pathway in the lung and contributes to S1P-induced allergic inflammation**  
*Riemma M.A., Sorrentino R., Terlizzi M., Mattera Iacono V., Rossi A., Spaziano G., Pinto A., D'Agostino B., Roviezzo F., Cirino G.*
- 23/4 Effects of hexarelin in a model of ards**  
*Rizzi L., Zambelli V., Molteni L., Delvecchio P., Bresciani E., Fehrentz J.A., Martinez J., Bellani G., Locatelli V., Torsello A.*
- 23/5 Alpha-1 antitrypsin (AAT) polymerization in alveolar macrophages of AAT deficient individuals and in smokers**  
*Sgambato M., Bazzan E., Tinè M., Miranda E., Biondini D., Turato G., Rigobello C., Rea F., Calabrese F., Baraldo S., Lomas D., Spaziano G., Saetta M., Cosio M., D'Agostino B.*
- 23/6 Nociceptin/orphanin fq (N/OFQ) could represent a novel target for the treatment of asthma**  
*Spaziano G., Rossi G., D'Agostino B.*
- 23/7 Nociceptin reduces the inflammatory immune microenvironment in a conventional murine model of airway hyperresponsiveness**  
*Spaziano G., Tartaglione G., Sorrentino R., Matteis M., Malgieri G., Sgambato M., Russo T., Terlizzi M., Roviezzo F., Liparulo A., Rossi F., Pinto A., Fattorusso R., D'Agostino B.*
- 23/8 The role of nociceptin/orphanin fq (N/OFQ) in inflammation and remodelling of the small airways in a murine model of airway hyperresponsiveness**  
*Tartaglione G., Spaziano G., Sgambato M., Liparulo A., Russo T., Esposito R., D'Agostino B.*
- 23/9 Development of hyaluronan/mannitol dry powders for flucytosine repositioning in local therapy of lung infections**  
*Tramontano T., D'Emmanuele Di Villa Bianca R., Mitidieri E., Costabile G., D'Angelo I., Pompili B., Del Porto P., Leoni L., Visca P., Miro A., Quaglia F., Imperi F., Ungaro F., Sorrentino R.*



## Poster Session

## P24 POSTER SESSION

## PHARMACOLOGY OF SYNAPTIC TRANSMISSIONS

Chairpersons: Fabrizio Gardoni (Milan) - Marco Milanese (Genoa)

- 24/1 Environmental training ameliorates the course of demyelinating disease in mice: a glutamatergic hypothesis  
*Bonfiglio T., Vergassola M., Olivero G., Iannuzzi F., Feligioni M., Di Cesare Mannelli L., Ghelardini C., Pittaluga A.*
- 24/2 The loss of Aristaless related homeobox (ARX) transcriptional repression activity on cation channel TRPV2 gene causes aberrant neuronal activity: implication for epilepsies  
*Iannotti F.A., Marina D., Poeta L., Valentino M., Di Marzo V., Miano M.*
- 24/3 Altered mechanisms underlying the abnormal glutamate release in amyotrophic lateral sclerosis at a pre-symptomatic stage of the disease  
*Bonifacino T., Musazzi L., Milanese M., Seguini M., Marte A., Gallia E., Cattaneo L., Onofri F., Popoli M., Bonanno G.*
- 24/4 Presynaptic GLP-1 receptors enhance glutamate and gaba release from purified mouse cortical and hippocampal synaptosomes  
*Rebosio C., Balbi M., Passalacqua M., Ricciarelli R., Fedele E.*
- 24/5 Prophylactic versus therapeutic fingolimod: restoration of presynaptic defects in mice suffering from experimental autoimmune encephalomyelitis  
*Vergassola M., Bonfiglio T., Olivero G., Grilli M., Milanese M., Di Cesare Mannelli L., Ghelardini C., Bonanno G., Marchi M., Pittaluga A.*

## P25 POSTER SESSION

## PHARMACOVIGILANCE

Chairpersons: Vincenzo Arcoraci (Messina), Ugo Moretti (Verona), Concetta Rafaniello (Naples), Emilio Russo (Catanzaro)

- 25/1 The importance of integrated care in the management of chronic disease. Patient support programs linked to drugs as tools for assistance and sources of pharmacovigilance data.  
*Angelini J., Fiorentino M., Pani A., Nunnari P., Rucci F., Marino R., Scaglione F., Scatigna M.*

## Poster Session

- 25/2 Occurrence of Liver Injury with drugs used for Multiple Sclerosis: signals emerging from the FDA Adverse Event Reporting System (FAERS)  
*Antonazzo I.C., Raschi E., Forcesi E., Poluzzi E., De Ponti F.*
- 25/3 VigiNetWork: a community pharmacies-network on pharmacovigilance in Veneto Region  
*Magro L., Viola E., Lora R., Arzenton E., Opri S., Gonella L., Stoppa G., Moretti U., Leone R.*
- 25/4 Safety profile of antipsychotic drugs: an analysis of Sicilian region spontaneous reporting system  
*Barbieri M.A., Migliardi G., Cicala G., Trombini M., Cutroneo P.M., Spina E.*
- 25/5 Analysis of the adverse drug reactions for fingolimod in the post-marketing phase  
*Auricchio F., Scavone C., Cimmaruta D., Larato A., Fiorentino S., Rossi F., Capuano A., Bernardi F.F.*
- 25/6 Safety of new direct-acting antivirals (DAAS): does cardiac toxicity represent a real warning?  
*Bertini M., Brusco S., Cantile C., Larato A., Di Mauro G., Sportiello L., Rossi F., Capuano A.*
- 25/7 Drugs-induced disseminated intravascular coagulation: a pharmacoepidemiological study based on who database of adverse drug reactions  
*Bonaldo G., Rossi L., Melis M., Gasperoni L., Grandi S., Vaccheri A., Motola D.*
- 25/8 Estimating incidence rates of adverse events of cholinesterase inhibitors in Alzheimer's disease patients using spontaneously reporting data  
*Brusco S., Bertini M., Cantile C., Larato A., Rafaniello C., Rossi F., Capuano A.*
- 25/9 Rosacea during fingolimod therapy in multiple sclerosis: a case series  
*Brusco S., Bertini M., Rafaniello C., Bisecco A., Gallo A., Capuano A.*
- 25/10 An alternative method for evaluating skin sensitizing potential of chemicals using forward scatter  
*Buzzella A., Mazzini G., Vicini R., Angelinetta C., Balestra B., Pastoris O.*
- 25/11 Long term drug safety in children: analysis on spontaneous reporting system of suspected adverse drug reactions within music project  
*Ferrajolo C., Trifirò G., Cimmaruta D., Ientile V., Moretti U., Sottosanti L., Rossi F., Capuano A.*



## Poster Session

- 25/12 On the possible relationship between narcolepsy and vaccines: the analysis of AEFI reports from the VAERS database**  
*Carnovale C., Peeters G., Gentili M., Stella F., Antoniazzi S., Pozzi M., Clementi E., Radice S.*
- 25/13 A clinician network for sharing patient experiences in pharmacovigilance: the pharmacowikilance project**  
*Convertino I., Galiulo M., Capogrosso-Sansone A., Marino A., Knezevic T., Pieroni S., De Nes M., Blandizzi C., Tuccori M.*
- 25/14 Trends in spontaneous adverse drug reaction reporting to a regional pharmacovigilance centre (years 2014-2016)**  
*Cutroneo P.M., Cananzi P., Oteri A., Minore C., Morreale I., Longo L., Mansueto S., Vitale D., Spina E.*
- 25/15 Adverse drug reactions associated with newer long-acting injectables antipsychotics: an analysis of the italian spontaneous reporting system database**  
*Cutroneo P.M., Barbieri M., Cicala G., Migliardi G., Marchione P., Biasotta A., Trifirò G., Spina E.*
- 25/16 Adverse drug reactions with biological drugs in rheumatology and dermatology units**  
*De Fina M., Palleria C., Bennardo L., Vona A., Bottoni U., L'Andolina M., Valenti G., D'Amico D., Russo E., De Sarro G.*
- 25/17 Trend of adverse drug reaction reporting in Calabria across the period 2011-2016: which impact by the new european pharmacovigilance legislation?**  
*Leporini C., Palleria C., Leo A., Lucia M., Florio L., Sorrentino A., Piro B., Costantino D., Russo E., De Sarro G.*
- 25/18 Adverse drug reactions by biological drugs in gastroenterology units**  
*Palleria C., De Sarro G., Bennardo L., Luzzza F., Larussa T., Doldo P., Spagnuolo R., Rodinò S., Russo E.*
- 25/19 Sprue-like enteropathy associated with olmesartan**  
*Deidda A., Pisanu C., Arcadu F., Derudas M., Chillotti C., Garau D., Stochino M.E.*
- 25/20 Frequency and characteristics of adverse drug reactions to antineoplastic and immunomodulatory medications in the metropolitan area of florence (Italy)**  
*Del Lungo M., Galloni C., De Angelis A., Parrilli M., Bettiol A., Lombardi N., Mugelli A., Vannacci A.*

## Poster Session

- 25/21 Adverse drug reactions in oncology: intensive monitoring program on drug toxicity of biotechnological medications and target therapies in Oncologic patients - the ALEXANDROS observational study**  
*Galiulo M., Convertino I., Blandizzi C., Tassi R., Diacciati S., Nobili S., Capogrosso Sansone A., Marino A., Mini E., Mazzei T., Vannacci A., Parrilli M., Corona T., Tuccori M.*
- 25/22 MARKAR survey: influence of direct antiviral drugs in patients with hepatitis C virus infection**  
*Gentili M., Magni C., Carnovale C., Landonio S., Schiavini M., Niero F., Rizzardini G., Clementi E., Radice S.*
- 25/23 Adverse drug reactions in emergency departments: a prospective 1-year characterization in Sicily**  
*Mocciaro E., Lo Giudice I., Giardina C., Santangelo A., Spina E., Arcoraci V., Cutroneo P.M.*
- 25/24 Off-label drug use and safety of intravitreal anti-VEGF: data from registries and pharmacovigilance network**  
*Gozzo L., Benfatto G., Longo L., Mansueto S., Vitale D.C., Lazzara A., Drago F.*
- 25/25 Off-label drug use at the Policlinic-University Hospital of Catania, from 2012 to 2015: focus on intra-ocular use of mitomycin**  
*Gozzo L., Benfatto G., Longo L., Mansueto S., Vitale D.C., Lazzara A., Drago F.*
- 25/26 Off-label drug use at the University Hospital of Catania: 2016 update**  
*Gozzo L., Benfatto G., Longo L., Mansueto S., Vitale D.C., Lazzara A., Drago F.*
- 25/27 Reporting of adverse drug reactions by nursing and medicine students in Italy: a questionnaire-based study**  
*Grandi S., Nappo A., Gasperoni L., Bonaldo G., Scalorbi S., Di Lorenzo D., Vaccheri A., Motola D.*
- 25/28 Real-life safety and effectiveness of apixaban in patients with non valvular atrial fibrillation**  
*Verdecchia P., Lanati E., Verdini V., Corrao G., Scotti L., Airolidi C., Iorio A.*
- 25/29 Evaluation of health direct costs associated with the use of biosimilar and originator erythropoiesis stimulating agents (ESAs): an italian, multi-regional, population based study**  
*Formica D., Ingrasciotta Y., Giorgianni F., Aliquò G., Chinellato A., Tari D., Gini R., Pastorello M., Scondotto S., Cananzi P., Traversa G., Genazzani A.A., Trifirò G.*

## Poster Session

- 25/30 Risk of bone fractures among users of oral anticoagulants: an administrative database cohort study**  
*Lucenteforte E., Bettiol A., Lombardi N., Mugelli A., Vannacci A.*
- 25/31 PHYTO.VIG.GEST: "Vigilance on use of drugs, herbal products and food supplements during pregnancy: focus on fosfomycin"**  
*Mannucci C., Dante G., Miroddi M., Facchinetti F., D'Anna R., Santamaria A., Calapai F., Lenti M.C., Perone M., Navarra M., Calapai G.*
- 25/32 Atypical symptoms of tramadol withdrawal: a case report**  
*Manzo V., Iannaccone T., D'Amore C., Petrocelli A., Piscitelli A., Costantino M., Filippelli A., Conti V.*
- 25/33 Cardiovascular safety of macrolide and fluoroquinolone antibiotics: an analysis of the who database of adverse drug reactions**  
*Andriani L., Melis M., Grandi S., Bonaldo G., Motola D., Vaccheri A.*
- 25/34 Hospice palliative care medication use: an italian regional study**  
*Penco I., Mores N., Bordin F., Turriziani A., Ginobbi P., Proli E.*
- 25/35 Drug-induced kounis syndrome: insights from combined literature review and analysis of the fda adverse event reporting system**  
*Raschi E., Fertanani Affini L., Forcesi E., Diemberger I., Poluzzi E., De Ponti F.*
- 25/36 Six-month levetiracetam treatment in epileptic patients after branded-to-generic switch; a community-based retrospective study**  
*Rigamonti A.E.*
- 25/37 Monitoring safety and use of old and new therapies for type 2 diabetic patients in Calabria: a two-year (2013-2016) analysis**  
*Leporini C., Piro R., Maida F., Citraro R., Mangano G., De Sarro C., Palleria C., Artudi F., Pavia M., Russo E.*
- 25/38 In search of biological substantiation through literature review and *in silico* analyses: the case of antipsychotic-associated pneumonia**  
*Sultana J., Crisafulli C., Mestres J., Garcia-Serna R., Calabrò M., Trifirò G.*
- 25/39 Intensive monitoring program of teratogen and non-teratogen risk of drugs during pregnancy: the stork project**  
*Tuccori M., Convertino I., Galiulo M., Capogrosso Sansone A., Mantarro S., Marino A., Vannacci A., Parrilli M., Corona T., Blandizzi C.*



## Poster Session

- 25/40 A prospective observational study to reduce medication errors in hospital**  
*Viola E., Magro L., Verlato G., Finocchio E., Bosello O., Lechi A., Leone R., Velo G.P.*
- 25/41 Increasing trend in admission rates and costs for acute diverticulitis during 2005-2015: real-life data from the Abruzzo Region**  
*Cammarota S., Citarella A., Manzoli L., Flacco M.E., Cuomo R.*
- 25/42 What is the effect of risk minimization measures on the risk of antipsychotic-associated stroke in elderly persons?**  
*Giorgianni F., Sultana J., Tillati S., Sturkenboom M., Trifirò G.*
- 25/43 Retrospective study on Italian ADPKD disease management cost**  
*Lanati E.P., Marcelli A., Ruggeri M., Rolli F.R., Caramuscio R., Ballantini F., Scolari F., Iorio A.*
- 25/44 NSAIDs utilization in a large cohort of Italian elderly in secondary prevention for cerebro/cardiovascular disease**  
*Roberto G., Bartolini C., Rea F., Onder G., Vitale C., Trifirò G., Kirchmayer U., Chinellato A., Lucenteforte E., Corrao G., Mugelli A., Lapi F., Gini R.*
- 25/45 Utilization of biological drugs for the treatment of rheumatoid arthritis in Tuscany, Italy**  
*Roberto G., Bardelli F., Bartolini C., Gini R.*
- 25/46 Gender specific drug use in pediatrics: real world data analysis on behalf of music project**  
*Ferrajolo C., Giorgianni F., Aliquò G., Ientile V., Tari M., Rossi F., Capuano A., Trifirò G.*
- 25/47 Use of electronic health records to study the real world utilization of antineoplastic drugs for the treatment of lung cancer at the University Hospital of Siena**  
*Pellicano F., Spini A., Donnini S., Giorgi S., Bartolini C., Gini R., Vannucci A., Voller F., Roberto G., Ziche M.*

## Poster Session

## P26 POSTER SESSION

## PSYCHOPHARMACOLOGY

Chairpersons: Maria Grazia Morgese (Foggia) - Marco Riva (Milan)

- 26/1 Psychotropic medications in mood disorders: current attitude in two psychiatric wards in Cagliari  
*Baggiani G., Ambrosiani L., Deidda A., Bocchetta A., Trincas P., Burrai C.*
- 26/2 Activity-based anorexia alters neurometabolic measures in adolescent female rats  
*Fumagalli F., Bonacina F., Messa G., Uboldi P., Norata G.D., Caffino L.*
- 26/3 Hyperprolactinemia induced by antipsychotics: from diagnosis to treatment approach  
*Capasso A., Milano W.*
- 26/4 Do cannabinoids confer neuroprotection against epilepsy?  
*Capasso A., Milano W.*
- 26/5 The psychobiology of endocannabinoids in the eating disorders  
*Capasso A., Milano W.*
- 26/6 Beneficial effects of polyphenols in neuroinflammation and related diseases  
*Capasso A., Milano W.*
- 26/7 Protective effect of hdac inhibitors in neurodegenerative disorders  
*Capasso A., Milano W.*
- 26/8 Cannabinoids involvement in neurodegenerative diseases  
*Capasso A., Milano W.*
- 26/9 The role of SNPs analysis in neurocognitive assessment of children with chronic or severe diseases such as epilepsy, asthma or acute lymphoblastic leukemia  
*Colliva C., Benatti C., Tascetta F., Dalla Porta F., Ferrari M., Bergamini B.M., Cellini M., Guerra A., Blom J.*
- 26/10 Cannabinoid involvement in the development of schizophrenia behavioral phenotypes  
*Contarini G., Mereu M., Papaleo F.*



## Poster Session

- 26/11 Acute behavioral and molecular effects of the cathinones MDPV and  $\alpha$ -PVP in the mouse brain  
*Caffino L., Canazza I., Mottarlini F., Bilel S., Ossato A., Giannotti G., Racagni G., Marti M., Fumagalli F.*
- 26/12 Chronic cannabidivarin administration rescues autism-like behaviors induced by prenatal valproic acid exposure in male offspring  
*Gabaglio M., Zamberletti E., Piscitelli F., Rubino T., Di Marzo V., Parolaro D.*
- 26/13 Multiple sclerosis and depression comorbidity: deciphering the role of early-life adversities  
*Paladini M.S., Coppolino G.T., Rossetti A.C., Marangon D., Fumagalli M., Lecca D., Abbracchio M.P., Molteni R.*
- 26/14 Modelling anhedonia to study mechanisms of resilience/vulnerability towards acute stress  
*Sala N., Musazzi L., Tornese P., Seguini M., Popoli M.*
- 26/15 Newer long-acting injectable antipsychotics in the treatment of schizophrenia: an observational comparative study of available formulations  
*Spina E., Santoro V., Bruno A., Muscatello M., Nucifora D., D'Amico G., Zoccali R.*
- 26/16 Inhibition of 5-alpha reductase rescues psychotic- and manic-like phenotypes induced by sleep deprivation  
*Traccis F., Bini V., Soggiu A., Scheggi S., Pardu A., Fanni S., Roncada P., Puligheddu M., Marrosu F., Caruso D., Devoto P., Frau R., Bortolato M.*
- 26/17 Effects of a novel selective short-acting kappa opioid receptor antagonist on cocaine intake during escalation and upon re-exposure after withdrawal  
*Valenza M., Butelman E.R., Kreek M.J.*

## Poster Session

## P27 POSTER SESSION

## RARE DISEASES

Chairpersons: Diego Fornasari (Milan) - Sabata Pierno (Bari)

- 27/1 The progestin desogestrel affects PHOX2B and its target genes expression: implications in the therapeutical approaches in congenital central hypoventilation syndrome (CCHS)

*Cardani S., Di Lascio S., Belperio D., Di Biase E., Benfante R., Fornasari D.*

- 27/2 Newly identified PHOX2B target genes as drug targets in congenital central hypoventilation syndrome (CCHS)

*Di Lascio S., Cardani S., Belperio D., Gritti L., VerPELLI C., Benfante R., Fornasari D.*

- 27/3 New biomarkers in als etiology: analysis of the biophysical properties of skeletal muscle in SOD-1 mouse models and repurposing of acetazolamide as a new therapeutic approach

*Fonzino A., Conte E., Liantonio A., Camerino G.M., De Bellis M., Mele A., Tricarico D., Dobrowolny G., Musarò A., Pierno S.*

- 27/4 Failures to further developing orphan medicinal products after designation granted in Europe

*Giannuzzi V., Landi A., Bosone E., Giannuzzi F., Nicotri S., Torrent-Farnell J., Bonifazi F., Felisi M., Bonifazi D., Ceci A.*

- 27/5 Effect of a long term treatment with metformin on *in vivo* and *ex vivo* pathology signs in exercised and non-exercised dystrophic MDX mice

*Mantuano P., Capogrosso R.F., Sanarica F., Cozzoli A., De Bellis M., Fonzino A., Conte E., Camerino G.M., De Luca A.*

- 27/6 A long term treatment with taurine counteracts the late cardiac dysfunction in dystrophic mdx mice: an ultrasonography study

*Mele A., Rana F., Sanarica F., Mantuano P., Capogrosso R.F., Morgese M.G., Trabace L., De Luca A.*

- 27/7 Selective dynorphin and nociceptin system alterations in the alpha-galactosidase A deficient mouse model of Fabry disease

*Rullo L., Caputi F.F., Romualdi P., Candeletti S.*



## Poster Session

- 27/8 *In vivo* and *in vitro* preclinical studies to assess the therapeutic potential of Src-TK inhibitors in Duchenne muscular dystrophy

*Sanarica E., Mantuano P., Cozzoli A., Conte E., Capogrosso R.F., Denora N., Cutrignelli A., Giustino A., De Bellis M., Camerino G.M., De Luca A.*

- 27/9 Kv7 channels are involved in human malignant hyperthermia

*Vellecco V., Martelli A., Tamma M., Citi V., Vallifuoco M., De Dominicis G., Mancini A., Di Martino A., Cirino G., Calderone V., Bucci M.*

## P28 POSTER SESSION

## RECEPTORS AND SIGNAL TRANSDUCTION MECHANISMS

Chairpersons: Claudio Bucolo (Catania), Cristiano Chiamulera (Verona)

- 28/1 Effects of RGD ligands on integrin-mediated adhesion, signaling and trafficking in cancer cells

*Baiula M., Giacomini D., Galletti P., Tolomelli A., Spampinato S.*

- 28/2 PGE<sub>2</sub> signaling induces EGFR nuclear translocation and tumor growth in lung adenocarcinoma cells

*Bazzani L., Terzuoli E., Donnini S., Morbidelli L., Christofori G., Ziche M.*

- 28/3 Long-lasting effects of stress in adolescence: analyses of behavioural and molecular alterations in an animal model of social isolation

*Begni V., Longo L., Riva M.A.*

- 28/4 *Lymnaea stagnalis* as a new model for translational medicine

*Benatti C., Colliva C., Alboni S., Brunello N., Tascetta F.*

- 28/5 Role of P2X7 receptor in early diabetic retinopathy

*Bucolo C., Platania C.B., Giurdanella G., Di Paola L., Leggio G.M., Salomone S., Drago F.*

- 28/6 Bivalent ligands disclose GPCR dimer's conformation, signaling and functions

*Busnelli M., Santini F., Kleinau G., Muttenthaler M., Stoev S., Manning M., Bibic L., Howell L.A., McCormick P.J., Di Lascio S., Braidà D., Sala M.E., Rovati G.E., Bellini T., Chini B.*

- 28/7 Analysis of topological features for the prioritization of protein succination

*Ferrara B., Miglio G.*



## Poster Session

- 28/8 Nicotinamide phosphoribosyltransferase (NAMPT) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH): interaction between moonlighting proteins as new molecular basis of cancer**  
*Grolla A.A., Garavaglia S., Del Grosso E., Genazzani A.A.*
- 28/9 Modulation of diabetic retinopathy by melanocortin MC1 and MC5 receptor subtypes activation in a mouse model of stz-induced diabetic retinopathy and retinal cells culture**  
*Maisto R., Gesualdo C., Trotta M.C., Rossi S., Simonelli F., Grieco P., Merlino F., Perretti M., Di Filippo C., D'Amico M.*
- 28/10 *Hydra vulgaris* as a model to study nociceptive-like pathways**  
*Malafoglia V., Ilari S., Colasanti M., Raffaelli W., Muscoli C.*
- 28/11 The ephrin receptor kinase inhibitor GLPG1790 reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cell lines *in vitro* and *in vivo***  
*Marampon F., Megiorni F., Gravina G.L., Festuccia C., Camero S., Saniere L., Dominici C., Mcdowell H.P., Maggio R.*
- 28/12 U0126 MEK/ERK inhibitor increases prostate cancer cells radiosensitivity *in vitro* and *in vivo* by downregulating MEK/ERK/c-MYC axys and affecting DNA repair signals**  
*Marampon F., Gravina GL., Festuccia C., Maggio R.*
- 28/13 Pharmacological characterization of presynaptic release-regulating mGLU2-preferring and mGLU3-preferring autoreceptors in mouse CNS**  
*Olivero G., Vergassola M., Bonfiglio T., Cervetto C., Usai C., Riozzi B., Battaglia G., Nicoletti F., Pittaluga A.*
- 28/14 Endocannabinoid system and mouse uterine contractility**  
*Parisi O.A., Pagano E., Orlando P., Rossi A., Buono L., Iannotti F.A., Piscitelli F., Izzo A.A., Di Marzo V., Borrelli F.*
- 28/15 Potential relationship between the expression of Cx26/Cx43 and the BRAF mutation status in human melanoma cells**  
*Polini B., Matii L., Moscato S., Carpi S., Breschi M.C., Nieri P., Fogli S.*

- 28/16 Investigation of a putative nicotinamide phosphoribosyltransferase (NAMPT) receptor**  
*Torretta S., Colombo G., Manfredi M., Travelli C., Ambra A.A., Genazzani A.A.*
- 28/17 Identification of a novel, functional cross-talk between EphB1 receptor and mu opioid receptor**  
*Vaca G., Bedini A., Lombardi S., Spampinato S.*





## Informazioni Scientifiche

### Macro Aree Congresso SIF 2017

- Farmacologia del sistema nervoso
- Farmacologia del sistema cardiovascolare e del rene
- Farmacologia del sistema endocrino e malattie dismetaboliche
- Farmacologia del sistema respiratorio
- Farmacologia degli organi di senso
- Farmacologia dell'apparato digerente
- Farmacologia del sistema immunitario e dell'infiammazione
- Farmacologia rigenerativa
- Farmacologia epigenetica
- Chemioterapia e vaccini
- Terapia oncologica
- Farmacognosia e farmaci naturali
- Prodotti naturali, nutraceutici e prevenzione
- Tossicologia
- Sicurezza pre-clinica e clinica dei farmaci e farmacovigilanza
- Farmacoepidemiologia e farmacoeconomia
- Aspetti regolatori, etica e sostenibilità
- Innovazione e sostenibilità
- Farmaci delle malattie rare
- Medicina personalizzata
- Ricerca di base e ricerca clinica
- Dispositivi medici
- Real World Evidence

### GUIDELINES FOR SYMPOSIA, LECTURES AND ORAL COMMUNICATIONS SPEAKERS

In order to guarantee the respect of timing, Speakers are kindly requested to comply with the guidelines reported below.

1. According to CME regulation, specific names of medicinal products should be avoided during CME sessions. Especially, only generic names (drugs, instruments, devices) are permitted and commercial names should not be reported even if they are not correlated to the topic presented. Furthermore, no sponsor can be indicated on the slides.
2. Speakers are invited to leave their presentations on CD or USB (pen-drive) support, at the reference slide center within 24 hours to their own session. Presentations can also be sent by e-mail at [c.imola@adriacongrex.it](mailto:c.imola@adriacongrex.it). Presentations of the 28<sup>th</sup> October only can be left within 3 hours to the session beginning. Presentations will be pre-loaded on the integrated software with a timer and will be accessible from the podium of the proper conference room directly, clicking on the own name.
3. Files should be in Power Point (.ppt or .pptx) format only.



## Informazioni Scientifiche

- PC connection to projectors is not allowed. All the projections will be managed by a unique system, which provides to pre-load to the computer in the proper session room.
- Speakers are strongly encouraged to an absolute timing respect for their presentation. A timer will be visualised to control the time left.

Presentations must absolutely finish at the scheduled time, so chairpersons are exhorted to respect also the session starting time.

A hostess and/or a technical assistant will be in the conference room to assist Speakers for any problem or extemporary request.

### GUIDELINES FOR CHAIRPERSONS

Chairpersons are strongly recommended to be present at the conference room at least 10 minutes before session start and, especially, to guarantee the respect of session and each presentation timing.

### GUIDELINES FOR POSTER SESSIONS

The presenting author is required to be available for discussion during the poster viewing session assigned (see details below):

#### POSTER PRESENTATIONS SESSION I: OCTOBER 26TH

POSTER SET-UP:	October 25 from 15.00 to 19.00
POSTER AUTHOR DISCUSSION:	October 26 from 19.00 to 21.00
POSTER DISMANTLE:	October 28 from 11.30

### POSTER AWARDS

At the closing ceremony of the conference (October 28th, 2017), the best posters presented by young (under 38) non-structured SIF members (up to date with SIF registration fee) will be announced and awarded. We remind that in case of absence of the awarded authors, prizes will be assigned to authors immediately following in the ranking.

### SLIDE CENTER

#### Palaecongressi di Rimini:

Sala della Fontana (1<sup>st</sup> floor) opening:

Tuesday October 25th, 2017	10.00 - 19.00
Wednesday October 26th, 2017	08.00 - 19.00
Thursday October 27th, 2017	08.00 - 19.00
Friday October 28th, 2017	08.00 - 12.00



## Informazioni Scientifiche

### E.C.M. - EDUCAZIONE CONTINUA IN MEDICINA

Il programma accreditato ECM è identificato nel programma scientifico con il logo ECM. Il Congresso è accreditato (6 crediti ECM) per 1000 partecipanti appartenenti alle seguenti categorie professionali:

- Farmacista (ospedaliero e territoriale);
- Biologo;
- Medico chirurgo (discipline: neurologia; neuropsichiatria infantile; oncologia; pediatria; psichiatria; radioterapia; reumatologia; cardiocirurgia; chirurgia generale; chirurgia maxillofacciale; chirurgia pediatrica; chirurgia plastica e ricostruttiva; chirurgia toracica; chirurgia vascolare; ginecologia e ostetricia; neurochirurgia; oftalmologia; ortopedia e traumatologia; otorinolaringoiatria; urologia; anatomia patologica; anestesia e rianimazione; biochimica clinica; farmacologia e tossicologia clinica; laboratorio di genetica medica; medicina trasfusionale; medicina legale; medicina nucleare; microbiologia e virologia; neurofisiopatologia; neuroradiologia; patologia clinica (laboratorio di analisi chimico cliniche e microbiologia); radiodiagnostica; igiene, epidemiologia e sanità pubblica; igiene degli alimenti e della nutrizione; medicina del lavoro e sicurezza degli ambienti di lavoro; medicina generale (medici di famiglia); continuità assistenziale; pediatria (pediatri di libera scelta); scienza dell'alimentazione e dietetica; direzione medica di presidio ospedaliero; organizzazione dei servizi sanitari di base; audiologia e foniatría; psicoterapia; cure palliative; epidemiologia; medicina di comunità; allergologia ed immunologia clinica; angiologia; cardiologia; dermatologia e venereologia; ematologia; endocrinologia; gastroenterologia; genetica medica; geriatria; malattie metaboliche e diabetologia; malattie dell'apparato respiratorio; malattie infettive; medicina e chirurgia di accettazione e di urgenza; medicina fisica e riabilitazione; medicina interna; medicina termale; medicina aeronautica e spaziale; medicina dello sport; nefrologia; neonatologia);
- Infermiere e infermiere pediatrico.

Per ottenere l'attribuzione dei crediti ECM è necessario:

- aver compilato correttamente e in ogni sua tutti i moduli e consegnarli alla segreteria
- crediti non sono frazionabili e verranno riconosciuti a chi avrà totalizzato 20 ore di frequenza
- garantire la propria presenza in misura superiore all'95% del programma accreditato.

Il certificato riportante i crediti ECM sarà inviato successivamente al completamento della procedura di validazione.

### ATTESTATO DI PARTECIPAZIONE

L'attestato di partecipazione verrà rilasciato a tutti gli iscritti che ne faranno richiesta alla Segreteria presso la Sede Congressuale, al termine dei lavori scientifici.



## Malattie rare. Perchè per noi ogni paziente è unico.

Grazie ad una ricerca scientifica all'avanguardia, **Amicus Therapeutics** rappresenta oggi una realtà importante nel panorama delle società operanti nel settore delle biotecnologie.

**Amicus Therapeutics** sviluppa infatti terapie innovative per il trattamento delle malattie rare.

L'attenzione che poniamo quotidianamente ai nostri pazienti si riflette nell'impegno profuso nell'individuare trattamenti mirati e nella volontà, da parte dell'azienda, di collaborare fattivamente con le associazioni pazienti e con i caregivers per assicurare il massimo sostegno possibile nell'affrontare la malattia.

AMC/ANP/002/MAG17



## Informazioni Generali

### SEGRETERIA ORGANIZZATIVA

Adria Congrex srl  
Via Sassonia, 30 - 47922 Rimini  
Tel. 0541 305873  
c.imola@adriacongrex.it  
www.adriacongrex.it

### SEDE DEL CONGRESSO

Palacongressi di Rimini  
Via della Fiera, 23 - 47922 Rimini  
<http://www.riminipalacongressi.it/>

### SEGRETERIA IN SEDE CONGRESSUALE

La Segreteria Organizzativa è a disposizione dei partecipanti presso le sedi congressuali nei seguenti orari:

martedì 24 ottobre 2017	dalle 12.00 alle 19.00
mercoledì 25 ottobre 2017	dalle 8.00 alle 19.00
giovedì 26 ottobre 2017	dalle 8.00 alle 19.00
venerdì 27 ottobre 2017	dalle 8.00 alle 19.00
sabato 28 ottobre 2017	dalle 8.00 alle 14.00

### ISCRIZIONE IN SEDE CONGRESSUALE

è possibile iscriversi presso la postazione della Segreteria Organizzativa solo con contanti o carta di credito

Soci SIF	€ 488,00
Non soci SIF	€ 760,00
Non soci SIF non strutturati di età inferiore ai 38 anni*	€ 200,00
Giornata singola non soci SIF	€ 250,00

\*Al momento dell'iscrizione è necessario presentare fotocopia della carta d'identità e dichiarazione del Direttore di Dipartimento.

La quota di iscrizione comprende: Accesso alle sale e agli spazi espositivi, Partecipazione ai lavori scientifici, light lunch, Accesso al coffee break, Borsa congressuale, Attestato di partecipazione, Iva 22%.

### PAGAMENTO QUOTA DI PARTECIPAZIONE

Le quote di partecipazione possono essere pagate tramite:

- contanti
- carta di credito via Pay Pal (Visa - American Express - Mastercard)

### ACCESSO ALLA SEDE CONGRESSUALE

L'accesso sarà consentito solo agli iscritti in possesso del badge nominativo.

### INTERNET POINT

Per l'intera durata del Congresso sarà allestita una postazione internet all'interno dell'area espositiva.



## Informazioni Generali

### GUARDAROBA

Per i partecipanti al Congresso è disponibile un guardaroba custodito presso la sede del Palacongressi di Rimini. Gli orari del servizio seguono quelli dei lavori congressuali. I partecipanti sono pregati di controllare gli orari e di ritirare i propri effetti personali entro l'orario di chiusura.

### PROGRAMMA GENERALE SIF

#### Cerimonia di apertura del congresso

Mercoledì 25 ottobre dalle ore 17 alle ore 16:30, Sala Anfiteatro

#### Assemblea della Sezione di Farmacologia clinica

Giovedì 26 ottobre dalle ore 18.30 Sala del Borgo

#### Assemblea del collegio nazionale dei Farmacologi Universitari

Giovedì 26 ottobre dalle ore 18.30 Sala del Tempio 1

#### Assemblea Straordinaria SITOX

Venerdì 27 ottobre dalle ore 10.30 Sala del Faro

#### Assemblea Straordinaria SIF

Venerdì 27 ottobre dalle ore 13.30 Sala del Faro

#### Assemblea generale SIF

Venerdì 27 ottobre dalle ore 18.30 Sala Anfiteatro

#### Cerimonia di consegna premi per migliori poster

Sabato 28 ottobre dalle ore 13.00 Sala Anfiteatro

### SEGRETERIA SIF

La Segreteria SIF è operativa presso il desk SIF durante tutta la durata del congresso per informazioni inerenti all'associazione.

### BADGE

A ciascun partecipante iscritto verrà consegnato un badge nominativo che dovrà essere sempre esibito per poter accedere alle aule dove si svolgono le sessioni scientifiche, ai lunch e ai coffee break. L'accesso all'area espositiva e alle sale delle sessioni scientifiche è infatti consentito esclusivamente agli iscritti al congresso in possesso del badge nominativo.

### APP CONGRESSUALE

Adria Congrex ha sviluppato un'applicazione congressuale scaricabile direttamente sul proprio smartphone o dispositivo. L'applicazione permette, tramite la sezione eventi, di accedere ai contenuti del 38° Congresso Nazionale della Società Italiana di Farmacologia:

- Programma Scientifico del Congresso Nazionale navigabile per Orario, Relatore e Sala
- Informazioni generali
- Aggiornamenti in diretta dalla sede congressuale

L'app SIF2017 è scaricabile su APP STORE e GOOGLE PLAY impostando nella ricerca: SIF 2017.



## Come arrivare alla Sede Congressuale

### AEROPORTO DI BOLOGNA

- dista 100 km. da Rimini in direzione nord
- è il 4° aeroporto in Italia per numero di voli
- 79 sono le destinazioni europee collegate quotidianamente, tra cui i principali hub
- intercontinentali (Francoforte, Londra, Parigi, Madrid, Amsterdam)
- Bologna è sede inoltre di importanti compagnie low-cost con voli regolari  
*Bologna -Rimini 16 corse giornaliere del servizio di navetta Romagna Shuttle collegano l'aeroporto di Bologna alla stazione di Rimini*

### AEROPORTO DI ANCONA

- dista 80 km. da Rimini in direzione sud
- Roma, Madrid, Londra, Monaco, Düsseldorf, Bruxelles e numerose destinazioni dell'Europa dell'Est sono collegate quotidianamente.

### AEROPORTI DI MILANO - Malpensa e Linate

- I principali voli intercontinentali ed europei atterrano nei due aeroporti di Milano
- Nel 2015 Milano Malpensa ha ricevuto il premio per il miglior aeroporto europeo nella categoria dai 10 ai 25 milioni di passeggeri

### AEROPORTO DI RIMINI

- A Rimini si trova inoltre un aeroporto a soli 4,5 km. dal centro città che attualmente dispone di diversi voli low-cost
- *Bologna/Ancona/Milano-Rimini*
- *frequenti collegamenti ferroviari Frecciabianca, Frecciarossa e Italo collegano le stazioni di Bologna, Ancona e Milano a quella di Rimini*



Sponsor

Sponsor

La Società Italiana di Farmacologia ringrazia gli sponsor

Platinum



*We Innovate Healthcare*

Gold



Silver



Bronze




Sponsor



Un ringraziamento particolare a





## Faculty index

# Inizia con una promessa: scoprire medicine che migliorano la vita.

Dal 1876, abbiamo lavorato instancabilmente per sviluppare e per fornire medicine affidabili che rispondano realmente ai bisogni sanitari, cercando soluzioni che aiutino le persone, senza tener conto delle probabilità di successo. Dallo sviluppo dell'insulina alla scoperta di nuovi trattamenti per le malattie mentali, siamo stati pionieri con farmaci fondamentali contro alcune patologie tra le più ostinate e devastanti. Oggi abbiamo la stessa determinazione nel lavoro, coniugando l'esperienza con la creatività dei nostri partner in ricerca nel mondo, per trovare soluzioni che migliorino la vita.

Per sapere di più riguardo la nostra promessa, visita [www.lilly.it](http://www.lilly.it)

*Lilly*



**38°**  
**Congresso Nazionale**  
**Farmaci, Salute,**  
**e Qualità**  
**della Vita**

Palacongressi di **Rimini**  
25-28 ottobre 2017



Faculty index

Faculty index

## Faculty index

CSL Behring è costantemente impegnata nel garantire la sopravvivenza e migliorare la qualità della vita di persone affette da gravi e rare malattie in tutto il mondo

Può contare su un patrimonio di oltre 100 anni di conoscenze ed esperienze nella ricerca e produzione di bioterapie che si traducono in farmaci derivati dal plasma e ricombinanti utilizzati in varie aree terapeutiche


- Immunologia
- Coagulazione
- Pneumologia
- Critical Care



Con lo sguardo sempre rivolto all'innovazione, CSL Behring è in prima linea nello sviluppo di nuove e migliori Bioterapie per la vita



# UNA SCELTA CHE SI-CURA DI TE.



**Solidità, Affidabilità, Flessibilità ed Empatia  
in un'unica scelta di cura.**

Fai anche tu una scelta SAFE con Aristo Pharma Italy:  
un'azienda impegnata ogni giorno nell'offrire un concetto globale  
di sicurezza e di qualità per la salute e il benessere delle persone.



UNA SCELTA DI CURA.